0001387131-16-005510.txt : 20160513 0001387131-16-005510.hdr.sgml : 20160513 20160513164102 ACCESSION NUMBER: 0001387131-16-005510 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 62 CONFORMED PERIOD OF REPORT: 20160331 FILED AS OF DATE: 20160513 DATE AS OF CHANGE: 20160513 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CareView Communications Inc CENTRAL INDEX KEY: 0001377149 STANDARD INDUSTRIAL CLASSIFICATION: RADIO & TV BROADCASTING & COMMUNICATIONS EQUIPMENT [3663] IRS NUMBER: 954659068 STATE OF INCORPORATION: NV FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-54090 FILM NUMBER: 161649009 BUSINESS ADDRESS: STREET 1: 405 STATE HIGHWAY 121 STREET 2: SUITE B-240 CITY: LEWISVILLE STATE: TX ZIP: 75067 BUSINESS PHONE: 972-943-6050 MAIL ADDRESS: STREET 1: 405 STATE HIGHWAY 121 STREET 2: SUITE B-240 CITY: LEWISVILLE STATE: TX ZIP: 75067 10-Q 1 crvw-10q_033116.htm QUARTERLY REPORT

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

☒

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2016

☐	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from________ to ___________

Commission File No. 000-54090

CAREVIEW COMMUNICATIONS, INC.

(Exact name of registrant as specified in its charter)

Nevada	95-4659068
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification No.)

405 State Highway 121, Suite B-240, Lewisville, TX 75067	(972) 943-6050
(Address of principal executive offices)	(Registrant’s Telephone Number)

N/A

(Former name, former address and former fiscal year, if changed since last report)

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer ☐ Accelerated filer ☐ Non-accelerated filer ☐ Smaller reporting company ☒

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes ☐ No ☒

The number of shares outstanding of each of the issuer’s classes of Common Stock as of May 13, 2016 was 139,380,742.

CAREVIEW COMMUNICATIONS, INC. AND SUBSIDIARIES

INDEX

			Page
PART I - FINANCIAL INFORMATION

	Item. 1	Financial Statements

		Condensed Consolidated Balance Sheets as of March 31, 2016 (Unaudited) and December 31, 2015	3

		Condensed Consolidated Statements of Operations for the Three Months Ended March 31, 2016 and 2015 (Unaudited)	4

		Condensed Consolidated Statement of Stockholders' Deficit for the period from January 1, 2016 to March 31, 2016 (Unaudited)	5

		Condensed Consolidated Statements of Cash Flows for the Three Months Ended March 31, 2016 and 2015 (Unaudited)	6

		Notes to the Condensed Consolidated Financial Statements	7

	Item 2.	Management's Discussion and Analysis of Financial Condition and Results of Operations	23

	Item 3.	Quantitative and Qualitative Disclosures about Market Risk	28

	Item 4.	Controls and Procedures	28

PART II - OTHER INFORMATION

	Item 1.	Legal Proceedings	28

	Item 1A.	Risk Factors	28

	Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	28

	Item 3.	Defaults Upon Senior Securities	28

	Item 4.	Mine Safety Disclosures	29

	Item 5.	Other Information	29

	Item 6.	Exhibits	29

CAREVIEW COMMUNICATIONS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS

	March 31,
	2016			December 31,
	(unaudited)			2015
ASSETS
Current Assets:
Cash and cash equivalents	$	15,568,573		$	17,678,969
Accounts receivable, net		1,185,132			1,176,404
Other current assets		493,179			471,075
Total current assets		17,246,884			19,326,448

Property and equipment, net		4,534,718			4,483,440

Other Assets:
Restricted cash		3,250,000			3,250,000
Intangible assets, net		530,519			380,765
Other assets		2,548,282			2,689,758
		6,328,801			6,320,523
Total assets	$	28,110,403		$	30,130,411

LIABILITIES AND STOCKHOLDERS' DEFICIT
Current Liabilities:
Accounts payable	$	387,303		$	332,402
Notes payable		441,498			441,498
Mandatorily redeemable equity in joint venture		441,498			441,498
Accrued interest		276,508			261,450
Other current liabilities		586,043			479,226
Total current liabilities		2,132,850			1,956,074

Long-term Liabilities:
Senior secured convertible notes, net of debt discount and debt costs of $22,951,069 and $23,041,363, respectively		35,593,463			33,729,093
Loan payable		20,000,000			20,000,000
Fair value of warrant liability		84,308			168,805
Total long-term liabilities		55,677,771			53,897,898
Total liabilities		57,810,621			55,853,972

Commitments and Contingencies

Stockholders' Deficit:
Preferred stock - par value $0.001; 20,000,000 shares authorized; no shares issued and outstanding		—			—
Common stock - par value $0.001; 300,000,000 shares authorized; 139,380,748 issued and outstanding		139,381			139,381
Additional paid in capital		83,142,148			82,434,461
Accumulated deficit		(112,463,946	)		(107,795,712	)
Total CareView Communications Inc. stockholders' deficit		(29,182,417	)		(25,221,870	)
Noncontrolling interest		(517,801	)		(501,691	)
Total stockholders' deficit		(29,700,218	)		(25,723,561	)
Total liabilities and stockholders' deficit	$	28,110,403		$	30,130,411

The accompanying footnotes are an integral part of these condensed consolidated financial statements.

CAREVIEW COMMUNICATIONS INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

FOR THE THREE MONTHS ENDED MARCH 31, 2016 AND 2015

(Unaudited)

	Three Months Ended
	March 31, 2016			March 31, 2015

Revenues, net	$	1,495,793		$	1,000,554

Operating expenses:
Network operations		1,152,107			830,094
General and administration		1,054,858			838,309
Sales and marketing		221,688			197,622
Research and development		249,098			225,196
Depreciation and amortization		445,416			415,904
Total operating expense		3,123,167			2,507,125

Operating loss		(1,627,374	)		(1,506,571	)

Other income and (expense)
Interest expense		(3,151,557	)		(2,045,901	)
Change in fair value of warrant liability		84,497			(238,101	)
Interest income		4,970			1,143
Other income		5,120			1,125
Total other income (expense)		(3,056,970	)		(2,281,734	)

Loss before taxes		(4,684,344	)		(3,788,305	)

Provision for income taxes		—			—

Net loss		(4,684,344	)		(3,788,305	)

Net loss attributable to noncontrolling interest		(16,110	)		(16,222	)

Net loss attributable to CareView Communications, Inc.	$	(4,668,234	)	$	(3,772,083	)

Net loss per share attributable to CareView Communications, Inc., basic and diluted	($	0.03	)	($	0.03	)

Weighted average number of common shares outstanding, basic and diluted		139,380,748			139,380,748

The accompanying footnotes are an integral part of these condensed consolidated financial statements.

CAREVIEW COMMUNICATIONS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' DEFICIT

FOR THE PERIOD FROM JANUARY 1, 2016 TO MARCH 31, 2016

(Unaudited)

					Additional
	Common Stock				Paid in		Accumulated			Noncontrolling
	Shares		Amount		Capital		Deficit			Interest			Total
Balance, January 1, 2016		139,380,748	$	139,381	$	82,434,461	$	(107,795,712	)	$	(501,691	)	$	(25,723,561	)

Stock options granted as compensation		—		—		190,843		—			—			190,843

Beneficial conversion features for senior secured convertible notes		—		—		516,844		—			—			516,844

Net loss		—		—		—		(4,668,234	)		(16,110	)		(4,684,344	)

Balance, March 31, 2016		139,380,748	$	139,381	$	83,142,148	$	(112,463,946	)	$	(517,801	)	$	(29,700,218	)

The accompanying footnotes are an integral part of these condensed consolidated financial statements.

CAREVIEW COMMUNICATIONS, INC. AND SUBSIDIARIES

FOR THE THREE MONTHS ENDED MARCH 31, 2016 AND 2015

(Unaudited)

	Three Months Ended
	March 31, 2016			March 31, 2015
CASH FLOWS FROM OPERATING ACTIVITES
Net loss	$	(4,684,344	)	$	(3,788,305	)
Adjustments to reconcile net loss to net cash flows used in operating activities:
Depreciation		423,560			409,634
Amortization of debt discount and debt costs		607,138			552,066
Amortization of deferred installation costs		102,541			66,631
Amortization of deferred debt issuance and debt financing costs		72,772			—
Amortization of intangible assets		21,856			6,270
Interest incurred and paid in kind		1,774,076			1,471,707
Stock based compensation related to options granted		190,843			190,106
(Gain) loss on disposal of assets		—			43,740
Change in fair value of warrant liability		(84,497	)		238,101
Changes in operating assets and liabilities:
Accounts receivable		(8,728	)		8,639
Other current assets		(18,929	)		(238,795	)
Other assets		4,098			4,098
Accounts payable		54,901			183,405
Accrued expenses and other current liabilities		121,875			(77,177	)
Net cash flows used in operating activities		(1,422,838	)		(929,880	)

CASH FLOWS FROM INVESTING ACTIVITIES
Purchase of property and equipment		(474,838	)		(103,098	)
Payment for deferred installation costs		(37,935	)		(47,371	)
Patent and trademark costs		(174,785	)		(10,273	)
Net cash flows used in investing activities		(687,558	)		(160,742	)

CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from notes and loan payable		—			5,931,520
Net cash flows provided by financing activities		—			5,931,520

Increase (decrease) in cash		(2,110,396	)		4,840,898
Cash and cash equivalent, beginning of period		17,678,969			2,546,262
Cash and cash equivalents, end of period	$	15,568,573		$	7,387,160

SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:

Cash paid for interest	$	682,150		$	5,150

Cash paid for income taxes	$	—		$	—

SUPPLEMENTAL SCHEDULE OF NON-CASH FINANCING ACTIVITIES:


Beneficial conversion features for senior secured convertible notes	$	516,844		$	456,987

Warrants issued in connection with senior secured convertible notes	$	—		$	1,471,105

The accompanying footnotes are an integral part of these condensed consolidated financial statements.

CAREVIEW COMMUNICATIONS, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

NOTE 1 – BASIS OF PRESENTATION AND RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS

Interim Financial Statements

The accompanying unaudited interim condensed consolidated financial statements of CareView Communications, Inc. (“CareView”, the “Company”, “we”, “us” or “our”) have been prepared in accordance with generally accepted accounting principles in the United States of America (“GAAP”) for interim financial information and with the instructions to Form 10-Q. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, such financial statements include all adjustments (consisting solely of normal recurring adjustments) necessary for the fair statement of the financial information included herein in accordance with GAAP and the rules and regulations of the Securities and Exchange Commission (the “SEC”). The balance sheet at December 31, 2015 has been derived from the audited consolidated financial statements at that date but does not include all of the information and footnotes required by GAAP for complete financial statements. The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the period. Actual results could differ from those estimates. Results of operations for interim periods are not necessarily indicative of results for the full year. The accompanying condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and related notes included in our Annual Report on Form 10-K for the year ended December 31, 2015 as filed with the SEC on March 30, 2016.

Fair Value of Financial Instruments

Our financial instruments consist primarily of receivables, accounts payable, accrued expenses and short- and long-term debt. The carrying amount of receivables, accounts payable and accrued expenses approximates our fair value because of the short-term maturity of such instruments. We have elected not to carry our debt instruments at fair value. The carrying amount of our debt approximates fair value. Interest rates that are currently available to us for issuance of short- and long-term debt with similar terms and remaining maturities are used to estimate the fair value of the our short- and long-term debt and would be considered Level 3 inputs under the fair value hierarchy.

We have categorized our assets and liabilities that are valued at fair value on a recurring basis into a three-level fair value hierarchy in accordance with GAAP. The fair value hierarchy gives the highest priority to quoted prices in active markets for identical assets and liabilities (Level 1) and lowest priority to unobservable inputs (Level 3).

Assets and liabilities recorded in the condensed consolidated balance sheets at fair value are categorized based on a hierarchy of inputs, as follows:

Level 1 - Unadjusted quoted prices in active markets for identical assets or liabilities.

Level 2 - Quoted prices for similar assets or liabilities in active markets or inputs that are observable for the asset or liability, either directly or indirectly through market corroboration, for substantially the full term of the financial instrument.

Level 3 - Unobservable inputs for the asset or liability.

The Company’s financial assets and liabilities recorded at fair value on a recurring basis include the fair value of warrant liability as detailed below. The fair value of this warrant liability is included in long-term liabilities on the accompanying condensed consolidated financial statements.

CAREVIEW COMMUNICATIONS, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

NOTE 1 – BASIS OF PRESENTATION AND RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS (Continued)

Fair Value of Financial Instruments (continued)

The following table provides the financial assets and liabilities reported at fair value and measured on a recurring basis:

Description		Assets/ (Liabilities) Measured at Fair Value				Quoted Prices in Active Markets for Identical Assets (Level 1)				Significant Other Observable Inputs (Level 2)				Significant Other Unobservable Inputs (Level 3)
Fair value of warrant liability		$	(84,308	)		$	—			$	—			$	(84,308	)

The following table provides a summary of changes in fair value associated with the Level 3 liabilities for the three months ended March 31, 2016:

	Fair Value Measurements Using Significant Unobservable Inputs (Level 3)
Balance at January 1, 2016	$	(168,805	)
Issuances of derivative liabilities		—
Change in fair value of warrant liability		(84,497	)
Transfers in and/out of Level 3		—
Ending balance at March 31, 2016	$	(84,308	)

The above table of Level 3 liabilities begins with the prior period balance and adjusts the balance for changes that occurred during the current period. The ending balance of the Level 3 securities presented above represent our best estimates and may not be substantiated by comparisons to independent markets and, in many cases, could not be realized in immediate settlement of the instruments.

Earnings Per Share

We calculate earnings per share (“EPS”) in accordance with GAAP, which requires the computation and disclosure of two EPS amounts, basic and diluted. Basic EPS is computed based on the weighted average number of shares of common stock outstanding during the period. Diluted EPS is computed based on the weighted average number of common shares outstanding plus all potentially dilutive common shares outstanding during the period under the treasury stock method. Such potential dilutive common shares consist of stock options, warrants and convertible debt. Potential common shares totaling 110,156,518 and 104,333,559 at March 31, 2016 and 2015, respectively, have been excluded from the diluted earnings per share calculation as they are anti-dilutive due to our reported net loss.

CAREVIEW COMMUNICATIONS, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

NOTE 1 – BASIS OF PRESENTATION AND RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS (Continued)

Recently Issued and Newly Adopted Accounting Pronouncements

In February 2016, the FASB issued ASU 2016-02, Leases (“ASU 2016-02”). The new standard establishes a right-of-use (“ROU”) model that requires a lessee to record a ROU asset and a lease liability on the balance sheet for all leases with terms longer than 12 months. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the income statement. ASU 2016-02 is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. Early adoption is permitted. A modified retrospective transition approach is required for lessees for capital and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain practical expedients available. We are evaluating the impact that ASU 2016-03 will have on our consolidated financial statements and related disclosures.

There have been no material changes to our significant accounting policies as summarized in NOTE 2 of our Annual Report on Form 10-K for the year ended December 31, 2015. We do not expect that the adoption of any recent accounting pronouncements will have a material impact on our accompanying condensed consolidated financial statements.

NOTE 2 – LIQUIDITY AND MANAGEMENT’S PLAN

Our cash position at March 31, 2016 was approximately $15,569,000. We also have $3,250,000 recorded as restricted cash related to a debt covenant in our credit agreement with PDL BioPharma, Inc. as discussed below.

Pursuant to the terms of a Note and Warrant Purchase Agreement dated April 21, 2011 (as subsequently amended) with HealthCor Partners Fund, LP and HealthCor Hybrid Offshore Master Fund, LP (“HealthCor”) we are required to maintain a minimum cash balance $2,000,000 (see NOTE 11 for further details), and we are in compliance with the minimum cash balance as of the date of this filing.

Our continued successful operation is dependent upon us achieving positive cash flow through operations while maintaining adequate liquidity. We expect that the cash on hand, as well as our existing and projected cash flow from billable contracts, will enable us to continue to operate for the next twelve month period. We believe that our sales and marketing plan to attract new business and our ongoing deployment and installation of units under existing hospital agreements, will meet our near-term cash needs and will help us achieve future operating profitability.

At present, we have sufficient inventory to install and service a select number of large customers, but eventually we will need to address additional capital requirements. To that end, on June 26, 2015, we entered into a Credit Agreement with PDL Biopharma, Inc., as administrative agent and lender (“the Lender”), (the “PDL Credit Agreement”) pursuant to which the Lender made available to us up to $40 million in two tranches of $20 million each, with each tranche contingent upon us meeting certain milestones. On October 7, 2015, pursuant to the First Amendment to the PDL Credit Agreement (the “First Amendment”) the Lender made the first tranche of $20 million available and funded us $19,533,992, net of fees. As of March 31, 2016, we are including $20 million in long-term liabilities on the accompanying condensed consolidated financial statements. Pursuant to the terms of the PDL Credit Agreement, we are required to maintain a minimum cash balance $3,250,000, and we are in compliance with the minimum cash balance as of the date of this filing (see NOTE13 for further details). No funds under the second tranche of the PDL Credit Agreement were available to us as of March 31, 2016.

CAREVIEW COMMUNICATIONS, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

NOTE 3 – STOCKHOLDERS’ EQUITY

Warrants to Purchase Common Stock of the Company

We use the Black-Scholes-Merton option pricing model (the “Black-Scholes Model”) to determine the fair value of warrants to purchase Common Stock of the Company (“Warrants”) (except certain Warrants issued to HealthCor in 2011 as discussed in NOTE 11 and the warrants issued in connection with a private placement completed in April 2013 (the “Private Placement Warrants”). The Private Placement Warrants contain provisions that protect the holders from a decline in the issue price of our common stock or “down round” provisions. In accordance with the accounting standards, we determined that these instruments qualify as derivative liabilities and should be recorded at their fair value on the date of issuance and re-measured at fair value each reporting period with the change reported in earnings). The Black-Scholes Model is an acceptable model in accordance with the GAAP. The Black-Scholes Model requires the use of a number of assumptions including volatility of the stock price, the weighted average risk-free interest rate, and the weighted average term of the Warrant. The fair value of the Warrants issued to HealthCor and the Private Placement Warrants was computed using the Binomial Lattice model, incorporating transaction details such as the price of our Common Stock, contractual terms, maturity and risk free rates, as well as assumptions about future financings, volatility, and holder behavior. Due to the down round provisions associated with the exercise price of these Warrants, we determined that the Binomial Lattice model was the most appropriate model for valuing these instruments. As discussed in NOTE 11, the Warrants issued to HealthCor in 2011 were substantially amended and no longer contain down round provisions. The risk-free interest rate assumption is based upon observed interest rates on zero coupon U.S. Treasury bonds whose maturity period is appropriate for the term of the Warrants and is calculated by using the average daily historical stock prices through the day preceding the grant date. Estimated volatility is a measure of the amount by which our stock price is expected to fluctuate each year during the expected life of the award. Our estimated volatility is an average of the historical volatility of our stock prices (and that of peer entities whose stock prices were publicly available). Our calculation of estimated volatility is based on historical stock prices over a period equal to the expected life of the awards. Where appropriate we used the historical volatility of peer entities due to the lack of sufficient historical data of our stock price during 2007-2009.

Warrant Activity during the Three Months Ended March 31, 2016

During the three months ended March 31, 2016, no Warrants were issued and none were exercised or expired.

As of December 31, 2015, we recorded a warrant liability of $168,805 in our consolidated financial statements. At March 31, 2016, the Private Placement Warrants were re-valued with a fair value determination of $84,308, resulting in a difference of $84,497, which was included as change in fair value of warrant liability in other income and expense in the accompanying condensed consolidated financial statements.

Warrant Activity during the Three Months Ended March 31, 2015

On February 17, 2015, we entered into a Fifth Amendment to the Note and Warrant Purchase Agreement with HealthCor and certain other investors and agreed to sell and issue (i) additional notes in the initial aggregate principal amount of $6,000,000, with a conversion price per share equal to $0.52 (subject to adjustment for standard anti-dilution provisions) and (ii) additional Warrants for an aggregate of up to 3,692,307 shares of our Common Stock at an exercise price per share equal to $0.52 (subject to adjustment for standard anti-dilution provisions) (the “Fifth Amendment Warrants”). The fair value of the convertible debt and the Fifth Amendment Warrants was determined to be $7,336,615, resulting in a relative fair value of $1,093,105 for the Fifth Amendment Warrants on the date of grant. (See NOTE 11 for further details.)

CAREVIEW COMMUNICATIONS, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

NOTE 3 – STOCKHOLDERS’ EQUITY (Continued)

Warrants to Purchase Common Stock of the Company (continued)

Warrant Activity during the Three Months Ended March 31, 2015 (continued)

On March 31, 2015, we issued HealthCor a Warrant for up to an aggregate of 1,000,000 shares of our Common Stock in consideration for certain prior waivers of the minimum cash balance requirement in the Purchase Agreement. This Warrant has an exercise price of $0.53 per share and an expiration date of March 31, 2025. (See NOTE 11 for further details).

During the three months ended March 31, 2015, warrants to purchase an aggregate of 2,882,626 shares of our Common Stock expired.

Options to Purchase Common Stock of the Company

During the three months ended March 31, 2016, we granted options to purchase 20,000 shares of our Common Stock (the ‘‘Option(s)’’) to an employee. During the three months ended March 31, 2015, we granted 1,815,000 Options to certain employees and members of our board of directors. During those same three month periods, 65,002 and 41,002 Options, respectively, were canceled and 66,667 and 6,231,310 Options, respectively, expired.

A summary of our stock option activity and related information follows:

	Number of Shares Under Options			Weighted Average Exercise Price		Weighted Average Remaining Contractual Life		Aggregate Intrinsic Value
Balance at December 31, 2015		9,350,667		$	0.58		7.6	$	15,705
Granted		20,000		$	0.30		10.0	$	—
Expired		(66,667	)
Canceled		(65,002	)
Balance at March 31, 2016		9,238,998		$	0.58		7.4	$	—
Vested and Exercisable at March 31, 2016		5,547,825		$	0.62		6.7	$	—

The valuation methodology used to determine the fair value of the Options issued was the Black-Scholes Model.

The assumptions used in the Black-Scholes Model are set forth in the table below.

	Three Months Ended March 31, 2016			Year Ended December 31, 2015
Risk-free interest rate		1.39	%		1.41-1.74	%
Volatility		63.49	%		61.00-71.86	%
Expected life in years		6			6
Dividend yield		0.00	%		0.00	%

CAREVIEW COMMUNICATIONS, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

NOTE 3 – STOCKHOLDERS’ EQUITY (Continued)

Options to Purchase Common Stock of the Company (continued)

The risk-free interest rate assumption is based upon observed interest rates on zero coupon U.S. Treasury bonds whose maturity period is appropriate for the expected term of the Option and is calculated by using the average daily historical stock prices through the day preceding the grant date. Estimated volatility is a measure of the amount by which our stock price is expected to fluctuate each year during the expected life of the award. Our estimated volatility is an average of the historical volatility of our stock prices. Our calculation of estimated volatility is based on historical stock prices over a period equal to the expected life of the awards.

Share-based compensation expense for Options charged to our operating results for the three months ended March 31, 2016 and 2015 ($190,843 and $190,106, respectively) is based on awards vested. The estimate of forfeitures are to be recorded at the time of grant and revised in subsequent periods if actual forfeitures differ from the estimates. We have not included an adjustment to our stock based compensation expense based on the nominal amount of the historical forfeiture rate. We do, however, revise our stock based compensation expense based on actual forfeitures during each reporting period.

At March 31, 2016, total unrecognized estimated compensation expense related to non-vested Options granted prior to that date was approximately $842,000, which is expected to be recognized over a weighted-average period of 1.5 years. No tax benefit was realized due to a continued pattern of operating losses.

NOTE 4 – OTHER CURRENT ASSETS

Other current assets consist of the following:

	March 31, 2016		December 31, 2015
Prepaid expenses	$	490,119	$	467,137
Other current assets		3,060		3,938
TOTAL OTHER CURRENT ASSETS	$	493,179	$	471,075

NOTE 5 – PROPERTY AND EQUIPMENT

Property and equipment consist of the following:

	March 31, 2016			December 31, 2015
Network equipment	$	11,762,725		$	11,310,494
Office equipment		218,875			200,683
Vehicles		158,803			158,803
Test equipment		117,871			115,712
Furniture		84,094			81,838
Warehouse equipment		9,524			9,524
Leasehold improvements		5,121			5,121
		12,357,013			11,882,175
Less: accumulated depreciation		(7,822,295	)		(7,398,735	)
TOTAL PROPERTY AND EQUIPMENT	$	4,534,718		$	4,483,440

Depreciation expense for the three months ended March 31, 2016 and 2015 was $423,560 and $409,634, respectively.

CAREVIEW COMMUNICATIONS, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

NOTE 6 – OTHER ASSETS

Intangible assets consist of the following:

	March 31, 2016
	Cost		Accumulated Amortization		Net
Patents and trademarks	$	591,747	$	74,018	$	517,729
Other intangible assets		56,263		43,473		12,790
TOTAL INTANGIBLE ASSETS	$	648,010	$	117,491	$	530,519

	December 31, 2015
	Cost		Accumulated Amortization		Net
Patents and trademarks	$	420,137	$	53,706	$	366,431
Other intangible assets		56,263		41,929		14,334
TOTAL INTANGIBLE ASSETS	$	476,400	$	95,635	$	380,765

Other assets consist of the following:

	March 31, 2016
	Cost		Accumulated Amortization		Net
Deferred debt issuance costs	$	1,257,778	$	136,763	$	1,121,015
Prepaid financing costs		805,917		101,919		703,998
Deferred installation costs		1,825,804		1,323,523		502,281
Prepaid license fee		249,999		75,135		174,864
Security deposit		46,124		—		46,124
TOTAL OTHER ASSETS	$	4,185,622	$	1,637,340	$	2,548,282

Other assets consist of the following:

	December 31, 2015
	Cost		Accumulated Amortization		Net
Deferred debt issuance costs	$	1,257,778	$	91,840	$	1,165,938
Deferred financing costs		805,917		74,070		731,847
Deferred installation costs		1,787,869		1,220,982		566,887
Prepaid license fee		249,999		71,037		178,962
Security deposit		46,124		—		46,124
TOTAL OTHER ASSETS	$	4,147,687	$	1,457,929	$	2,689,758

CAREVIEW COMMUNICATIONS, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

NOTE 7 – OTHER CURRENT LIABILITIES

Other current liabilities consist of the following:

	March 31, 2016		December 31, 2015
Accrued taxes	$	243,683	$	235,162
Accrued insurance		135,059		—
Allowance for system removal		102,800		54,771
Accrued paid time off		68,007		108,526
Accrued professional services		11,284		67,500
Other accrued liabilities		25,210		13,267
TOTAL OTHER CURRENT LIABILITIES	$	586,043	$	479,226

NOTE 8 – INCOME TAXES

Deferred income tax assets and liabilities are determined based upon differences between the financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. We do not expect to pay any significant federal or state income tax for 2016 as a result of the losses recorded during the three months ended March 31, 2016 and the additional losses expected for the remainder of 2016 and net operating loss carry forwards from prior years. Accounting standards require the consideration of a valuation allowance for deferred tax assets if it is “more likely than not” that some component or all of the benefits of deferred tax assets will not be realized. As of March 31, 2016, we maintained a full valuation allowance for all deferred tax assets. Based on these requirements, no provision or benefit for income taxes has been recorded. There were no recorded unrecognized tax benefits at the end of the reporting period.

NOTE 9 – JOINT VENTURE AGREEMENT

On November 16, 2009, we entered into a Master Investment Agreement (the “Rockwell Agreement”) with Rockwell Holdings I, LLC, a Wisconsin limited liability (“Rockwell”). Under the terms of the Rockwell Agreement, we used funds from Rockwell to fully implement the CareView System™ in Hillcrest Medical Center in Tulsa, Oklahoma (“Hillcrest”) and Saline Memorial Hospital in Benton, Arkansas (“Saline”) (the “Project Hospital(s)”). CareView-Hillcrest, LLC and CareView-Saline, LLC were created as the operating entities for the Project Hospitals under the Rockwell Agreement (the “Project LLC(s) “).

Rockwell and the Company own 50% of each Project LLC. We contributed our intellectual property rights and hospital contract with each Project Hospital and Rockwell contributed cash to be used for the purchase of equipment for the Project LLCs. Rockwell provided $1,151,205 as the initial funding, $575,603 was provided under promissory notes (the “Project Notes”) and $575,602 was provided under an investment interest (“Rockwell’s Preferential Return”). We classified Rockwell’s Preferential Return as a liability since it represents an unconditional obligation by us and is recorded in mandatorily redeemable equity in joint venture on the accompanying consolidated financial statements. The Project Notes and Rockwell’s Preferential Returns both earn interest at the rate of ten percent (10%) and are secured by a security interest in all of the equipment in the Project Hospitals, intellectual property rights, and the Project Hospital Contract.

CAREVIEW COMMUNICATIONS, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

NOTE 9 – JOINT VENTURE AGREEMENT (Continued)

In accordance with GAAP, we determined the Project LLCs are VIEs based on the fact that the total equity investment at risk was not sufficient to finance the entities activities without additional financial support. We consolidate the Project LLCs as we have the power to direct the activities and an obligation to absorb losses of the VIEs. We have no contractual liability to Rockwell with respect to the repayment obligations of the Project LLCs.

As additional consideration to Rockwell for providing the funding, we granted Rockwell 1,151,206 Warrants on the date of the Rockwell Agreement, and using the Black-Scholes Model valued the Warrants at $1,124,728 (the “Project Warrant”). The Project Warrant is classified as equity and is included in additional paid-in-capital on the accompanying condensed consolidated financial statements. We allocated the proceeds to the Project Warrant, the Project Notes and Preferential Returns based on the relative fair value. The originally recorded debt discount of $636,752 was amortized over the expected life of the debt and was fully amortized as of March 31, 2013.

Hillcrest notified us of its desire to terminate its hospital agreement effective January 27, 2012. This termination resulted in the loss of monthly revenue totaling approximately $20,000, which revenue was used to make payments on our indebtedness to Rockwell. To date, we have incurred system removal costs of approximately $3,000 for removing our equipment from the hospital premises. We currently have approximately 100 units remaining on site at Hillcrest. Included in other current liabilities in the accompanying condensed consolidated financial statements is an allowance for system removal totaling $10,250 to reserve for the removal of the remaining units.

As of March 31, 2016, the Project LLCs’ indebtedness to Rockwell, including principal and interest totaled approximately $1,200,000. On February 19, 2015, the Project Notes and Rockwell’s Preferential Returns due dates were extended to June 30, 2016. In October 2015, the expiration date of the Project Warrants was extended to November 16, 2017. All other provisions of the Project Warrant remained unchanged. The Project Warrant were revalued in October 2015 resulting in a $102,457 increase in fair value, which has been recorded as non-cash costs included in general and administration expense in the accompanying condensed consolidated financial statements. CareView, as 50% owner of the LLCs, is currently negotiating with Rockwell to settle the debt of the LLCs through the issuance of shares of CareView’s Common Stock. Although CareView anticipates that this settlement will be forthcoming in the near future, CareView and the LLCs can give no assurances that a settlement will be negotiated, or if negotiated and settled, that it will be through the issuance of CareView’s Common Stock.

CAREVIEW COMMUNICATIONS, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

NOTE 10 – VARIABLE INTEREST ENTITIES

The Company consolidates VIEs of which it is the primary beneficiary. The liabilities recognized as a result of consolidating these VIEs do not necessarily represent additional claims on our general assets; rather, they represent claims against the specific assets of the consolidated VIEs. Conversely, assets recognized as a result of consolidating these VIEs do not represent additional assets that could be used to satisfy claims against our general assets.

The total consolidated VIE assets and liabilities reflected on our condensed consolidated balance sheets at March 31, 2016 and December 31, 2015 are as follows:

	March 31, 2016		December 31, 2015
Assets
Cash	$	332	$	2,146
Receivables		4,731		4,731
Total current assets		5,063		6,877
Property, net		43,463		50,382
Total assets	$	48,526	$	57,259

Liabilities
Accounts payable	$	134,573	$	132,170
Accrued interest		276,508		261,450
Other current liabilities		27,749		26,936
Notes payable		441,498		441,498
Mandatorily redeemable interest		441,498		441,498
Total liabilities	$	1,321,826	$	1,303,552

The financial performance of the consolidated VIEs reflected on our condensed consolidated statements of operations for the three months ended March 31, 2016 and 2015 is as follows:

	March 31,
	2016			2015
Revenue	$	7,097		$	7,097
Network operations expense		4,164			4,164
General and administrative expense		813			1,130
Depreciation		12,133			12,467
Total operating costs		17,110			17,761
Operating loss		(10,013	)		(10,664	)
Other expense		(22,207	)		(21,780	)
Loss before taxes		(32,220	)		(32,444	)
Provision for taxes		—			—
Net loss		(32,220	)		(32,444	)
Net loss attributable to noncontrolling interest		(16,110	)		(16,222	)
Net loss attributable to CareView Communications, Inc.	$	(16,110	)	$	(16,222	)

CAREVIEW COMMUNICATIONS, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

NOTE 11 – AGREEMENT WITH HEALTHCOR

On April 21, 2011, we entered into a Note and Warrant Purchase Agreement (as subsequently amended) (the “HealthCor Purchase Agreement”) with HealthCor. Pursuant to the terms HealthCor Purchase Agreement, we sold Senior Secured Convertible Notes to HealthCor in the principal amount of $9,316,000 and $10,684,000, respectively (collectively the “2011 HealthCor Notes”). The 2011 HealthCor Notes have a maturity date of April 20, 2021. We also issued Warrants to HealthCor for the purchase of an aggregate of up to 5,488,456 and 6,294,403 shares, respectively, of our Common Stock at an exercise price of $1.40 per share (collectively the “2011 HealthCor Warrants”).

So long as no event of default has occurred, the outstanding principal balances of the 2011 HealthCor Notes accrue interest from April 21, 2011 through April 20, 2016 (the “First Five Year Note Period”) at the rate of 12.5% per annum, compounding quarterly and shall be added to the outstanding principal balances of the 2011 HealthCor Notes on the last day of each calendar quarter. Interest accruing from April 21, 2016 through April 20, 2021 (the “Second Five Year Note Period”) at a rate of 10% per annum, compounding quarterly, may be paid quarterly in arrears in cash or, at our option, such interest may be added to the outstanding principal balances of the 2011 HealthCor Notes on the last day of each calendar quarter.

From the date any event of default occurs, the interest rate, then applicable, shall be increased by five percent (5%) per annum. HealthCor has the right, upon an event of default, to declare due and payable any unpaid principal amount of the 2011 HealthCor Notes then outstanding, plus previously accrued but unpaid interest and charges, together with the interest then scheduled to accrue (calculated at the default rate described in the immediately preceding sentence) through the end of the First Five Year Note Period or the Second Five Year Note Period, as applicable.

At any time after April 21, 2011, HealthCor is entitled to convert any portion of the outstanding and unpaid accrued interest on and principal balances of the 2011 HealthCor Notes into fully paid and non-assessable shares of our Common Stock at a conversion rate of $1.25 per share, subject to adjustment in accordance with anti-dilution provisions set forth in the 2011 HealthCor Notes. As of March 31, 2016, the underlying shares of our Common Stock related to the 2011 HealthCor Notes totaled approximately 30,000,000.

On January 31, 2012, we entered into the Second Amendment to the HealthCor Purchase Agreement with HealthCor (the “Second Amendment”) amending the HealthCor Purchase Agreement, and sold Senior Secured Convertible Notes to HealthCor in the principal amounts of $2,329,000 and $2,671,000, respectively (collectively the “2012 HealthCor Notes”). As provided by the Second Amendment, the 2012 HealthCor Notes are in substantially the same form as the 2011 HealthCor Notes, with changes to the “Issuance Date,” “Maturity Date,” “First Five Year Note Period” and other terms to take into account the timing of the issuance of the 2012 HealthCor Notes. The 2012 HealthCor Notes have a maturity date of January 30, 2022. In addition, the provisions regarding interest payments, interest acceleration, optional conversion, negative covenants, and events of default, preemptive rights and registration rights are the same as those of the 2011 HealthCor Notes. At any time after January 30, 2012, HealthCor is entitled to convert any portion of the outstanding and unpaid accrued interest on and principal balances of the 2012 HealthCor Notes into fully paid and non-assessable shares of our Common Stock at a conversion rate of $1.25 per share, subject to adjustment in accordance with anti-dilution provisions set forth in the 2012 HealthCor Notes. As of March 31, 2016, the underlying shares of our Common Stock related to the 2012 HealthCor Notes totaled approximately 7,000,000.

CAREVIEW COMMUNICATIONS, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

NOTE 11 – AGREEMENT WITH HEALTHCOR (Continued)

On August 20, 2013, we entered into a Third Amendment to the HealthCor Purchase Agreement with HealthCor (the “Third Amendment”) to redefine our minimum cash balance requirements. Previously we were required to maintain a minimum cash balance of $5,000,000 and should we drop below that balance, it triggered a default. The Third Amendment allowed for a reduced minimum cash period, as defined in the HealthCor Purchase Agreement, which allowed us to drop below $5,000,000, but not below $4,000,000. All other terms and conditions of the HealthCor Purchase Agreement, including all amendments thereto, remain the same. Upon entering the reduced minimum cash period (which occurred on October 7, 2013), we had 120 days to return our minimum cash balance to the original $5,000,000. On January 16, 2014, we increased our cash balance to in excess of the original $5,000,000 minimum allowable balance.

On January 16, 2014, we entered into a Fourth Amendment to the HealthCor Purchase Agreement with HealthCor (the “Fourth Amendment”) and sold Senior Secured Convertible Notes to HealthCor in the principal amounts of $2,329,000 and $2,671,000 (collectively the ‘‘2014 HealthCor Notes’’). As provided by the Fourth Amendment, the 2014 HealthCor Notes are in substantially the same form as the 2011 HealthCor Notes, with changes to the “Issuance Date,” “Maturity Date,” “First Five Year Note Period” and other terms to take into account the timing of the issuance of the 2014 HealthCor Notes. The 2014 HealthCor Notes have a maturity date of January 15, 2024. In addition, the provisions regarding interest payments, interest acceleration, optional conversion, negative covenants, and events of default, preemptive rights and registration rights are the same as those of the 2011 HealthCor Notes. At any time after January 16, 2014, HealthCor is entitled to convert any portion of the outstanding and unpaid accrued interest on and principal balances of the 2014 HealthCor Notes into fully paid and non-assessable shares of our Common Stock at a conversion rate of $0.40 per share, subject to adjustment in accordance with anti-dilution provisions set forth in the 2014 HealthCor Notes. Additionally we issued Warrants to HealthCor for the purchase of an aggregate of up to 4,000,000 shares of our Common Stock at an exercise price of $0.40 per share (collectively the “2014 HealthCor Warrants”). As of March 31, 2016, the underlying shares of our Common Stock related to the 2014 HealthCor Notes totaled approximately 16,000,000.

On December 4, 2014, we entered into a Fifth Amendment to the HealthCor Purchase Agreement (the “Fifth Amendment”) with HealthCor and certain additional investors (such additional investors, the “New Investors” and, collectively with HealthCor Partners Fund, LP, the “Investors”) and agreed to sell and issue (i) additional notes in the initial aggregate principal amount of $6,000,000,with a conversion price per share of $0.52 (subject to adjustment as described therein) (the “Fifth Amendment Notes”) and (ii) additional Warrants for an aggregate of up to 3,692,308 shares of our Common Stock at an exercise price per share of $0.52 (subject to adjustment as described therein) (the “Fifth Amendment Warrants”). As provided by the Fifth Amendment, the Fifth Amendment Notes are in substantially the same form as the 2011 HealthCor Notes, with changes to the “Issuance Date,” “Maturity Date,” “First Five Year Note Period” and other terms to take into account the timing of the issuance of the Fifth Amendment Notes. The Fifth Amendment Notes have a maturity date of February 16, 2025. In addition, the provisions regarding interest payments, interest acceleration, optional conversion, negative covenants, and events of default, preemptive rights and registration rights are the same as those of the 2011 HealthCor Notes. The New Investors are composed of all but one of our current directors and one of our officers. On February 17, 2015, the Company and the Investors closed on the transactions contemplated by the Fifth Amendment. In connection with this closing, the Company and the Investors entered into an Amended and Restated Pledge and Security Agreement (the “Amended Security Agreement”), amending and restating that certain Pledge and Security Agreement dated as of April 20, 2011, and an Amended and Restated Intellectual Property Security Agreement (the “Amended IP Security Agreement”), amending and restating that certain Intellectual Property Security Agreement dated as of April 20, 2011. As of March 31, 2016, the underlying shares of our Common Stock related to the Fifth Amendment Notes totaled approximately 2,000,000 to HealthCor and 11,000,000 to the New Investors.

CAREVIEW COMMUNICATIONS, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

NOTE 11 – AGREEMENT WITH HEALTHCOR (Continued)

On March 31, 2015, we entered into the Sixth Amendment to the HealthCor Purchase Agreement (the “Sixth Amendment”) pursuant to which, among other things, (i) the requirement to maintain a minimum cash balance of $5,000,000 was reduced to a minimum cash balance of $2,000,000 and (ii) the amendment provision was revised to permit the HealthCor Purchase Agreement to be amended by the Company and the holders of the majority of the Common Stock underlying the outstanding notes and warrants to purchase shares of our Common Stock sold pursuant to the HealthCor Purchase Agreement. On March 31, 2015, we also issued a warrant to HealthCor to purchase up to an aggregate of 1,000,000 shares of our Common Stock in consideration for certain prior waivers of the minimum cash balance requirement in the HealthCor Purchase Agreement (the “Sixth Amendment Warrant”). The Sixth Amendment Warrant has an exercise price per share of $0.53 (subject to adjustment as described therein) and an expiration date of March 31, 2025.

On June 26, 2015, we (i) entered into a Seventh Amendment to the HealthCor Purchase Agreement (the “Seventh Amendment”) pursuant to which the HealthCor Purchase Agreement was amended to permit the Company to enter into and perform its obligations under the Credit Agreement entered into with PDL BioPharma, Inc., as administrative agent and lender (the “Lender”) (the “PDL Credit Agreement”); (ii) executed an Amendment to the Registration Rights Agreement between the Company and HealthCor dated April 21, 2011 (the “RR Agreement”) pursuant to which the RR Agreement was amended to make its priority of registration consistent with the Registration Rights Agreement executed by the Company and Lender (as detailed in NOTE 12); (iii) amended the 2011 HealthCor Notes to extend the maturity date, in the event that Tranche Two of the PDL Credit Agreement is funded, for such notes to 90 days after the earlier of the Tranche Two maturity date or repayment date, but not later than December 31, 2022, (iv) amended the 2012 HealthCor Notes, to set the maturity date at January 30, 2022 and, in the event that Tranche Two of the PDL Credit Agreement is funded, to extend such maturity date to 90 days after the earlier of the Tranche Two maturity date or repayment date, but later than December 31, 2022; and (v) amended each of the Senior Secured Convertible Notes issued under the HealthCor Purchase Agreement (the “HealthCor Notes”) to, among other things, subordinate the HealthCor Notes to the loans under the PDL Credit Agreement (as detailed in NOTE 12) and to increase certain event of default acceleration and payment thresholds.

Accounting Treatment

When issuing debt or equity securities convertible into common stock at a discount to the fair value of the common stock at the date the debt or equity financing is committed, a company is required to record a beneficial conversion feature (“BCF”) charge. We had three separate issuances of equity securities convertible into common stock that qualify under this accounting treatment, (i) the 2011 HealthCor Notes, (ii) the 2012 HealthCor Notes and (iii) the 2014 HealthCor Notes. Because the conversion option and the 2011 HealthCor Warrants on the 2011 HealthCor Notes were originally classified as a liability when issued due to the down round provision and the removal of the provision requiring liability treatment, and subsequently reclassified to equity on December 31, 2011 when the 2011 HealthCor Notes were amended, only the accrued interest capitalized as payment in kind (‘‘PIK’’) since reclassification qualifies under this accounting treatment. The face amount of the 2012 and 2014 HealthCor Notes and all accrued PIK interest also qualify for this accounting treatment. During the three months ended March 31, 2016 and 2015, we recorded a BCF of $516,844 and $456,987, respectively. The BCF was recorded as a charge to debt discount and a credit to additional paid in capital, with the debt discount, using the effective interest method, amortized to interest expense over the term of the notes. As Warrants were issued with the Fifth Amendment Notes, the proceeds were allocated to the instruments based on relative fair value as the Warrants did not contain any features requiring liability treatment and therefore were classified as equity. The Warrants issued with the Sixth Amendment also did not contain features requiring liability accounting and were recorded at fair value on the date of issuance with the offsetting credit recorded in equity. The value allocated to the Fifth Amendment Warrants was $1,093,105, which was

CAREVIEW COMMUNICATIONS, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

NOTE 11 – AGREEMENT WITH HEALTHCOR (Continued)

Accounting Treatment (continued)

recorded as debt discount with the credit to additional paid in capital. We recorded an aggregate of $592,688 and $552,066 in interest expense for the three months ended March 31, 2016 and 2015, respectively, related to these transactions. The carrying value of the debt with HealthCor and the New Investors at March 31, 2016 approximates fair value as the interest rates used are those currently available to us and would be considered level 3 inputs under the fair value hierarchy.

The value allocated to the Sixth Amendment Warrant was $378,000, which was recorded as deferred debt costs with the credit to additional paid in capital. We recorded an aggregate of $14,450 in financing costs for the three months ended March 31, 2016 related to this transaction.

NOTE 12 – AGREEMENT WITH PDL BIOPHARMA, INC.

On June 26, 2015, we entered into a Credit Agreement with PDL BioPharma, Inc., as administrative agent and lender (“PDL” or the “Lender”) (the “PDL Credit Agreement”). Under the PDL Credit Agreement the Lender made available to us up to $40 million in two tranches of $20 million each.

Certain covenants of the PDL Credit Agreement include (a) in the event that a milestone relating to the placement of 9,000 billable units occurs on or before October 31, 2015, the Lender will fund us $20 million (the “Tranche One Loan”) and (b) in the event that additional milestones relating to (i) the placement of 27,750 billable units and (ii) the Company recording earnings before interest, tax, depreciation, and amortization (EBITDA) of not less than $7,000,000 on an annualized basis for the three calendar month period prior to the funding (on or before June 30, 2017), the Lender will fund us an additional $20 million (the “Tranche Two Loan” and, together with the Tranche One Loan, the “Loans”). Outstanding borrowings under the Tranche One Loan bear interest at the rate of 13.5% per annum, payable quarterly in arrears. Outstanding borrowings under the Tranche Two Loan bear interest at the rate of 13.0% per annum, payable quarterly in arrears. From the date any event of default occurs, the interest rate shall be increased by five percent (5%) per annum. The PDL Credit Agreement includes a minimum cash balance requirement of $3,250,000 and should we drop below $3,250,000, it will trigger a default. The $3,250,000 has been recorded as restricted cash on the condensed consolidated balance sheets at March 31, 2016 and December 31, 2015.

On October 7, 2015, the Company entered into a First Amendment (the “First Amendment”) to the PDL Credit Agreement. The First Amendment modified the conditions precedent to the funding of each tranche, such that, among other things, we no longer need to attain a specified milestone relating to the placement of our products in order for the Lender to fund us the Tranche One Loan. Contemporaneously with the execution of the First Amendment we borrowed the Tranche One Loan and issued to the Lender a term note in the principal amount of $20 million (the “Tranche One Term Note”), payable in accordance with the terms of the Credit Agreement, as amended. The First Amendment also included a revision to the Tranche Two Milestone, which changed from a minimum of 27,750 billable units (defined as one unit for each room control platform and two units for each nurse station monitor) to 31,500 Bed Equivalent Units (defined as a billable unit plus 14 units for each head-end server operating as the communication center and fractional units for mobile assets as applicable).

CAREVIEW COMMUNICATIONS, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

NOTE 12 – AGREEMENT WITH PDL BIOPHARMA, INC. (Continued)

Once funded, the PDL Credit Agreement requires interest only payments for the first eight interest payment dates and principal plus interest payments will commence on the ninth interest payment date. We may elect to pay a portion of the interest due in the form of additional loans (interest paid in kind) during the first eight interest payment dates. The first principal payment on the Tranche One Term Note is due on January 8, 2018 in the amount of $1,666,667, with similar amounts due quarterly thereafter with the final payment due on October 8, 2020. Each tranche will mature on the fifth anniversary of the date borrowed. We may elect to prepay the Loans at any time without any premium or penalty, subject to certain conditions.

The obligations under the PDL Credit Agreement are secured by a pledge of substantially all of the assets of the Company and certain of its domestic subsidiaries. We executed a Subordination and Intercreditor Agreement (the “Subordination and Intercreditor Agreement”), with the Lender, HealthCor and the New Investors (as defined in NOTE 11) pursuant to which we granted first-priority liens on our pledged assets to the Lender and second-priority liens on such pledged assets to HealthCor and the New Investors.

The PDL Credit Agreement contains customary affirmative covenants for transactions of this type and other affirmative covenants agreed to by the Company and the Lender, including, among others, the provision of annual and quarterly reports, maintenance of property, insurance, compliance with laws and contractual obligations and payment of taxes. The PDL Credit Agreement contains customary negative covenants for transactions of this type and other negative covenants agreed to by the Company and the Lender, including, among others, restrictions on the incurrence of indebtedness, the granting of liens, making restricted payments and investments, entering into affiliate transactions and transferring assets. The PDL Credit Agreement also provides for a number of customary events of default, including payment, bankruptcy, covenant, representation and warranty and judgment defaults.

Contemporaneously with the execution of the PDL Credit Agreement, we issued to the Lender a warrant to purchase 4,444,445 shares of our Common Stock at an exercise price of $0.45 per share, subject to adjustment as described therein (the “PDL Warrant”). The PDL Warrant expires on June 26, 2025. Pursuant to the terms of the First Amendment we amended and restated the PDL Warrant, reducing the exercise price per share from $0.45 to $0.40 (the “Amended Warrant”). All other provisions of the Amended Warrant remained unchanged.

In addition, contemporaneously with the execution of the PDL Credit Agreement the Company and the Lender executed (i) a Registration Rights Agreement pursuant to which the Company agreed to provide the Lender with certain registration rights with respect to the shares of Common Stock issuable upon exercise of the PDL Warrant (the “PDL RRA”), (ii) a Guarantee and Collateral Agreement (the “Guarantee and Collateral Agreement”) pursuant to which certain of our subsidiaries guaranteed the performance of our obligations under the PDL Credit Agreement and granted the Lender a security interest in such subsidiaries’ tangible and intangible assets securing our performance of the same, and (iii) a Patent Security Agreement and a Trademark Security Agreement pursuant to which we granted the Lender a security interest in a certain subsidiary’s tangible and intangible assets securing the performance of our obligations under the PDL Credit Agreement.

CAREVIEW COMMUNICATIONS, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

NOTE 12 – AGREEMENT WITH PDL BIOPHARMA, INC. (Continued)

Accounting Treatment

In connection with the Credit Agreement, we issued the PDL Warrant to the Lender. The fair value of the PDL Warrant at issuance was $1,257,778, which has been recorded as deferred issuance costs in the accompanying condensed consolidated financial statements. The deferred debt issuance costs associated with the PDL Credit Agreement are recorded as assets in accordance with the accounting standards as the PDL Credit Agreement is considered to be a credit facility and the warrants were payment for the facility and not the drawdowns. These costs are amortized to interest expense using the straight line method over the term of the Credit Agreement. Upon amendment of the PDL Warrant, we evaluated whether there was an increase in fair value which would require recognition of additional costs. No such increase in fair value was noted and no adjustment to the PDL Warrant valuation was necessary. For the three months ended March 31, 2016, $44,922 was amortized to interest expense. For the period from June 25, 2015 through December 31, 2015, $91,840 was amortized to interest expense. The PDL Warrant has not been exercised. We also incurred certain financing costs totaling $805,917 in the accompanying condensed consolidated financial statements. These costs have been recorded as deferred financing costs and are being amortized to interest expense over the term of the Credit Agreement. For the three months ended March 31, 2016, $27,849 was amortized to interest expense. For the period from June 25, 2015 through December 31, 2015, $74,071 has been amortized.

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

General

The following discussion and analysis provides information which our management believes to be relevant to an assessment and understanding of our results of operations and financial condition. This discussion should be read together with our financial statements and the notes to the financial statements, which are included in this Quarterly Report on Form 10-Q (the “Report”). This information should also be read in conjunction with the information contained in our Form 10-K filed with the Securities and Exchange Commission (the “SEC”) on March 30, 2016, including the audited consolidated financial statements and notes included therein as of and for the year ended December 31, 2015. The reported results will not necessarily reflect future results of operations or financial condition.

Throughout this Annual Report on Form 10-K (the “Report”), the terms “we,” “us,” “our,” “CareView,” or “Company” refers to CareView Communications, Inc., a Nevada corporation, and unless otherwise specified, includes our wholly owned subsidiaries, CareView Communications, Inc., a Texas corporation (“CareView-TX”) and CareView Operations, LLC, a Nevada limited liability company (“CareView Operations”) (collectively known as the “Company’s Subsidiaries”) and its LLCs, CareView-Hillcrest and CareView-Saline, determined to be variable interest entities (“VIEs”) in which the Company exercises control and is deemed the Primary Beneficiary (collectively known as the “Company’s LLCs”).

We maintain a website at www.care-view.com and our Common Stock trades on the OTCQB under the symbol “CRVW.’’

Company Overview

Our mission is to be the leading provider of products and on-demand application services for the healthcare industry, specializing in bedside video monitoring, software tools to improve hospital communications and operations, and patient education and entertainment packages. Our proprietary, high-speed data network system is the next generation of patient care monitoring that allows real-time bedside and point-of-care video monitoring designed to improve patient safety and overall hospital costs. The entertainment packages and patient education enhance the patient’s quality of stay. Reported results from CareView-driven hospitals prove that our products reduce falls, reduce the cost of sitter fees, increase patient satisfaction and reduce bed turnaround time to increase patient flow. For patients, we have a convenient in-room, entertainment package that includes high-speed Internet, access to first-run on-demand movies and visual connectivity to family and friends from anywhere in the world. For the hospital, we offer tools to provide superior patient care, peace of mind and customer service satisfaction.

Our CareView System^® suite of video monitoring, guest services and related applications connect patients, families and healthcare providers. Through the use of telecommunications technology and the Internet, our evolving products and on-demand services greatly increase the access to quality medical care and education for patients/consumers and healthcare professionals. We understand the importance of providing high quality patient care in a safe environment and believe in partnering with hospitals to improve the quality of patient care and safety by providing a system that monitors and records continuously. We are committed to providing an affordable video monitoring tool to improve the practice of nursing, create a better work environment and make the patient’s hospital stay more informative and satisfying. Our suite of products and services can simplify and streamline the task of preventing and managing patients’ falls, enhance patient safety, improve quality of care and reduce costs associated with bringing information technology directly to patients, families and healthcare providers. Our products and services can be used in all types of hospitals, nursing homes, adult living centers and selected outpatient care facilities domestically and internationally.

CareView’s secure video monitoring system connects the patient room to a touch-screen monitor at the nursing station or a mobile handheld device, allowing the nursing staff to maintain a level of visual contact with each patient. This configuration enhances the use of the nurse call system, reduces unnecessary steps to and from patient rooms, and facilitates a host of modules for patient safety and workflow improvements. The CareView System suite can be easily configured to meet the individual privacy and security requirements of any hospital or nursing facility. The Health Insurance Portability and Accountability Act of 1996 (“HIPAA’) compliant, patient approved video record can be included as part of the patient’s medical record and serves as additional documentation of bedside care, procedures performed, patient and hospital ancillary activities, safety or care incidents, support to necessitate additional clinical services, and, if necessary, as evidence. Additional HIPAA-compliance features allow privacy options to be enabled at any time by the patient, nurse or physician.

In addition to patient safety and security, we also provides a suite of services to increase patient satisfaction scores and enhance the overall image of the hospital including first-run on-demand movies, Internet access via the patient’s television, and video visits with family and friends from most places throughout the world. Through continued investment in patient care technology, our products and services help hospitals and assisted living facilities build a safe, high quality healthcare delivery system that best serves the patient, while striving for the highest level of satisfaction and comfort.

Events Occurring During First Quarter 2016

During the three months ended March 31, 2016, we granted options to purchase 20,000 shares of our Common Stock (the ‘‘Option(s)’’) to an employee. Also during the same three month period, 65,002 Options were canceled and 66,667 Options expired.

Summary of Product and Service Usage

The following table shows the number of healthcare facilities using our products and services including the number of deployed units, installed units and billable units as of April 30, 2016. The table also shows the number of pilot programs in place and hospital proposals pending approval, estimated bed count if the pilot programs and pending proposals result in executed contracts, and the estimated total number of licensed beds available under the pilot programs and hospital proposals. There are no assurances that the pilot programs will be extended or the pending proposals will be approved to ultimately result in the number of estimated beds. Further, there are no assurances that we will have access to the total number of licensed beds in each healthcare facility.

Installed Hospitals				Installed Units				Billable Units				Total Staffed Beds in Contracted/ Pilot Hospitals				*Potential Units Available Under Current Contract/Pilot Contracts^()**				Units in Negotiation Prior to Contract/ Pilot
	106				9,160				8,148				131,158				56,239				36,750

______________________

(*) This number represents management’s best estimate of the number of units available to us in hospitals that are currently under contract. We assume that in any given acute care facility, our products and services are appropriate for deployment in approximately 70% of the total staffed beds. If we have specific information from a current contracted or pilot hospital that the number of potential units in that hospital is either higher or lower than 70%, specific number has been used in the aggregate estimate.

Results of Operations

Three months ended March 31, 2016 compared to three months ended March 31, 2015

	Three months ended March 31,
	2016			2015			Change
	(000’s)
Revenue	$	1,496		$	1,001		$	495
Operating expenses		3,123			2,507			616
Operating loss		(1,627	)		(1,506	)		(121	)
Other, net		(3,057	)		(2,282	)		(775	)
Net loss		(4,684	)		(3,788	)		(896	)

Net income (loss) attributable to noncontrolling interest		(16	)		(16	)		—
Net loss attributed to CareView	$	(4,668	)	$	(3,772	)	$	(896	)

Revenue

Revenue increased approximately $495,000 for the three months ended March 31, 2016 as compared to the same period in 2015. This increase is a direct result of hospitals with billable units improving from 93 on March 31, 2015 to 94 on March 31, 2016. Of the 94 hospitals with billable units on March 31, 2016, two hospital groups accounted for 46% of the total. Billable units (RCPs and Nurse Stations) for all hospitals totaled 8,227 (7,658 and 569, respectively) on March 31, 2016 as compared to 5,411 (5,091 and 320, respectively) on March 31, 2015.

Operating Expenses

Our principal operating costs include the following items as a percentage of total operating expense.

	Three Months Ended March 31,
	2016			2015
Human resource costs, including non-cash compensation		48	%		48	%
Professional and consulting costs		8	%		2	%
Depreciation and amortization		14	%		17	%
Oher product deployment costs		10	%		7	%
Travel and entertainment expense		9	%		12	%
Other expenses, net		11	%		14	%

Operating expenses increased by 25% as a result of the following items:

		(000’s)
Increase:
Human resource costs, including benefits	$	283
Professional and consulting costs		189
Other product deployment costs, excluding human resources and travel and entertainment expense		148
Depreciation and amortization		30
Decrease:
Travel and entertainment expense		(14	)
Other expenses		(20	)
	$	616

Human resource related costs (including salaries and benefits) increased primarily as a result of a higher average head count during the three months ended March 31, 2016 compared to the same period in 2015. While we had 72 employees at March 31, 2016 as compared to 56 for the comparable date for the prior year, on average we employed 74 employees over the course of current period as compared to 54 for the comparable prior year period. Professional and consulting fees increased approximately $189,000. The increase in product deployment costs is primarily a result of a $48,000 accrual for product removal costs recorded during the three months ended March 31, 2016 coupled with a reversal of $98,500 in previously accrued product removal costs recovered during the three months ended March 31, 2015.

Other, net

Other non-operating income and expense increased by $775,000, or 34%, for the three months ended March 31, 2016 in comparison to the same period in 2015, primarily a result of an increase in interest expense related to the HealthCor and PLD funding transactions, partially offset by the favorable change in fair value of warrant liability related to warrants sold in conjunction with our April 2013 private placement totaling approximately $323,000.

Net Loss Attributable to CareView Communications, Inc.

As a result of the factors above, and after applying the $16,000 net loss attributed to noncontrolling interests, our first quarter 2016 net loss of $4,668,000 increased $896,000, or 24%, as compared to the $3,772,000 net loss for the first quarter of 2015.

Liquidity and Capital Resources

Our cash position at March 31, 2016 was approximately $15,569,000. We also have $3,250,000 recorded as restricted cash related to a debt covenant in our credit agreement with PDL BioPharma, Inc.

At present, we have sufficient inventory to install and service a select number of large customers, but eventually we will need to address additional capital requirements. To that end, on June 26, 2015, we entered into a Credit Agreement with PDL Biopharma, Inc., as administrative agent and lender (the “PDL or the “Lender”), (the “PDL Credit Agreement”) pursuant to which the Lender made available to us up to $40 million in two tranches of $20 million each, with each tranche contingent upon us meeting certain milestones. On October 7, 2015, pursuant to the First Amendment to the PDL Credit Agreement (the “First Amendment”) the Lender made the first tranche of $20 million available and funded us $19,533,992, net of fees. As of March 31, 2016, we are including $20 million in long-term liabilities on the accompanying condensed consolidated financial statements. Pursuant to the terms of the PDL Credit Agreement, we are required to maintain a minimum cash balance $3,250,000, and we are in compliance with the minimum cash balance as of the date of this filing (see NOTE 13 for further details). No funds under the second tranche of the PDL Credit Agreement were available to us as of March 31, 2016.

Off-Balance Sheet Arrangements

As of March 31, 2016, we had no material off-balance sheet arrangements.

In the ordinary course of business, we enter into agreements with third parties that include indemnification provisions which, in our judgment, are normal and customary for companies in our industry sector. These agreements are typically with business partners, clinical sites, and suppliers. Pursuant to these agreements, we generally agree to indemnify, hold harmless, and reimburse indemnified parties for losses suffered or incurred by the indemnified parties with respect to our product candidates, use of such product candidates, or other actions taken or omitted by us. The maximum potential amount of future payments we could be required to make under these indemnification provisions is unlimited. We have not incurred material costs to defend lawsuits or settle claims related to these indemnification provisions. As a result, the estimated fair value of liabilities relating to these provisions is minimal. Accordingly, we have no liabilities recorded for these provisions as of March 31, 2016.

In the normal course of business, we may be confronted with issues or events that may result in a contingent liability. These generally relate to lawsuits, claims, environmental actions or the actions of various regulatory agencies. We consult with counsel and other appropriate experts to assess the claim. If, in our opinion, we have incurred a probable loss as set forth by accounting principles generally accepted in the U.S., an estimate is made of the loss and the appropriate accounting entries are reflected in our financial statements. After consultation with legal counsel, we do not anticipate that liabilities arising out of currently threatened lawsuits and claims, if any, will have a material adverse effect on our financial position, results of operations or cash flows.

Critical Accounting Estimates

Please refer to our Annual Report on Form 10-K for the year ended December 31, 2015 filed with the Commission on March 30, 2016 and incorporated herein by reference, for detailed explanations of our critical accounting estimates, which have not changed significantly during the three months ended March 31, 2016.

New Accounting Pronouncements

Recent Events

None.

Item 3. Quantitative and Qualitative Disclosures about Market Risk

None.

Item 4. Controls and Procedures

Disclosure Controls and Procedures

Disclosure controls and procedures are designed to ensure that information required to be disclosed in the reports filed or submitted under the Securities Exchange Act of 1934 (the “Exchange Act”) is recorded, processed, summarized and reported, within the time period specified in the SEC’s rules and forms and is accumulated and communicated to our management, as appropriate, in order to allow timely decisions in connection with required disclosure.

Evaluation of Disclosure Controls and Procedures

Pursuant to Rule 13a-15(b) under the Securities Exchange Act of 1934 (“Exchange Act”), we carried out an evaluation, with the participation of our management, including Steve G. Johnson, our Chief Executive Officer (“CEO”) and principal executive officer, and L. Allen Wheeler, our principal financial officer and chief accounting officer, of the effectiveness of our disclosure controls and procedures (as defined under Rule 13a-15(e) under the Exchange Act) as of the end of the period covered by this Report.

Based upon that evaluation, our CEO and Chief Accounting Officer concluded that our disclosure controls and procedures were effective as of March 31, 2016 to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act, is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to our management, including our CEO and Chief Accounting Officer, as appropriate, to allow timely decisions regarding required disclosure.

Changes in Internal Controls

During the three months ended March 31, 2016, there were no changes in our internal control over financial reporting that occurred that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II - OTHER INFORMATION

Item 1. Legal Proceedings.

None.

Item 1A. Risk Factors.

Our Company is a “smaller reporting company” as defined by Rule 12b-2 of the Exchange Act, and as such, is not required to provide the information required under this Item.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

None.

Item 3. Defaults Upon Senior Securities.

None.

Item 4. Mine Safety Disclosures.

Not applicable.

Item 5. Other Information.

None.

Item 6. Exhibits.

Exhibit No.	Date of Document	Name of Document

31.1	5/13/16	Certification of Chief Executive Officer of Periodic Report pursuant to Rule 13a-14a and Rule 14d-14(a).*
31.2	5/13/16	Certification of Chief Financial Officer of Periodic Report pursuant to Rule 13a-14a and Rule 15d-14(a).*
32.1	5/13/16	Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350.*
32.2	5/13/16	Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350.*
101.INS	n/a	XBRL Instance Document*
101.SCH	n/a	XBRL Taxonomy Extension Schema Document*
101.CAL	n/a	XBRL Taxonomy Extension Calculation Linkbase Document*
101.DEF	n/a	XBRL Taxonomy Extension Definition Linkbase Document*
101.LAB	n/a	XBRL Taxonomy Extension Label Linkbase Document*
101.PRE	n/a	XBRL Taxonomy Extension Presentation Linkbase Document*

___________________

Filed herewith.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

DATE: May 13, 2016

	CAREVIEW COMMUNICATIONS, INC.


	By:	/s/ Steven G. Johnson
		Steven G. Johnson
		Chief Executive Officer
		Principal Executive Officer

	By:	/s/ L. Allen Wheeler
		L. Allen Wheeler
		Principal Financial Officer
		Chief Accounting Officer

EX-31.1 2 ex31-1.htm CERTIFICATION OF CHIEF EXECUTIVE OFFICER

CareView Communications, Inc. 10-Q

Exhibit 31.1

CERTIFICATION PURSUANT TO

SECTION 302 OF

THE SARBANES-OXLEY ACT OF 2002

I, Steven G. Johnson, certify that:

	(1)	I have reviewed this quarterly report on Form 10-Q of CareView Communications, Inc.;

	(2)	Based on my knowledge, this report does not contain any untrue statements of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report’

	(3)	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

	(4)	The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

	a.	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

	b.	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

	c.	Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluations; and

	d.	Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

	(5)	The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of the internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

	a.	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

May 13, 2016	/s/ Steven G. Johnson
	Steven G. Johnson
	Chief Executive Officer
	Principal Executive Officer

EX-31.2 3 ex31-2.htm CERTIFICATION OF CHIEF FINANCIAL OFFICER

CareView Communications, Inc. 10-Q

Exhibit 31.2

CERTIFICATION PURSUANT TO

SECTION 302 OF

THE SARBANES-OXLEY ACT OF 2002

I, L. Allen Wheeler, certify that:

	(1)	I have reviewed this quarterly report on Form 10-Q of CareView Communications, Inc.;

	(2)	Based on my knowledge, this report does not contain any untrue statements of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report’

	(3)	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

	(4)	The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

	a.	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

	b.	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

	c.	Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluations; and

	d.	Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

	(5)	The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of the internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

	a.	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

May 13, 2016	/s/ L. Allen Wheeler
	L. Allen Wheeler
	Principal Financial Officer
	Chief Account Officer

EX-32.1 4 ex32-1.htm CERTIFICATION OF CHIEF EXECUTIVE OFFICER

CareView Communications, Inc. 10-Q

EXHIBIT 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the quarterly report of CareView Communications, Inc. (the “Company”) on Form 10-Q for the period ending March 31, 2016, as filed with the Securities and Exchange Commission (the “Report”), I, Steven G. Johnson, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

(1)

The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)

The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

/s/ Steven G. Johnson

Steven G. Johnson

Chief Executive Officer

May 13, 2016

A signed original of this certification has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

EX-32.2 5 ex32-2.htm CERTIFICATION OF CHIEF FINANCIAL OFFICER

CareView Communications, Inc. 10-Q

EXHIBIT 32.2

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the quarterly report of CareView Communications, Inc. (the “Company”) on Form 10-Q for the period ending March 31, 2016, as filed with the Securities and Exchange Commission (the “Report”), I, L. Allen Wheeler, Principal Financial Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

(1)

The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)

The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

/s/ L. Allen Wheeler

L. Allen Wheeler

Principal Financial Officer

May 13, 2016

A signed original of this certification has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

EX-101.INS 6 crvw-20160331.xml XBRL INSTANCE DOCUMENT 0001377149 2016-01-01 2016-03-31 0001377149 2016-05-13 0001377149 us-gaap:CommonStockMember 2015-12-31 0001377149 us-gaap:CommonStockMember 2016-03-31 0001377149 us-gaap:AdditionalPaidInCapitalMember 2016-01-01 2016-03-31 0001377149 us-gaap:AdditionalPaidInCapitalMember 2015-12-31 0001377149 us-gaap:AdditionalPaidInCapitalMember 2016-03-31 0001377149 us-gaap:RetainedEarningsMember 2016-01-01 2016-03-31 0001377149 us-gaap:RetainedEarningsMember 2015-12-31 0001377149 us-gaap:RetainedEarningsMember 2016-03-31 0001377149 us-gaap:NoncontrollingInterestMember 2016-01-01 2016-03-31 0001377149 us-gaap:NoncontrollingInterestMember 2015-12-31 0001377149 us-gaap:NoncontrollingInterestMember 2016-03-31 0001377149 2015-12-31 0001377149 2016-03-31 0001377149 us-gaap:ConvertibleDebtMember 2016-03-31 0001377149 us-gaap:ConvertibleDebtMember 2015-12-31 0001377149 2015-01-01 2015-03-31 0001377149 2014-12-31 0001377149 2015-03-31 0001377149 crvw:HealthCor3Member crvw:ConvertibleDebt2Member crvw:SecondFiveYearNotePeriodMember 2011-04-20 2011-04-21 0001377149 crvw:HealthCor3Member crvw:ConvertibleDebt2Member crvw:FirstFiveYearNotePeriodMember 2011-04-20 2011-04-21 0001377149 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel3Member 2016-03-31 0001377149 us-gaap:FairValueMeasurementsRecurringMember us-gaap:EstimateOfFairValueFairValueDisclosureMember 2016-03-31 0001377149 crvw:PDLBioPharmaIncMember 2015-06-26 0001377149 crvw:PDLBioPharmaIncMember us-gaap:SecuredDebtMember 2016-03-31 0001377149 crvw:PDLBioPharmaIncMember crvw:SecuredDebt1Member 2016-03-31 0001377149 2015-10-06 2015-10-07 0001377149 us-gaap:StockOptionMember 2016-01-01 2016-03-31 0001377149 us-gaap:StockOptionMember 2015-01-01 2015-12-31 0001377149 us-gaap:StockOptionMember us-gaap:MinimumMember 2015-01-01 2015-12-31 0001377149 us-gaap:StockOptionMember us-gaap:MaximumMember 2015-01-01 2015-12-31 0001377149 crvw:HealthCor4Member 2015-02-17 0001377149 crvw:HealthCor4Member crvw:LongTermDebt1Member 2015-02-16 2015-02-17 0001377149 crvw:Warrant1Member 2016-03-31 0001377149 crvw:Warrant1Member 2016-01-01 2016-03-31 0001377149 crvw:HealthCorMember crvw:WarrantPurchaseAgreementMember 2015-03-31 0001377149 crvw:HealthCorMember crvw:WarrantPurchaseAgreementMember 2015-03-30 2015-03-31 0001377149 us-gaap:WarrantMember 2015-01-01 2015-03-31 0001377149 us-gaap:StockOptionMember crvw:Employee1Member 2015-01-01 2015-03-31 0001377149 crvw:NetworkEquipmentMember 2015-12-31 0001377149 us-gaap:OfficeEquipmentMember 2015-12-31 0001377149 us-gaap:VehiclesMember 2015-12-31 0001377149 crvw:TestEquipmentMember 2015-12-31 0001377149 us-gaap:FurnitureAndFixturesMember 2015-12-31 0001377149 us-gaap:EquipmentMember 2015-12-31 0001377149 us-gaap:LeaseholdImprovementsMember 2015-12-31 0001377149 crvw:NetworkEquipmentMember 2016-03-31 0001377149 us-gaap:OfficeEquipmentMember 2016-03-31 0001377149 us-gaap:VehiclesMember 2016-03-31 0001377149 crvw:TestEquipmentMember 2016-03-31 0001377149 us-gaap:FurnitureAndFixturesMember 2016-03-31 0001377149 us-gaap:EquipmentMember 2016-03-31 0001377149 us-gaap:LeaseholdImprovementsMember 2016-03-31 0001377149 crvw:PatentsTrademarksMember 2016-03-31 0001377149 us-gaap:OtherIntangibleAssetsMember 2016-03-31 0001377149 crvw:PatentsTrademarksMember 2015-12-31 0001377149 us-gaap:OtherIntangibleAssetsMember 2015-12-31 0001377149 crvw:DeferredDebtIssuanceCostsMember 2016-03-31 0001377149 crvw:PrepaidFinancingCostsMember 2016-03-31 0001377149 crvw:DeferredInstallationCostsMember 2016-03-31 0001377149 crvw:PrepaidLicenseFeeMember 2016-03-31 0001377149 crvw:SecurityDepositMember 2016-03-31 0001377149 crvw:DeferredDebtIssuanceCostsMember 2015-12-31 0001377149 crvw:DeferredFinancingCostsMember 2015-12-31 0001377149 crvw:DeferredInstallationCostsMember 2015-12-31 0001377149 crvw:PrepaidLicenseFeeMember 2015-12-31 0001377149 crvw:SecurityDepositMember 2015-12-31 0001377149 crvw:RockwellMember us-gaap:WarrantMember 2009-11-15 2009-11-16 0001377149 crvw:RockwellMember 2009-11-15 2009-11-16 0001377149 crvw:RockwellMember 2009-11-16 0001377149 crvw:RockwellMember 2016-03-31 0001377149 crvw:RockwellMember 2015-10-01 2015-10-31 0001377149 crvw:RockwellMember 2012-01-26 2012-01-27 0001377149 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember 2016-03-31 0001377149 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember 2015-12-31 0001377149 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember 2016-01-01 2016-03-31 0001377149 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember 2015-01-01 2015-03-31 0001377149 crvw:PDLBioPharmaIncMember us-gaap:SecuredDebtMember 2015-06-26 0001377149 crvw:PDLBioPharmaIncMember crvw:SecuredDebt1Member 2015-06-26 0001377149 crvw:PDLBioPharmaInc1Member crvw:SecuredDebt1Member 2015-10-07 0001377149 crvw:PDLBioPharmaIncMember us-gaap:SecuredDebtMember 2015-06-25 2015-06-26 0001377149 crvw:PDLBioPharmaIncMember crvw:SecuredDebt1Member 2015-06-25 2015-06-26 0001377149 crvw:PDLBioPharmaIncMember 2015-06-25 2015-06-26 0001377149 crvw:PDLBioPharmaInc1Member crvw:SecuredDebt1Member 2015-10-06 2015-10-07 0001377149 crvw:PDLBioPharmaIncMember us-gaap:WarrantMember 2015-06-26 0001377149 crvw:PDLBioPharmaIncMember us-gaap:WarrantMember 2015-06-25 2015-06-26 0001377149 crvw:PDLBioPharmaInc1Member us-gaap:WarrantMember 2015-10-07 0001377149 crvw:PDLBioPharmaInc2Member us-gaap:WarrantMember 2015-10-07 0001377149 crvw:PDLBioPharmaIncMember us-gaap:WarrantMember 2016-03-31 0001377149 crvw:PDLBioPharmaIncMember us-gaap:WarrantMember 2016-01-01 2016-03-31 0001377149 crvw:PDLBioPharmaIncMember us-gaap:WarrantMember 2015-06-25 2015-12-31 0001377149 crvw:HealthCor3Member us-gaap:ConvertibleDebtMember 2011-04-21 0001377149 crvw:HealthCor3Member us-gaap:ConvertibleDebtMember 2011-04-20 2011-04-21 0001377149 crvw:HealthCor3Member crvw:ConvertibleDebt1Member 2011-04-21 0001377149 crvw:HealthCor3Member crvw:ConvertibleDebt1Member 2011-04-20 2011-04-21 0001377149 crvw:HealthCor3Member crvw:ConvertibleDebt2Member 2011-04-20 2011-04-21 0001377149 crvw:HealthCor3Member crvw:ConvertibleDebt2Member 2011-04-21 0001377149 crvw:HealthCor3Member crvw:ConvertibleDebt2Member 2016-01-01 2016-03-31 0001377149 crvw:HealthCor4Member crvw:ConvertibleDebt3Member 2016-01-01 2016-03-31 0001377149 crvw:HealthCor4Member crvw:ConvertibleDebt3Member 2012-01-31 0001377149 crvw:HealthCor4Member crvw:ConvertibleDebt4Member 2012-01-30 2012-01-31 0001377149 crvw:HealthCor4Member crvw:ConvertibleDebt4Member 2012-01-31 0001377149 crvw:HealthCor4Member crvw:ConvertibleDebt5Member 2012-01-30 2012-01-31 0001377149 crvw:HealthCor4Member crvw:ConvertibleDebt5Member 2012-01-31 0001377149 crvw:HealthCor5Member 2013-08-21 0001377149 crvw:HealthCor5Member us-gaap:MinimumMember 2013-08-21 0001377149 crvw:HealthCor5Member us-gaap:MaximumMember 2013-08-21 0001377149 crvw:HealthCor6Member crvw:ConvertibleDebt6Member 2014-01-16 0001377149 crvw:HealthCor6Member crvw:ConvertibleDebt7Member 2014-01-16 0001377149 crvw:HealthCor6Member crvw:ConvertibleDebt8Member 2014-01-15 2014-01-16 0001377149 crvw:HealthCor6Member crvw:ConvertibleDebt8Member 2014-01-16 0001377149 crvw:HealthCor6Member crvw:ConvertibleDebt8Member 2016-01-01 2016-03-31 0001377149 crvw:HealthCor7Member 2014-12-03 2014-12-04 0001377149 crvw:HealthCor7Member 2014-12-04 0001377149 crvw:HealthCor7Member crvw:HealthCorNewInvestorsMember 2016-01-01 2016-03-31 0001377149 crvw:HealthCor7Member crvw:HealthCorMember 2016-01-01 2016-03-31 0001377149 crvw:HealthCor8Member 2015-03-30 2015-03-31 0001377149 crvw:HealthCor8Member 2015-03-31 0001377149 crvw:HealthCor8Member us-gaap:MinimumMember 2015-03-31 0001377149 crvw:HealthCor5Member us-gaap:MaximumMember 2014-01-16 0001377149 crvw:HealthCor3Member 2016-01-01 2016-03-31 0001377149 crvw:HealthCor3Member 2015-01-01 2015-03-31 0001377149 crvw:HealthCor7Member 2016-01-01 2016-03-31 0001377149 crvw:HealthCor7Member 2015-01-01 2015-03-31 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure crvw:Number CareView Communications Inc 0001377149 10-Q 2016-03-31 false --12-31 No No Yes Smaller Reporting Company Q1 2016 139380742

139380748

139381

82434461

83142148

-107795712

-112463946

-501691

-517801

-25723561

-29700218

-4684344

-4668234

-16110

-3788305

516844

190843

17678969

15568573

2546262

7387160

1176404

1185132

4731

471075

493179

19326448

17246884

5063

6877

4483440

4534718

43463

50382

3250000

380765

530519

517729

12790

366431

14334

2689758

2548282

1121015

703998

502281

174864

46124

1165938

731847

566887

178962

46124

6320523

6328801

30130411

28110403

48526

57259

332402

387303

134573

132170

441498

261450

276508

261450

479226

586043

10250

27749

26936

1956074

2132850

33729093

35593463

6000000

20000000

168805

84308

53897898

55677771

55853972

57810621

1321826

1303552

139381

82434461

83142148

-107795712

-112463946

-25221870

-29182417

-501691

-517801

30130411

28110403

22951069

23041363

636752

1093105

0.001

20000000

0.001

300000000

139380748

1495793

1000554

7097

1152107

830094

4164

1054858

838309

813

1130

221688

197622

249098

225196

445416

415904

12133

12467

3123167

2507125

17110

17761

-1627374

-1506571

-10013

-10664

3151557

2045901

592688

552066

84497

-238101

4970

1143

5120

1125

3056970

2281734

-4684344

-3788305

-32220

-32444

-16110

-16222

-16110

-16222

-4668234

-3772083

-16110

-16222

-0.03

139380748

423560

409634

607138

552066

102541 66631 72772

21856

6270

1774076

1471707

190843

190106

-43740

84497

-238101

8728

-8639

18929

238795

-4098

54901

183405

121875

-77177

-1422838

-929880

474838

103098

37935 47371

174785

10273

-687558

-160742

5931520

-2110396

4840898

682150

5150

516844

456987

516844

456987

1471105

NOTE 1 BASIS OF PRESENTATION AND RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS   Interim Financial Statements   The accompanying unaudited interim condensed consolidated financial statements of CareView Communications, Inc. (CareView, the Company, we, us or our) have been prepared in accordance with generally accepted accounting principles in the United States of America (GAAP) for interim financial information and with the instructions to Form 10-Q. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, such financial statements include all adjustments (consisting solely of normal recurring adjustments) necessary for the fair statement of the financial information included herein in accordance with GAAP and the rules and regulations of the Securities and Exchange Commission (the SEC). The balance sheet at December 31, 2015 has been derived from the audited consolidated financial statements at that date but does not include all of the information and footnotes required by GAAP for complete financial statements. The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the period. Actual results could differ from those estimates. Results of operations for interim periods are not necessarily indicative of results for the full year. The accompanying condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and related notes included in our Annual Report on Form 10-K for the year ended December 31, 2015 as filed with the SEC on March 30, 2016.   Fair Value of Financial Instruments   Our financial instruments consist primarily of receivables, accounts payable, accrued expenses and short- and long-term debt. The carrying amount of receivables, accounts payable and accrued expenses approximates our fair value because of the short-term maturity of such instruments. We have elected not to carry our debt instruments at fair value. The carrying amount of our debt approximates fair value. Interest rates that are currently available to us for issuance of short- and long-term debt with similar terms and remaining maturities are used to estimate the fair value of the our short- and long-term debt and would be considered Level 3 inputs under the fair value hierarchy.   We have categorized our assets and liabilities that are valued at fair value on a recurring basis into a three-level fair value hierarchy in accordance with GAAP. The fair value hierarchy gives the highest priority to quoted prices in active markets for identical assets and liabilities (Level 1) and lowest priority to unobservable inputs (Level 3).   Assets and liabilities recorded in the condensed consolidated balance sheets at fair value are categorized based on a hierarchy of inputs, as follows:   Level 1 - Unadjusted quoted prices in active markets for identical assets or liabilities. Level 2 - Quoted prices for similar assets or liabilities in active markets or inputs that are observable for the asset or liability, either directly or indirectly through market corroboration, for substantially the full term of the financial instrument. Level 3 - Unobservable inputs for the asset or liability.   The Companys financial assets and liabilities recorded at fair value on a recurring basis include the fair value of warrant liability as detailed below. The fair value of this warrant liability is included in long-term liabilities on the accompanying condensed consolidated financial statements.   The following table provides the financial assets and liabilities reported at fair value and measured on a recurring basis:   <table cellspacing="0" cellpadding="0" style="font-size: 10pt; line-height: normal; width: 100%; border-collapse: collapse; font-size-adjust: none; font-stretch: normal"> <tr style="vertical-align: bottom"> <td style="text-align: center; border-bottom: black 1pt solid">Description</td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="text-align: center; border-bottom: black 1pt solid">Assets/ (Liabilities) Measured at Fair Value</td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="text-align: center; border-bottom: black 1pt solid">Quoted Prices in Active Markets for Identical Assets (Level 1)</td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="text-align: center; border-bottom: black 1pt solid">Significant Other Observable Inputs (Level 2)</td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="text-align: center; border-bottom: black 1pt solid">Significant Other Unobservable Inputs (Level 3)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255)"> <td style="width: 44%; padding-bottom: 2.5pt">Fair value of warrant liability</td> <td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="width: 1%; text-align: left; border-bottom: black 2.5pt double">$</td> <td style="width: 10%; text-align: right; border-bottom: black 2.5pt double">(84,308</td> <td style="width: 1%; text-align: left; padding-bottom: 2.5pt">)</td> <td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="width: 1%; text-align: left; border-bottom: black 2.5pt double">$</td> <td style="width: 10%; text-align: right; border-bottom: black 2.5pt double">  </td> <td style="width: 1%; text-align: left; padding-bottom: 2.5pt"> </td> <td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="width: 1%; text-align: left; border-bottom: black 2.5pt double">$</td> <td style="width: 10%; text-align: right; border-bottom: black 2.5pt double">  </td> <td style="width: 1%; text-align: left; padding-bottom: 2.5pt"> </td> <td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="width: 1%; text-align: left; border-bottom: black 2.5pt double">$</td> <td style="width: 10%; text-align: right; border-bottom: black 2.5pt double">(84,308</td> <td style="width: 1%; text-align: left; padding-bottom: 2.5pt">)</td></tr> </table>   The following table provides a summary of changes in fair value associated with the Level 3 liabilities for the three months ended March 31, 2016   <table align="center" cellspacing="0" cellpadding="0" style="font-size: 12pt; line-height: normal; width: 60%; border-collapse: collapse; font-size-adjust: none; font-stretch: normal"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td> <td style="font: 10pt/normal Times New Roman, Times, Serif; padding-bottom: 1pt; font-size-adjust: none; font-stretch: normal"> </td> <td colspan="3" style="font: 10pt/normal Times New Roman, Times, Serif; text-align: center; border-bottom: black 1pt solid; font-size-adjust: none; font-stretch: normal">Fair Value Measurements Using Significant Unobservable Inputs (Level 3)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255)"> <td style="font: 10pt/normal Times New Roman, Times, Serif; width: 71%; font-size-adjust: none; font-stretch: normal">Balance at January 1, 2016</td> <td style="font: 10pt/normal Times New Roman, Times, Serif; width: 10%; font-size-adjust: none; font-stretch: normal"> </td> <td style="font: 10pt/normal Times New Roman, Times, Serif; width: 1%; text-align: left; font-size-adjust: none; font-stretch: normal">$</td> <td style="font: 10pt/normal Times New Roman, Times, Serif; width: 17%; text-align: right; font-size-adjust: none; font-stretch: normal">(168,805</td> <td style="font: 10pt/normal Times New Roman, Times, Serif; width: 1%; text-align: left; font-size-adjust: none; font-stretch: normal">)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="font: 10pt/normal Times New Roman, Times, Serif; text-align: left; font-size-adjust: none; font-stretch: normal">Issuances of derivative liabilities</td> <td style="font: 10pt/normal Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> </td> <td style="font: 10pt/normal Times New Roman, Times, Serif; text-align: left; font-size-adjust: none; font-stretch: normal"> </td> <td style="font: 10pt/normal Times New Roman, Times, Serif; text-align: right; font-size-adjust: none; font-stretch: normal">  </td> <td style="font: 10pt/normal Times New Roman, Times, Serif; text-align: left; font-size-adjust: none; font-stretch: normal"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255)"> <td style="font: 10pt/normal Times New Roman, Times, Serif; text-align: left; font-size-adjust: none; font-stretch: normal">Change in fair value of warrant liability</td> <td style="font: 10pt/normal Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> </td> <td style="font: 10pt/normal Times New Roman, Times, Serif; text-align: left; font-size-adjust: none; font-stretch: normal"> </td> <td style="font: 10pt/normal Times New Roman, Times, Serif; text-align: right; font-size-adjust: none; font-stretch: normal">(84,497</td> <td style="font: 10pt/normal Times New Roman, Times, Serif; text-align: left; font-size-adjust: none; font-stretch: normal">)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="font: 10pt/normal Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; font-size-adjust: none; font-stretch: normal">Transfers in and/out of Level 3</td> <td style="font: 10pt/normal Times New Roman, Times, Serif; padding-bottom: 1pt; font-size-adjust: none; font-stretch: normal"> </td> <td style="font: 10pt/normal Times New Roman, Times, Serif; text-align: left; border-bottom: black 1pt solid; font-size-adjust: none; font-stretch: normal"> </td> <td style="font: 10pt/normal Times New Roman, Times, Serif; text-align: right; border-bottom: black 1pt solid; font-size-adjust: none; font-stretch: normal">  </td> <td style="font: 10pt/normal Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; font-size-adjust: none; font-stretch: normal"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255)"> <td style="font: 10pt/normal Times New Roman, Times, Serif; padding-bottom: 2.5pt; font-size-adjust: none; font-stretch: normal">Ending balance at March 31, 2016</td> <td style="font: 10pt/normal Times New Roman, Times, Serif; padding-bottom: 2.5pt; font-size-adjust: none; font-stretch: normal"> </td> <td style="font: 10pt/normal Times New Roman, Times, Serif; text-align: left; border-bottom: black 2.5pt double; font-size-adjust: none; font-stretch: normal">$</td> <td style="font: 10pt/normal Times New Roman, Times, Serif; text-align: right; border-bottom: black 2.5pt double; font-size-adjust: none; font-stretch: normal">(84,308</td> <td style="font: 10pt/normal Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt; font-size-adjust: none; font-stretch: normal">)</td></tr> </table>   The above table of Level 3 liabilities begins with the prior period balance and adjusts the balance for changes that occurred during the current period. The ending balance of the Level 3 securities presented above represent our best estimates and may not be substantiated by comparisons to independent markets and, in many cases, could not be realized in immediate settlement of the instruments.   Earnings Per Share   We calculate earnings per share (EPS) in accordance with GAAP, which requires the computation and disclosure of two EPS amounts, basic and diluted. Basic EPS is computed based on the weighted average number of shares of common stock outstanding during the period. Diluted EPS is computed based on the weighted average number of common shares outstanding plus all potentially dilutive common shares outstanding during the period under the treasury stock method. Such potential dilutive common shares consist of stock options, warrants and convertible debt. Potential common shares totaling 110,156,518 and 104,333,559 at March 31, 2016 and 2015, respectively, have been excluded from the diluted earnings per share calculation as they are anti-dilutive due to our reported net loss.   Recently Issued and Newly Adopted Accounting Pronouncements   In February 2016, the FASB issued ASU 2016-02, Leases (ASU 2016-02). The new standard establishes a right-of-use (ROU) model that requires a lessee to record a ROU asset and a lease liability on the balance sheet for all leases with terms longer than 12 months. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the income statement. ASU 2016-02 is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. Early adoption is permitted. A modified retrospective transition approach is required for lessees for capital and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain practical expedients available. We are evaluating the impact that ASU 2016-03 will have on our consolidated financial statements and related disclosures.   There have been no material changes to our significant accounting policies as summarized in NOTE 2 of our Annual Report on Form 10-K for the year ended December 31, 2015. We do not expect that the adoption of any recent accounting pronouncements will have a material impact on our accompanying condensed consolidated financial statements.

NOTE 2 LIQUIDITY AND MANAGEMENTS PLAN   Our cash position at March 31, 2016 was approximately $15,569,000. We also have $3,250,000 recorded as restricted cash related to a debt covenant in our credit agreement with PDL BioPharma, Inc. as discussed below.   Pursuant to the terms of a Note and Warrant Purchase Agreement dated April 21, 2011 (as subsequently amended) with HealthCor Partners Fund, LP and HealthCor Hybrid Offshore Master Fund, LP (HealthCor) we are required to maintain a minimum cash balance $2,000,000 (see NOTE 11 for further details), and we are in compliance with the minimum cash balance as of the date of this filing.   Our continued successful operation is dependent upon us achieving positive cash flow through operations while maintaining adequate liquidity. We expect that the cash on hand, as well as our existing and projected cash flow from billable contracts, will enable us to continue to operate for the next twelve month period. We believe that our sales and marketing plan to attract new business and our ongoing deployment and installation of units under existing hospital agreements, will meet our near-term cash needs and will help us achieve future operating profitability.   At present, we have sufficient inventory to install and service a select number of large customers, but eventually we will need to address additional capital requirements. To that end, on June 26, 2015, we entered into a Credit Agreement with PDL Biopharma, Inc., as administrative agent and lender (the Lender), (the PDL Credit Agreement) pursuant to which the Lender made available to us up to $40 million in two tranches of $20 million each, with each tranche contingent upon us meeting certain milestones. On October 7, 2015, pursuant to the First Amendment to the PDL Credit Agreement (the First Amendment) the Lender made the first tranche of $20 million available and funded us $19,533,992, net of fees. As of March 31, 2016, we are including $20 million in long-term liabilities on the accompanying condensed consolidated financial statements. Pursuant to the terms of the PDL Credit Agreement, we are required to maintain a minimum cash balance $3,250,000, and we are in compliance with the minimum cash balance as of the date of this filing (see NOTE13 for further details). No funds under the second tranche of the PDL Credit Agreement were available to us as of March 31, 2016.

NOTE 4 OTHER CURRENT ASSETS   Other current assets consist of the following:   <table align="center" cellspacing="0" cellpadding="0" style="font-size: 10pt; line-height: normal; width: 80%; border-collapse: collapse; font-size-adjust: none; font-stretch: normal"> <tr style="vertical-align: bottom"> <td style="font: 12pt/normal Arial, Helvetica, Sans-Serif; text-align: justify; font-size-adjust: none; font-stretch: normal"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="text-align: center; border-bottom: black 1pt solid">March 31, 2016</td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="text-align: center; border-bottom: black 1pt solid">December 31, 2015</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255)"> <td style="width: 61%; text-align: justify; padding-left: 5.4pt">Prepaid expenses</td> <td style="width: 8%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 12%; text-align: right">490,119</td> <td style="width: 1%; text-align: left"> </td> <td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 12%; text-align: right">467,137</td> <td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify; padding-bottom: 1pt; padding-left: 5.4pt">Other current assets</td> <td style="padding-bottom: 1pt"> </td> <td style="text-align: left; border-bottom: black 1pt solid"> </td> <td style="text-align: right; border-bottom: black 1pt solid">3,060</td> <td style="text-align: left; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="text-align: left; border-bottom: black 1pt solid"> </td> <td style="text-align: right; border-bottom: black 1pt solid">3,938</td> <td style="text-align: left; padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255)"> <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 5.4pt">          TOTAL OTHER CURRENT ASSETS</td> <td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left; border-bottom: black 2.5pt double">$</td> <td style="text-align: right; border-bottom: black 2.5pt double">493,179</td> <td style="text-align: left; padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left; border-bottom: black 2.5pt double">$</td> <td style="text-align: right; border-bottom: black 2.5pt double">471,075</td> <td style="text-align: left; padding-bottom: 2.5pt"> </td></tr> </table>

NOTE 5 PROPERTY AND EQUIPMENT   Property and equipment consist of the following:   <table align="center" cellspacing="0" cellpadding="0" style="font-size: 10pt; line-height: normal; width: 80%; border-collapse: collapse; font-size-adjust: none; font-stretch: normal"> <tr style="vertical-align: bottom"> <td style="font: 12pt/normal Arial, Helvetica, Sans-Serif; text-align: justify; font-size-adjust: none; font-stretch: normal"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="text-align: center; border-bottom: black 1pt solid">March 31, 2016</td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="text-align: center; border-bottom: black 1pt solid">December 31, 2015</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255)"> <td style="width: 61%; text-align: justify">Network equipment</td> <td style="width: 8%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 12%; text-align: right">11,762,725</td> <td style="width: 1%; text-align: left"> </td> <td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 12%; text-align: right">11,310,494</td> <td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify">Office equipment</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">218,875</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">200,683</td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255)"> <td style="text-align: justify">Vehicles</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">158,803</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">158,803</td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify">Test equipment</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">117,871</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">115,712</td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255)"> <td style="text-align: justify">Furniture</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">84,094</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">81,838</td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify">Warehouse equipment</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">9,524</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">9,524</td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255)"> <td style="text-align: justify; padding-bottom: 1pt">Leasehold improvements</td> <td style="padding-bottom: 1pt"> </td> <td style="text-align: left; border-bottom: black 1pt solid"> </td> <td style="text-align: right; border-bottom: black 1pt solid">5,121</td> <td style="text-align: left; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="text-align: left; border-bottom: black 1pt solid"> </td> <td style="text-align: right; border-bottom: black 1pt solid">5,121</td> <td style="text-align: left; padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="font: 12pt/normal Arial, Helvetica, Sans-Serif; text-align: justify; font-size-adjust: none; font-stretch: normal"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">12,357,013</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">11,882,175</td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255)"> <td style="text-align: justify; padding-bottom: 1pt">Less: accumulated depreciation</td> <td style="padding-bottom: 1pt"> </td> <td style="text-align: left; border-bottom: black 1pt solid"> </td> <td style="text-align: right; border-bottom: black 1pt solid">(7,822,295</td> <td style="text-align: left; padding-bottom: 1pt">)</td> <td style="padding-bottom: 1pt"> </td> <td style="text-align: left; border-bottom: black 1pt solid"> </td> <td style="text-align: right; border-bottom: black 1pt solid">(7,398,735</td> <td style="text-align: left; padding-bottom: 1pt">)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: left; padding-bottom: 2.5pt; vertical-align: bottom">TOTAL PROPERTY AND EQUIPMENT</td> <td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left; border-bottom: black 2.5pt double">$</td> <td style="text-align: right; border-bottom: black 2.5pt double">4,534,718</td> <td style="text-align: left; padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left; border-bottom: black 2.5pt double">$</td> <td style="text-align: right; border-bottom: black 2.5pt double">4,483,440</td> <td style="text-align: left; padding-bottom: 2.5pt"> </td></tr> </table>   Depreciation expense for the three months ended March 31, 2016 and 2015 was $423,560 and $409,634, respectively.

NOTE 6 OTHER ASSETS   Intangible assets consist of the following:   <table cellspacing="0" cellpadding="0" style="font-size: 10pt; line-height: normal; width: 100%; border-collapse: collapse; font-size-adjust: none; font-stretch: normal"> <tr style="vertical-align: bottom"> <td style="font: 12pt/normal Arial, Helvetica, Sans-Serif; text-align: justify; font-size-adjust: none; font-stretch: normal"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="11" style="text-align: center; border-bottom: black 1pt solid">March 31, 2016</td></tr> <tr style="vertical-align: bottom"> <td style="font: 12pt/normal Arial, Helvetica, Sans-Serif; text-align: justify; font-size-adjust: none; font-stretch: normal"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="text-align: center; border-bottom: black 1pt solid">Cost</td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="text-align: center; border-bottom: black 1pt solid">Accumulated Amortization</td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="text-align: center; border-bottom: black 1pt solid">Net</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255)"> <td style="width: 46%; text-align: justify">Patents and trademarks</td> <td style="width: 5%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 11%; text-align: right">591,747</td> <td style="width: 1%; text-align: left"> </td> <td style="width: 5%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 11%; text-align: right">74,018</td> <td style="width: 1%; text-align: left"> </td> <td style="width: 5%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 11%; text-align: right">517,729</td> <td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify; padding-bottom: 1pt">Other intangible assets</td> <td style="padding-bottom: 1pt"> </td> <td style="text-align: left; border-bottom: black 1pt solid"> </td> <td style="text-align: right; border-bottom: black 1pt solid">56,263</td> <td style="text-align: left; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="text-align: left; border-bottom: black 1pt solid"> </td> <td style="text-align: right; border-bottom: black 1pt solid">43,473</td> <td style="text-align: left; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="text-align: left; border-bottom: black 1pt solid"> </td> <td style="text-align: right; border-bottom: black 1pt solid">12,790</td> <td style="text-align: left; padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255)"> <td style="text-align: left; padding-bottom: 2.5pt">     TOTAL INTANGIBLE ASSETS</td> <td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left; border-bottom: black 2.5pt double">$</td> <td style="text-align: right; border-bottom: black 2.5pt double">648,010</td> <td style="text-align: left; padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left; border-bottom: black 2.5pt double">$</td> <td style="text-align: right; border-bottom: black 2.5pt double">117,491</td> <td style="text-align: left; padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left; border-bottom: black 2.5pt double">$</td> <td style="text-align: right; border-bottom: black 2.5pt double">530,519</td> <td style="text-align: left; padding-bottom: 2.5pt"> </td></tr> </table>   <table cellspacing="0" cellpadding="0" style="font-size: 10pt; line-height: normal; width: 100%; border-collapse: collapse; font-size-adjust: none; font-stretch: normal"> <tr style="vertical-align: bottom"> <td style="font: 12pt/normal Arial, Helvetica, Sans-Serif; text-align: justify; font-size-adjust: none; font-stretch: normal"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="11" style="text-align: center; border-bottom: black 1pt solid">December 31, 2015</td></tr> <tr style="vertical-align: bottom"> <td style="font: 12pt/normal Arial, Helvetica, Sans-Serif; text-align: justify; font-size-adjust: none; font-stretch: normal"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="text-align: center; border-bottom: black 1pt solid">Cost</td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="text-align: center; border-bottom: black 1pt solid">Accumulated Amortization</td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="text-align: center; border-bottom: black 1pt solid">Net</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255)"> <td style="width: 46%; text-align: justify">Patents and trademarks</td> <td style="width: 5%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 11%; text-align: right">420,137</td> <td style="width: 1%; text-align: left"> </td> <td style="width: 5%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 11%; text-align: right">53,706</td> <td style="width: 1%; text-align: left"> </td> <td style="width: 5%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 11%; text-align: right">366,431</td> <td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify; padding-bottom: 1pt">Other intangible assets</td> <td style="padding-bottom: 1pt"> </td> <td style="text-align: left; border-bottom: black 1pt solid"> </td> <td style="text-align: right; border-bottom: black 1pt solid">56,263</td> <td style="text-align: left; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="text-align: left; border-bottom: black 1pt solid"> </td> <td style="text-align: right; border-bottom: black 1pt solid">41,929</td> <td style="text-align: left; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="text-align: left; border-bottom: black 1pt solid"> </td> <td style="text-align: right; border-bottom: black 1pt solid">14,334</td> <td style="text-align: left; padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255)"> <td style="text-align: left; padding-bottom: 2.5pt">     TOTAL INTANGIBLE ASSETS</td> <td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left; border-bottom: black 2.5pt double">$</td> <td style="text-align: right; border-bottom: black 2.5pt double">476,400</td> <td style="text-align: left; padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left; border-bottom: black 2.5pt double">$</td> <td style="text-align: right; border-bottom: black 2.5pt double">95,635</td> <td style="text-align: left; padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left; border-bottom: black 2.5pt double">$</td> <td style="text-align: right; border-bottom: black 2.5pt double">380,765</td> <td style="text-align: left; padding-bottom: 2.5pt"> </td></tr> </table>   Other assets consist of the following:   <table cellspacing="0" cellpadding="0" style="font-size: 10pt; line-height: normal; width: 100%; border-collapse: collapse; font-size-adjust: none; font-stretch: normal"> <tr style="vertical-align: bottom"> <td style="font: 12pt/normal Arial, Helvetica, Sans-Serif; text-align: justify; font-size-adjust: none; font-stretch: normal"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="11" style="text-align: center; border-bottom: black 1pt solid">March 31, 2016</td></tr> <tr style="vertical-align: bottom"> <td style="font: 12pt/normal Arial, Helvetica, Sans-Serif; text-align: justify; font-size-adjust: none; font-stretch: normal"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="text-align: center; border-bottom: black 1pt solid">Cost</td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="text-align: center; border-bottom: black 1pt solid">Accumulated Amortization</td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="text-align: center; border-bottom: black 1pt solid">Net</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255)"> <td style="width: 46%; text-align: justify">Deferred debt issuance costs</td> <td style="width: 5%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 11%; text-align: right">1,257,778</td> <td style="width: 1%; text-align: left"> </td> <td style="width: 5%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 11%; text-align: right">136,763</td> <td style="width: 1%; text-align: left"> </td> <td style="width: 5%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 11%; text-align: right">1,121,015</td> <td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify">Prepaid financing costs</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">805,917</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">101,919</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">703,998</td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255)"> <td style="text-align: justify">Deferred installation costs</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">1,825,804</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">1,323,523</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">502,281</td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify">Prepaid license fee</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">249,999</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">75,135</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">174,864</td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255)"> <td style="text-align: justify; padding-bottom: 1pt">Security deposit</td> <td style="padding-bottom: 1pt"> </td> <td style="text-align: left; border-bottom: black 1pt solid"> </td> <td style="text-align: right; border-bottom: black 1pt solid">46,124</td> <td style="text-align: left; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="text-align: left; border-bottom: black 1pt solid"> </td> <td style="text-align: right; border-bottom: black 1pt solid">  </td> <td style="text-align: left; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="text-align: left; border-bottom: black 1pt solid"> </td> <td style="text-align: right; border-bottom: black 1pt solid">46,124</td> <td style="text-align: left; padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: left; padding-bottom: 2.5pt; vertical-align: bottom">     TOTAL OTHER ASSETS</td> <td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left; border-bottom: black 2.5pt double">$</td> <td style="text-align: right; border-bottom: black 2.5pt double">4,185,622</td> <td style="text-align: left; padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left; border-bottom: black 2.5pt double">$</td> <td style="text-align: right; border-bottom: black 2.5pt double">1,637,340</td> <td style="text-align: left; padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left; border-bottom: black 2.5pt double">$</td> <td style="text-align: right; border-bottom: black 2.5pt double">2,548,282</td> <td style="text-align: left; padding-bottom: 2.5pt"> </td></tr> </table>   Other assets consist of the following:   <table cellspacing="0" cellpadding="0" style="font-size: 10pt; line-height: normal; width: 100%; border-collapse: collapse; font-size-adjust: none; font-stretch: normal"> <tr style="vertical-align: bottom"> <td style="font: 12pt/normal Arial, Helvetica, Sans-Serif; text-align: justify; font-size-adjust: none; font-stretch: normal"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="11" style="text-align: center; border-bottom: black 1pt solid">December 31, 2015</td></tr> <tr style="vertical-align: bottom"> <td style="font: 12pt/normal Arial, Helvetica, Sans-Serif; text-align: justify; font-size-adjust: none; font-stretch: normal"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="text-align: center; border-bottom: black 1pt solid">Cost</td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="text-align: center; border-bottom: black 1pt solid">Accumulated Amortization</td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="text-align: center; border-bottom: black 1pt solid">Net</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255)"> <td style="width: 46%; text-align: justify">Deferred debt issuance costs</td> <td style="width: 5%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 11%; text-align: right">1,257,778</td> <td style="width: 1%; text-align: left"> </td> <td style="width: 5%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 11%; text-align: right">91,840</td> <td style="width: 1%; text-align: left"> </td> <td style="width: 5%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 11%; text-align: right">1,165,938</td> <td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify">Deferred financing costs</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">805,917</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">74,070</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">731,847</td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255)"> <td style="text-align: justify">Deferred installation costs</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">1,787,869</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">1,220,982</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">566,887</td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify">Prepaid license fee</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">249,999</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">71,037</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">178,962</td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255)"> <td style="text-align: justify; padding-bottom: 1pt">Security deposit</td> <td style="padding-bottom: 1pt"> </td> <td style="text-align: left; border-bottom: black 1pt solid"> </td> <td style="text-align: right; border-bottom: black 1pt solid">46,124</td> <td style="text-align: left; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="text-align: left; border-bottom: black 1pt solid"> </td> <td style="text-align: right; border-bottom: black 1pt solid">  </td> <td style="text-align: left; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="text-align: left; border-bottom: black 1pt solid"> </td> <td style="text-align: right; border-bottom: black 1pt solid">46,124</td> <td style="text-align: left; padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: left; padding-bottom: 2.5pt; vertical-align: bottom">     TOTAL OTHER ASSETS</td> <td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left; border-bottom: black 2.5pt double">$</td> <td style="text-align: right; border-bottom: black 2.5pt double">4,147,687</td> <td style="text-align: left; padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left; border-bottom: black 2.5pt double">$</td> <td style="text-align: right; border-bottom: black 2.5pt double">1,457,929</td> <td style="text-align: left; padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left; border-bottom: black 2.5pt double">$</td> <td style="text-align: right; border-bottom: black 2.5pt double">2,689,758</td> <td style="text-align: left; padding-bottom: 2.5pt"> </td></tr> </table>

NOTE 7 OTHER CURRENT LIABILITIES   Other current liabilities consist of the following:   <table align="center" cellspacing="0" cellpadding="0" style="font-size: 10pt; line-height: normal; width: 80%; border-collapse: collapse; font-size-adjust: none; font-stretch: normal"> <tr style="vertical-align: bottom"> <td style="font: 12pt/normal Arial, Helvetica, Sans-Serif; text-align: justify; font-size-adjust: none; font-stretch: normal"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center">March 31, 2016</td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center">December 31, 2015</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255)"> <td style="width: 61%; text-align: justify">Accrued taxes</td> <td style="width: 8%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 12%; text-align: right">243,683</td> <td style="width: 1%; text-align: left"> </td> <td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 12%; text-align: right">235,162</td> <td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify">Accrued insurance</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">135,059</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">  </td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255)"> <td style="text-align: justify">Allowance for system removal</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">102,800</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">54,771</td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify">Accrued paid time off</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">68,007</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">108,526</td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255)"> <td style="text-align: justify">Accrued professional services</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">11,284</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">67,500</td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify; padding-bottom: 1pt">Other accrued liabilities</td> <td style="padding-bottom: 1pt"> </td> <td style="text-align: left; border-bottom: black 1pt solid"> </td> <td style="text-align: right; border-bottom: black 1pt solid">25,210</td> <td style="text-align: left; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="text-align: left; border-bottom: black 1pt solid"> </td> <td style="text-align: right; border-bottom: black 1pt solid">13,267</td> <td style="text-align: left; padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255)"> <td style="text-align: left; padding-bottom: 2.5pt; vertical-align: bottom">TOTAL OTHER CURRENT LIABILITIES</td> <td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left; border-bottom: black 2.5pt double">$</td> <td style="text-align: right; border-bottom: black 2.5pt double">586,043</td> <td style="text-align: left; padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left; border-bottom: black 2.5pt double">$</td> <td style="text-align: right; border-bottom: black 2.5pt double">479,226</td> <td style="text-align: left; padding-bottom: 2.5pt"> </td></tr> </table>

NOTE 8 INCOME TAXES   Deferred income tax assets and liabilities are determined based upon differences between the financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. We do not expect to pay any significant federal or state income tax for 2016 as a result of the losses recorded during the three months ended March 31, 2016 and the additional losses expected for the remainder of 2016 and net operating loss carry forwards from prior years. Accounting standards require the consideration of a valuation allowance for deferred tax assets if it is more likely than not that some component or all of the benefits of deferred tax assets will not be realized. As of March 31, 2016, we maintained a full valuation allowance for all deferred tax assets. Based on these requirements, no provision or benefit for income taxes has been recorded. There were no recorded unrecognized tax benefits at the end of the reporting period.

NOTE 9 JOINT VENTURE AGREEMENT   On November 16, 2009, we entered into a Master Investment Agreement (the Rockwell Agreement) with Rockwell Holdings I, LLC, a Wisconsin limited liability (Rockwell). Under the terms of the Rockwell Agreement, we used funds from Rockwell to fully implement the CareView System in Hillcrest Medical Center in Tulsa, Oklahoma (Hillcrest) and Saline Memorial Hospital in Benton, Arkansas (Saline) (the Project Hospital(s)). CareView-Hillcrest, LLC and CareView-Saline, LLC were created as the operating entities for the Project Hospitals under the Rockwell Agreement (the Project LLC(s) ).   Rockwell and the Company own 50% of each Project LLC. We contributed our intellectual property rights and hospital contract with each Project Hospital and Rockwell contributed cash to be used for the purchase of equipment for the Project LLCs. Rockwell provided $1,151,205 as the initial funding, $575,603 was provided under promissory notes (the Project Notes) and $575,602 was provided under an investment interest (Rockwells Preferential Return). We classified Rockwells Preferential Return as a liability since it represents an unconditional obligation by us and is recorded in mandatorily redeemable equity in joint venture on the accompanying consolidated financial statements. The Project Notes and Rockwells Preferential Returns both earn interest at the rate of ten percent (10%) and are secured by a security interest in all of the equipment in the Project Hospitals, intellectual property rights, and the Project Hospital Contract   In accordance with GAAP, we determined the Project LLCs are VIEs based on the fact that the total equity investment at risk was not sufficient to finance the entities activities without additional financial support. We consolidate the Project LLCs as we have the power to direct the activities and an obligation to absorb losses of the VIEs. We have no contractual liability to Rockwell with respect to the repayment obligations of the Project LLCs.   As additional consideration to Rockwell for providing the funding, we granted Rockwell 1,151,206 Warrants on the date of the Rockwell Agreement, and using the Black-Scholes Model valued the Warrants at $1,124,728 (the Project Warrant). The Project Warrant is classified as equity and is included in additional paid-in-capital on the accompanying condensed consolidated financial statements. We allocated the proceeds to the Project Warrant, the Project Notes and Preferential Returns based on the relative fair value. The originally recorded debt discount of $636,752 was amortized over the expected life of the debt and was fully amortized as of March 31, 2013.   Hillcrest notified us of its desire to terminate its hospital agreement effective January 27, 2012. This termination resulted in the loss of monthly revenue totaling approximately $20,000, which revenue was used to make payments on our indebtedness to Rockwell. To date, we have incurred system removal costs of approximately $3,000 for removing our equipment from the hospital premises. We currently have approximately 100 units remaining on site at Hillcrest. Included in other current liabilities in the accompanying condensed consolidated financial statements is an allowance for system removal totaling $10,250 to reserve for the removal of the remaining units.   As of March 31, 2016, the Project LLCs indebtedness to Rockwell, including principal and interest totaled approximately $1,200,000. On February 19, 2015, the Project Notes and Rockwells Preferential Returns due dates were extended to June 30, 2016. In October 2015, the expiration date of the Project Warrants was extended to November 16, 2017. All other provisions of the Project Warrant remained unchanged. The Project Warrant were revalued in October 2015 resulting in a $102,457 increase in fair value, which has been recorded as non-cash costs included in general and administration expense in the accompanying condensed consolidated financial statements. CareView, as 50% owner of the LLCs, is currently negotiating with Rockwell to settle the debt of the LLCs through the issuance of shares of CareViews Common Stock. Although CareView anticipates that this settlement will be forthcoming in the near future, CareView and the LLCs can give no assurances that a settlement will be negotiated, or if negotiated and settled, that it will be through the issuance of CareViews Common Stock.

NOTE 10 VARIABLE INTEREST ENTITIES   The Company consolidates VIEs of which it is the primary beneficiary. The liabilities recognized as a result of consolidating these VIEs do not necessarily represent additional claims on our general assets; rather, they represent claims against the specific assets of the consolidated VIEs. Conversely, assets recognized as a result of consolidating these VIEs do not represent additional assets that could be used to satisfy claims against our general assets.   The total consolidated VIE assets and liabilities reflected on our condensed consolidated balance sheets at March 31, 2016 and December 31, 2015 are as follows:   <table align="center" cellspacing="0" cellpadding="0" style="font-size: 10pt; line-height: normal; width: 80%; border-collapse: collapse; font-size-adjust: none; font-stretch: normal"> <tr style="vertical-align: bottom"> <td style="text-align: center; font-size: 12pt"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="text-align: center; border-bottom: black 1pt solid">March 31, 2016</td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="text-align: center; border-bottom: black 1pt solid">December 31, 2015</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; font-weight: bold">Assets</td> <td style="font-size: 12pt"> </td> <td colspan="3" style="text-align: right; font-size: 12pt"> </td> <td style="font-size: 12pt"> </td> <td colspan="3" style="text-align: right; font-size: 12pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255)"> <td style="width: 61%">Cash</td> <td style="width: 8%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 12%; text-align: right">332</td> <td style="width: 1%; text-align: left"> </td> <td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 12%; text-align: right">2,146</td> <td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1pt">Receivables</td> <td style="padding-bottom: 1pt"> </td> <td style="text-align: left; border-bottom: black 1pt solid"> </td> <td style="text-align: right; border-bottom: black 1pt solid">4,731</td> <td style="text-align: left; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="text-align: left; border-bottom: black 1pt solid"> </td> <td style="text-align: right; border-bottom: black 1pt solid">4,731</td> <td style="text-align: left; padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255)"> <td style="text-align: left">    Total current assets</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">5,063</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">6,877</td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: left; padding-bottom: 1pt">Property, net</td> <td style="padding-bottom: 1pt"> </td> <td style="text-align: left; border-bottom: black 1pt solid"> </td> <td style="text-align: right; border-bottom: black 1pt solid">43,463</td> <td style="text-align: left; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="text-align: left; border-bottom: black 1pt solid"> </td> <td style="text-align: right; border-bottom: black 1pt solid">50,382</td> <td style="text-align: left; padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255)"> <td style="text-align: left; padding-bottom: 2.5pt">     Total assets</td> <td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left; border-bottom: black 2.5pt double">$</td> <td style="text-align: right; border-bottom: black 2.5pt double">48,526</td> <td style="text-align: left; padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left; border-bottom: black 2.5pt double">$</td> <td style="text-align: right; border-bottom: black 2.5pt double">57,259</td> <td style="text-align: left; padding-bottom: 2.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="font-size: 12pt"> </td> <td style="font-size: 12pt"> </td> <td style="text-align: left; font-size: 12pt"> </td> <td style="text-align: right; font-size: 12pt"> </td> <td style="text-align: left; font-size: 12pt"> </td> <td style="font-size: 12pt"> </td> <td style="text-align: left; font-size: 12pt"> </td> <td style="text-align: right; font-size: 12pt"> </td> <td style="text-align: left; font-size: 12pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; font-weight: bold">Liabilities</td> <td style="font-size: 12pt"> </td> <td style="text-align: left; font-size: 12pt"> </td> <td style="text-align: right; font-size: 12pt"> </td> <td style="text-align: left; font-size: 12pt"> </td> <td style="font-size: 12pt"> </td> <td style="text-align: left; font-size: 12pt"> </td> <td style="text-align: right; font-size: 12pt"> </td> <td style="text-align: left; font-size: 12pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255)"> <td style="text-align: left">Accounts payable</td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right">134,573</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right">132,170</td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: left">Accrued interest</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">276,508</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">261,450</td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255)"> <td style="text-align: left">Other current liabilities</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">27,749</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">26,936</td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: left">Notes payable</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">441,498</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">441,498</td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255)"> <td style="text-align: left; padding-bottom: 1pt">Mandatorily redeemable interest</td> <td style="padding-bottom: 1pt"> </td> <td style="text-align: left; border-bottom: black 1pt solid"> </td> <td style="text-align: right; border-bottom: black 1pt solid">441,498</td> <td style="text-align: left; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="text-align: left; border-bottom: black 1pt solid"> </td> <td style="text-align: right; border-bottom: black 1pt solid">441,498</td> <td style="text-align: left; padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: left; padding-bottom: 2.5pt">            Total liabilities</td> <td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left; border-bottom: black 2.5pt double">$</td> <td style="text-align: right; border-bottom: black 2.5pt double">1,321,826</td> <td style="text-align: left; padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left; border-bottom: black 2.5pt double">$</td> <td style="text-align: right; border-bottom: black 2.5pt double">1,303,552</td> <td style="text-align: left; padding-bottom: 2.5pt"> </td></tr> </table>   The financial performance of the consolidated VIEs reflected on our condensed consolidated statements of operations for the three months ended March 31, 2016 and 2015 is as follows:   <table align="center" cellspacing="0" cellpadding="0" style="font-size: 10pt; line-height: normal; width: 80%; border-collapse: collapse; font-size-adjust: none; font-stretch: normal"> <tr style="vertical-align: bottom"> <td style="font-size: 12pt"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="7" style="text-align: center; border-bottom: black 1pt solid">March 31,</td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 12pt"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="text-align: center; border-bottom: black 1pt solid">2016</td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="text-align: center; border-bottom: black 1pt solid">2015</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255)"> <td style="width: 61%; padding-bottom: 1pt">Revenue</td> <td style="width: 8%; padding-bottom: 1pt"> </td> <td style="width: 1%; text-align: left; border-bottom: black 1pt solid">$</td> <td style="width: 12%; text-align: right; border-bottom: black 1pt solid">7,097</td> <td style="width: 1%; text-align: left; padding-bottom: 1pt"> </td> <td style="width: 3%; padding-bottom: 1pt"> </td> <td style="width: 1%; text-align: left; border-bottom: black 1pt solid">$</td> <td style="width: 12%; text-align: right; border-bottom: black 1pt solid">7,097</td> <td style="width: 1%; text-align: left; padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: left">Network operations expense</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">4,164</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">4,164</td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255)"> <td style="text-align: left">General and administrative expense</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">813</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">1,130</td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1pt">Depreciation</td> <td style="padding-bottom: 1pt"> </td> <td style="text-align: left; border-bottom: black 1pt solid"> </td> <td style="text-align: right; border-bottom: black 1pt solid">12,133</td> <td style="text-align: left; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="text-align: left; border-bottom: black 1pt solid"> </td> <td style="text-align: right; border-bottom: black 1pt solid">12,467</td> <td style="text-align: left; padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255)"> <td style="text-align: left; padding-bottom: 1pt">    Total operating costs</td> <td style="padding-bottom: 1pt"> </td> <td style="text-align: left; border-bottom: black 1pt solid"> </td> <td style="text-align: right; border-bottom: black 1pt solid">17,110</td> <td style="text-align: left; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="text-align: left; border-bottom: black 1pt solid"> </td> <td style="text-align: right; border-bottom: black 1pt solid">17,761</td> <td style="text-align: left; padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: left">      Operating loss</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(10,013</td> <td style="text-align: left">)</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(10,664</td> <td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255)"> <td style="text-align: left; padding-bottom: 1pt">Other expense</td> <td style="padding-bottom: 1pt"> </td> <td style="text-align: left; border-bottom: black 1pt solid"> </td> <td style="text-align: right; border-bottom: black 1pt solid">(22,207</td> <td style="text-align: left; padding-bottom: 1pt">)</td> <td style="padding-bottom: 1pt"> </td> <td style="text-align: left; border-bottom: black 1pt solid"> </td> <td style="text-align: right; border-bottom: black 1pt solid">(21,780</td> <td style="text-align: left; padding-bottom: 1pt">)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: left">Loss before taxes</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(32,220</td> <td style="text-align: left">)</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(32,444</td> <td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255)"> <td style="text-align: left; padding-bottom: 1pt">Provision for taxes</td> <td style="padding-bottom: 1pt"> </td> <td style="text-align: left; border-bottom: black 1pt solid"> </td> <td style="text-align: right; border-bottom: black 1pt solid">  </td> <td style="text-align: left; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="text-align: left; border-bottom: black 1pt solid"> </td> <td style="text-align: right; border-bottom: black 1pt solid">  </td> <td style="text-align: left; padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: left">Net loss</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(32,220</td> <td style="text-align: left">)</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(32,444</td> <td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255)"> <td style="text-align: left; padding-bottom: 1pt">Net loss attributable to noncontrolling interest</td> <td style="padding-bottom: 1pt"> </td> <td style="text-align: left; border-bottom: black 1pt solid"> </td> <td style="text-align: right; border-bottom: black 1pt solid">(16,110</td> <td style="text-align: left; padding-bottom: 1pt">)</td> <td style="padding-bottom: 1pt"> </td> <td style="text-align: left; border-bottom: black 1pt solid"> </td> <td style="text-align: right; border-bottom: black 1pt solid">(16,222</td> <td style="text-align: left; padding-bottom: 1pt">)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: left; padding-bottom: 2.5pt">Net loss attributable to CareView Communications, Inc.</td> <td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left; border-bottom: black 2.5pt double">$</td> <td style="text-align: right; border-bottom: black 2.5pt double">(16,110</td> <td style="text-align: left; padding-bottom: 2.5pt">)</td> <td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left; border-bottom: black 2.5pt double">$</td> <td style="text-align: right; border-bottom: black 2.5pt double">(16,222</td> <td style="text-align: left; padding-bottom: 2.5pt">)</td></tr> </table>

NOTE 12 AGREEMENT WITH PDL BIOPHARMA, INC.   On June 26, 2015, we entered into a Credit Agreement with PDL BioPharma, Inc., as administrative agent and lender (PDL or the Lender) (the PDL Credit Agreement). Under the PDL Credit Agreement the Lender made available to us up to $40 million in two tranches of $20 million each.   Certain covenants of the PDL Credit Agreement include (a) in the event that a milestone relating to the placement of 9,000 billable units occurs on or before October 31, 2015, the Lender will fund us $20 million (the Tranche One Loan) and (b) in the event that additional milestones relating to (i) the placement of 27,750 billable units and (ii) the Company recording earnings before interest, tax, depreciation, and amortization (EBITDA) of not less than $7,000,000 on an annualized basis for the three calendar month period prior to the funding (on or before June 30, 2017), the Lender will fund us an additional $20 million (the Tranche Two Loan and, together with the Tranche One Loan, the Loans). Outstanding borrowings under the Tranche One Loan bear interest at the rate of 13.5% per annum, payable quarterly in arrears. Outstanding borrowings under the Tranche Two Loan bear interest at the rate of 13.0% per annum, payable quarterly in arrears. From the date any event of default occurs, the interest rate shall be increased by five percent (5%) per annum. The PDL Credit Agreement includes a minimum cash balance requirement of $3,250,000 and should we drop below $3,250,000, it will trigger a default. The $3,250,000 has been recorded as restricted cash on the condensed consolidated balance sheets at March 31, 2016 and December 31, 2015.   On October 7, 2015, the Company entered into a First Amendment (the First Amendment) to the PDL Credit Agreement. The First Amendment modified the conditions precedent to the funding of each tranche, such that, among other things, we no longer need to attain a specified milestone relating to the placement of our products in order for the Lender to fund us the Tranche One Loan. Contemporaneously with the execution of the First Amendment we borrowed the Tranche One Loan and issued to the Lender a term note in the principal amount of $20 million (the Tranche One Term Note), payable in accordance with the terms of the Credit Agreement, as amended. The First Amendment also included a revision to the Tranche Two Milestone, which changed from a minimum of 27,750 billable units (defined as one unit for each room control platform and two units for each nurse station monitor) to 31,500 Bed Equivalent Units (defined as a billable unit plus 14 units for each head-end server operating as the communication center and fractional units for mobile assets as applicable).    Once funded, the PDL Credit Agreement requires interest only payments for the first eight interest payment dates and principal plus interest payments will commence on the ninth interest payment date. We may elect to pay a portion of the interest due in the form of additional loans (interest paid in kind) during the first eight interest payment dates. The first principal payment on the Tranche One Term Note is due on January 8, 2018 in the amount of $1,666,667, with similar amounts due quarterly thereafter with the final payment due on October 8, 2020. Each tranche will mature on the fifth anniversary of the date borrowed. We may elect to prepay the Loans at any time without any premium or penalty, subject to certain conditions.   The obligations under the PDL Credit Agreement are secured by a pledge of substantially all of the assets of the Company and certain of its domestic subsidiaries. We executed a Subordination and Intercreditor Agreement (the Subordination and Intercreditor Agreement), with the Lender, HealthCor and the New Investors (as defined in NOTE 11) pursuant to which we granted first-priority liens on our pledged assets to the Lender and second-priority liens on such pledged assets to HealthCor and the New Investors.   The PDL Credit Agreement contains customary affirmative covenants for transactions of this type and other affirmative covenants agreed to by the Company and the Lender, including, among others, the provision of annual and quarterly reports, maintenance of property, insurance, compliance with laws and contractual obligations and payment of taxes. The PDL Credit Agreement contains customary negative covenants for transactions of this type and other negative covenants agreed to by the Company and the Lender, including, among others, restrictions on the incurrence of indebtedness, the granting of liens, making restricted payments and investments, entering into affiliate transactions and transferring assets. The PDL Credit Agreement also provides for a number of customary events of default, including payment, bankruptcy, covenant, representation and warranty and judgment defaults.   Contemporaneously with the execution of the PDL Credit Agreement, we issued to the Lender a warrant to purchase 4,444,445 shares of our Common Stock at an exercise price of $0.45 per share, subject to adjustment as described therein (the PDL Warrant). The PDL Warrant expires on June 26, 2025. Pursuant to the terms of the First Amendment we amended and restated the PDL Warrant, reducing the exercise price per share from $0.45 to $0.40 (the Amended Warrant). All other provisions of the Amended Warrant remained unchanged.   In addition, contemporaneously with the execution of the PDL Credit Agreement the Company and the Lender executed (i) a Registration Rights Agreement pursuant to which the Company agreed to provide the Lender with certain registration rights with respect to the shares of Common Stock issuable upon exercise of the PDL Warrant (the PDL RRA), (ii) a Guarantee and Collateral Agreement (the Guarantee and Collateral Agreement) pursuant to which certain of our subsidiaries guaranteed the performance of our obligations under the PDL Credit Agreement and granted the Lender a security interest in such subsidiaries tangible and intangible assets securing our performance of the same, and (iii) a Patent Security Agreement and a Trademark Security Agreement pursuant to which we granted the Lender a security interest in a certain subsidiarys tangible and intangible assets securing the performance of our obligations under the PDL Credit Agreement.   Accounting Treatment   In connection with the Credit Agreement, we issued the PDL Warrant to the Lender. The fair value of the PDL Warrant at issuance was $1,257,778, which has been recorded as deferred issuance costs in the accompanying condensed consolidated financial statements. The deferred debt issuance costs associated with the PDL Credit Agreement are recorded as assets in accordance with the accounting standards as the PDL Credit Agreement is considered to be a credit facility and the warrants were payment for the facility and not the drawdowns. These costs are amortized to interest expense using the straight line method over the term of the Credit Agreement. Upon amendment of the PDL Warrant, we evaluated whether there was an increase in fair value which would require recognition of additional costs. No such increase in fair value was noted and no adjustment to the PDL Warrant valuation was necessary. For the three months ended March 31, 2016, $44,922 was amortized to interest expense. For the period from June 25, 2015 through December 31, 2015, $91,840 was amortized to interest expense. The PDL Warrant has not been exercised. We also incurred certain financing costs totaling $805,917 in the accompanying condensed consolidated financial statements. These costs have been recorded as deferred financing costs and are being amortized to interest expense over the term of the Credit Agreement. For the three months ended March 31, 2016, $27,849 was amortized to interest expense. For the period from June 25, 2015 through December 31, 2015, $74,071 has been amortized.

Fair Value of Financial Instruments   Our financial instruments consist primarily of receivables, accounts payable, accrued expenses and short- and long-term debt. The carrying amount of receivables, accounts payable and accrued expenses approximates our fair value because of the short-term maturity of such instruments. We have elected not to carry our debt instruments at fair value. The carrying amount of our debt approximates fair value. Interest rates that are currently available to us for issuance of short- and long-term debt with similar terms and remaining maturities are used to estimate the fair value of the our short- and long-term debt and would be considered Level 3 inputs under the fair value hierarchy.   We have categorized our assets and liabilities that are valued at fair value on a recurring basis into a three-level fair value hierarchy in accordance with GAAP. The fair value hierarchy gives the highest priority to quoted prices in active markets for identical assets and liabilities (Level 1) and lowest priority to unobservable inputs (Level 3).   Assets and liabilities recorded in the condensed consolidated balance sheets at fair value are categorized based on a hierarchy of inputs, as follows:   Level 1 - Unadjusted quoted prices in active markets for identical assets or liabilities. Level 2 - Quoted prices for similar assets or liabilities in active markets or inputs that are observable for the asset or liability, either directly or indirectly through market corroboration, for substantially the full term of the financial instrument. Level 3 - Unobservable inputs for the asset or liability.   The Companys financial assets and liabilities recorded at fair value on a recurring basis include the fair value of warrant liability as detailed below. The fair value of this warrant liability is included in long-term liabilities on the accompanying condensed consolidated financial statements.    The following table provides the financial assets and liabilities reported at fair value and measured on a recurring basis:   <table cellspacing="0" cellpadding="0" style="font-size: 10pt; line-height: normal; width: 100%; border-collapse: collapse; font-size-adjust: none; font-stretch: normal"> <tr style="vertical-align: bottom"> <td style="text-align: center; border-bottom: black 1pt solid">Description</td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="text-align: center; border-bottom: black 1pt solid">Assets/ (Liabilities) Measured at Fair Value</td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="text-align: center; border-bottom: black 1pt solid">Quoted Prices in Active Markets for Identical Assets (Level 1)</td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="text-align: center; border-bottom: black 1pt solid">Significant Other Observable Inputs (Level 2)</td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="text-align: center; border-bottom: black 1pt solid">Significant Other Unobservable Inputs (Level 3)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255)"> <td style="width: 44%; padding-bottom: 2.5pt">Fair value of warrant liability</td> <td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="width: 1%; text-align: left; border-bottom: black 2.5pt double">$</td> <td style="width: 10%; text-align: right; border-bottom: black 2.5pt double">(84,308</td> <td style="width: 1%; text-align: left; padding-bottom: 2.5pt">)</td> <td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="width: 1%; text-align: left; border-bottom: black 2.5pt double">$</td> <td style="width: 10%; text-align: right; border-bottom: black 2.5pt double">  </td> <td style="width: 1%; text-align: left; padding-bottom: 2.5pt"> </td> <td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="width: 1%; text-align: left; border-bottom: black 2.5pt double">$</td> <td style="width: 10%; text-align: right; border-bottom: black 2.5pt double">  </td> <td style="width: 1%; text-align: left; padding-bottom: 2.5pt"> </td> <td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="width: 1%; text-align: left; border-bottom: black 2.5pt double">$</td> <td style="width: 10%; text-align: right; border-bottom: black 2.5pt double">(84,308</td> <td style="width: 1%; text-align: left; padding-bottom: 2.5pt">)</td></tr> </table>   The following table provides a summary of changes in fair value associated with the Level 3 liabilities for the three months ended March 31, 2016   <table align="center" cellspacing="0" cellpadding="0" style="font-size: 12pt; line-height: normal; width: 60%; border-collapse: collapse; font-size-adjust: none; font-stretch: normal"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td> <td style="font: 10pt/normal Times New Roman, Times, Serif; padding-bottom: 1pt; font-size-adjust: none; font-stretch: normal"> </td> <td colspan="3" style="font: 10pt/normal Times New Roman, Times, Serif; text-align: center; border-bottom: black 1pt solid; font-size-adjust: none; font-stretch: normal">Fair Value Measurements Using Significant Unobservable Inputs (Level 3)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255)"> <td style="font: 10pt/normal Times New Roman, Times, Serif; width: 71%; font-size-adjust: none; font-stretch: normal">Balance at January 1, 2016</td> <td style="font: 10pt/normal Times New Roman, Times, Serif; width: 10%; font-size-adjust: none; font-stretch: normal"> </td> <td style="font: 10pt/normal Times New Roman, Times, Serif; width: 1%; text-align: left; font-size-adjust: none; font-stretch: normal">$</td> <td style="font: 10pt/normal Times New Roman, Times, Serif; width: 17%; text-align: right; font-size-adjust: none; font-stretch: normal">(168,805</td> <td style="font: 10pt/normal Times New Roman, Times, Serif; width: 1%; text-align: left; font-size-adjust: none; font-stretch: normal">)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="font: 10pt/normal Times New Roman, Times, Serif; text-align: left; font-size-adjust: none; font-stretch: normal">Issuances of derivative liabilities</td> <td style="font: 10pt/normal Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> </td> <td style="font: 10pt/normal Times New Roman, Times, Serif; text-align: left; font-size-adjust: none; font-stretch: normal"> </td> <td style="font: 10pt/normal Times New Roman, Times, Serif; text-align: right; font-size-adjust: none; font-stretch: normal">  </td> <td style="font: 10pt/normal Times New Roman, Times, Serif; text-align: left; font-size-adjust: none; font-stretch: normal"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255)"> <td style="font: 10pt/normal Times New Roman, Times, Serif; text-align: left; font-size-adjust: none; font-stretch: normal">Change in fair value of warrant liability</td> <td style="font: 10pt/normal Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> </td> <td style="font: 10pt/normal Times New Roman, Times, Serif; text-align: left; font-size-adjust: none; font-stretch: normal"> </td> <td style="font: 10pt/normal Times New Roman, Times, Serif; text-align: right; font-size-adjust: none; font-stretch: normal">(84,497</td> <td style="font: 10pt/normal Times New Roman, Times, Serif; text-align: left; font-size-adjust: none; font-stretch: normal">)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="font: 10pt/normal Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; font-size-adjust: none; font-stretch: normal">Transfers in and/out of Level 3</td> <td style="font: 10pt/normal Times New Roman, Times, Serif; padding-bottom: 1pt; font-size-adjust: none; font-stretch: normal"> </td> <td style="font: 10pt/normal Times New Roman, Times, Serif; text-align: left; border-bottom: black 1pt solid; font-size-adjust: none; font-stretch: normal"> </td> <td style="font: 10pt/normal Times New Roman, Times, Serif; text-align: right; border-bottom: black 1pt solid; font-size-adjust: none; font-stretch: normal">  </td> <td style="font: 10pt/normal Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; font-size-adjust: none; font-stretch: normal"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255)"> <td style="font: 10pt/normal Times New Roman, Times, Serif; padding-bottom: 2.5pt; font-size-adjust: none; font-stretch: normal">Ending balance at March 31, 2016</td> <td style="font: 10pt/normal Times New Roman, Times, Serif; padding-bottom: 2.5pt; font-size-adjust: none; font-stretch: normal"> </td> <td style="font: 10pt/normal Times New Roman, Times, Serif; text-align: left; border-bottom: black 2.5pt double; font-size-adjust: none; font-stretch: normal">$</td> <td style="font: 10pt/normal Times New Roman, Times, Serif; text-align: right; border-bottom: black 2.5pt double; font-size-adjust: none; font-stretch: normal">(84,308</td> <td style="font: 10pt/normal Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt; font-size-adjust: none; font-stretch: normal">)</td></tr> </table>   The above table of Level 3 liabilities begins with the prior period balance and adjusts the balance for changes that occurred during the current period. The ending balance of the Level 3 securities presented above represent our best estimates and may not be substantiated by comparisons to independent markets and, in many cases, could not be realized in immediate settlement of the instruments.

Earnings Per Share   We calculate earnings per share (EPS) in accordance with GAAP, which requires the computation and disclosure of two EPS amounts, basic and diluted. Basic EPS is computed based on the weighted average number of shares of common stock outstanding during the period. Diluted EPS is computed based on the weighted average number of common shares outstanding plus all potentially dilutive common shares outstanding during the period under the treasury stock method. Such potential dilutive common shares consist of stock options, warrants and convertible debt. Potential common shares totaling 110,156,518 and 104,333,559 at March 31, 2016 and 2015, respectively, have been excluded from the diluted earnings per share calculation as they are anti-dilutive due to our reported net loss

Recently Issued and Newly Adopted Accounting Pronouncements   In February 2016, the FASB issued ASU 2016-02, Leases (ASU 2016-02). The new standard establishes a right-of-use (ROU) model that requires a lessee to record a ROU asset and a lease liability on the balance sheet for all leases with terms longer than 12 months. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the income statement. ASU 2016-02 is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. Early adoption is permitted. A modified retrospective transition approach is required for lessees for capital and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain practical expedients available. We are evaluating the impact that ASU 2016-03 will have on our consolidated financial statements and related disclosures.   There have been no material changes to our significant accounting policies as summarized in NOTE 2 of our Annual Report on Form 10-K for the year ended December 31, 2015. We do not expect that the adoption of any recent accounting pronouncements will have a material impact on our accompanying condensed consolidated financial statements.

The following table provides the financial assets and liabilities reported at fair value and measured on a recurring basis:   <table cellspacing="0" cellpadding="0" style="font-size: 10pt; line-height: normal; width: 100%; border-collapse: collapse; font-size-adjust: none; font-stretch: normal"> <tr style="vertical-align: bottom"> <td style="text-align: center; border-bottom: black 1pt solid">Description</td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="text-align: center; border-bottom: black 1pt solid">Assets/ (Liabilities) Measured at Fair Value</td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="text-align: center; border-bottom: black 1pt solid">Quoted Prices in Active Markets for Identical Assets (Level 1)</td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="text-align: center; border-bottom: black 1pt solid">Significant Other Observable Inputs (Level 2)</td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="text-align: center; border-bottom: black 1pt solid">Significant Other Unobservable Inputs (Level 3)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255)"> <td style="width: 44%; padding-bottom: 2.5pt">Fair value of warrant liability</td> <td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="width: 1%; text-align: left; border-bottom: black 2.5pt double">$</td> <td style="width: 10%; text-align: right; border-bottom: black 2.5pt double">(84,308</td> <td style="width: 1%; text-align: left; padding-bottom: 2.5pt">)</td> <td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="width: 1%; text-align: left; border-bottom: black 2.5pt double">$</td> <td style="width: 10%; text-align: right; border-bottom: black 2.5pt double">  </td> <td style="width: 1%; text-align: left; padding-bottom: 2.5pt"> </td> <td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="width: 1%; text-align: left; border-bottom: black 2.5pt double">$</td> <td style="width: 10%; text-align: right; border-bottom: black 2.5pt double">  </td> <td style="width: 1%; text-align: left; padding-bottom: 2.5pt"> </td> <td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="width: 1%; text-align: left; border-bottom: black 2.5pt double">$</td> <td style="width: 10%; text-align: right; border-bottom: black 2.5pt double">(84,308</td> <td style="width: 1%; text-align: left; padding-bottom: 2.5pt">)</td></tr> </table>

The following table provides a summary of changes in fair value associated with the Level 3 liabilities for the three months ended March 31, 2016   <table align="center" cellspacing="0" cellpadding="0" style="font: 10pt/normal Times New Roman, Times, Serif; width: 60%; border-collapse: collapse; font-size-adjust: none; font-stretch: normal"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td> <td style="line-height: normal; padding-bottom: 1pt; font-size-adjust: none; font-stretch: normal"> </td> <td colspan="3" style="line-height: normal; text-align: center; border-bottom: black 1pt solid; font-size-adjust: none; font-stretch: normal">Fair Value Measurements Using Significant Unobservable Inputs (Level 3)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255)"> <td style="line-height: normal; width: 71%; font-size-adjust: none; font-stretch: normal">Balance at January 1, 2016</td> <td style="line-height: normal; width: 10%; font-size-adjust: none; font-stretch: normal"> </td> <td style="line-height: normal; width: 1%; text-align: left; font-size-adjust: none; font-stretch: normal">$</td> <td style="line-height: normal; width: 17%; text-align: right; font-size-adjust: none; font-stretch: normal">(168,805</td> <td style="line-height: normal; width: 1%; text-align: left; font-size-adjust: none; font-stretch: normal">)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: normal; text-align: left; font-size-adjust: none; font-stretch: normal">Issuances of derivative liabilities</td> <td style="line-height: normal; font-size-adjust: none; font-stretch: normal"> </td> <td style="line-height: normal; text-align: left; font-size-adjust: none; font-stretch: normal"> </td> <td style="line-height: normal; text-align: right; font-size-adjust: none; font-stretch: normal">  </td> <td style="line-height: normal; text-align: left; font-size-adjust: none; font-stretch: normal"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255)"> <td style="line-height: normal; text-align: left; font-size-adjust: none; font-stretch: normal">Change in fair value of warrant liability</td> <td style="line-height: normal; font-size-adjust: none; font-stretch: normal"> </td> <td style="line-height: normal; text-align: left; font-size-adjust: none; font-stretch: normal"> </td> <td style="line-height: normal; text-align: right; font-size-adjust: none; font-stretch: normal">(84,497</td> <td style="line-height: normal; text-align: left; font-size-adjust: none; font-stretch: normal">)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: normal; text-align: left; padding-bottom: 1pt; font-size-adjust: none; font-stretch: normal">Transfers in and/out of Level 3</td> <td style="line-height: normal; padding-bottom: 1pt; font-size-adjust: none; font-stretch: normal"> </td> <td style="line-height: normal; text-align: left; border-bottom: black 1pt solid; font-size-adjust: none; font-stretch: normal"> </td> <td style="line-height: normal; text-align: right; border-bottom: black 1pt solid; font-size-adjust: none; font-stretch: normal">  </td> <td style="line-height: normal; text-align: left; padding-bottom: 1pt; font-size-adjust: none; font-stretch: normal"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255)"> <td style="line-height: normal; padding-bottom: 2.5pt; font-size-adjust: none; font-stretch: normal">Ending balance at March 31, 2016</td> <td style="line-height: normal; padding-bottom: 2.5pt; font-size-adjust: none; font-stretch: normal"> </td> <td style="line-height: normal; text-align: left; border-bottom: black 2.5pt double; font-size-adjust: none; font-stretch: normal">$</td> <td style="line-height: normal; text-align: right; border-bottom: black 2.5pt double; font-size-adjust: none; font-stretch: normal">(84,308</td> <td style="line-height: normal; text-align: left; padding-bottom: 2.5pt; font-size-adjust: none; font-stretch: normal">)</td></tr> </table>

A summary of our stock option activity and related information follows:   <table align="center" cellspacing="0" cellpadding="0" style="font: 10pt/normal Times New Roman, Times, Serif; width: 90%; border-collapse: collapse; font-size-adjust: none; font-stretch: normal"> <tr style="vertical-align: bottom"> <td> </td> <td style="line-height: normal; padding-bottom: 1pt; font-size-adjust: none; font-stretch: normal"> </td> <td colspan="3" style="line-height: normal; text-align: center; border-bottom: black 1pt solid; font-size-adjust: none; font-stretch: normal">Number of Shares Under Options</td> <td style="line-height: normal; padding-bottom: 1pt; font-size-adjust: none; font-stretch: normal"> </td> <td colspan="3" style="line-height: normal; text-align: center; border-bottom: black 1pt solid; font-size-adjust: none; font-stretch: normal">Weighted Average Exercise Price</td> <td style="line-height: normal; padding-bottom: 1pt; font-size-adjust: none; font-stretch: normal"> </td> <td colspan="3" style="line-height: normal; text-align: center; border-bottom: black 1pt solid; font-size-adjust: none; font-stretch: normal">Weighted Average Remaining Contractual Life</td> <td style="line-height: normal; padding-bottom: 1pt; font-size-adjust: none; font-stretch: normal"> </td> <td colspan="3" style="line-height: normal; text-align: center; border-bottom: black 1pt solid; font-size-adjust: none; font-stretch: normal">Aggregate Intrinsic Value</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255)"> <td style="line-height: normal; width: 44%; font-size-adjust: none; font-stretch: normal">Balance at December 31, 2015</td> <td style="line-height: normal; width: 2%; font-size-adjust: none; font-stretch: normal"> </td> <td style="line-height: normal; width: 1%; text-align: left; font-size-adjust: none; font-stretch: normal"> </td> <td style="line-height: normal; width: 10%; text-align: right; font-size-adjust: none; font-stretch: normal">9,350,667</td> <td style="line-height: normal; width: 1%; text-align: left; font-size-adjust: none; font-stretch: normal"> </td> <td style="line-height: normal; width: 2%; font-size-adjust: none; font-stretch: normal"> </td> <td style="line-height: normal; width: 1%; text-align: left; font-size-adjust: none; font-stretch: normal">$</td> <td style="line-height: normal; width: 10%; text-align: right; font-size-adjust: none; font-stretch: normal">0.58</td> <td style="line-height: normal; width: 1%; text-align: left; font-size-adjust: none; font-stretch: normal"> </td> <td style="line-height: normal; width: 2%; font-size-adjust: none; font-stretch: normal"> </td> <td style="line-height: normal; width: 1%; text-align: left; font-size-adjust: none; font-stretch: normal"> </td> <td style="line-height: normal; width: 10%; text-align: right; font-size-adjust: none; font-stretch: normal">7.6</td> <td style="line-height: normal; width: 1%; text-align: left; font-size-adjust: none; font-stretch: normal"> </td> <td style="line-height: normal; width: 2%; font-size-adjust: none; font-stretch: normal"> </td> <td style="line-height: normal; width: 1%; text-align: left; font-size-adjust: none; font-stretch: normal">$</td> <td style="line-height: normal; width: 10%; text-align: right; font-size-adjust: none; font-stretch: normal">15,705</td> <td style="line-height: normal; width: 1%; text-align: left; font-size-adjust: none; font-stretch: normal"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: normal; font-size-adjust: none; font-stretch: normal">   Granted</td> <td style="line-height: normal; font-size-adjust: none; font-stretch: normal"> </td> <td style="line-height: normal; text-align: left; font-size-adjust: none; font-stretch: normal"> </td> <td style="line-height: normal; text-align: right; font-size-adjust: none; font-stretch: normal">20,000</td> <td style="line-height: normal; text-align: left; font-size-adjust: none; font-stretch: normal"> </td> <td style="line-height: normal; font-size-adjust: none; font-stretch: normal"> </td> <td style="line-height: normal; text-align: left; font-size-adjust: none; font-stretch: normal">$</td> <td style="line-height: normal; text-align: right; font-size-adjust: none; font-stretch: normal">0.30</td> <td style="line-height: normal; text-align: left; font-size-adjust: none; font-stretch: normal"> </td> <td style="line-height: normal; font-size-adjust: none; font-stretch: normal"> </td> <td style="line-height: normal; text-align: left; font-size-adjust: none; font-stretch: normal"> </td> <td style="line-height: normal; text-align: right; font-size-adjust: none; font-stretch: normal">10.0</td> <td style="line-height: normal; text-align: left; font-size-adjust: none; font-stretch: normal"> </td> <td style="line-height: normal; font-size-adjust: none; font-stretch: normal"> </td> <td style="line-height: normal; text-align: left; font-size-adjust: none; font-stretch: normal">$</td> <td style="line-height: normal; text-align: right; font-size-adjust: none; font-stretch: normal">  </td> <td style="line-height: normal; text-align: left; font-size-adjust: none; font-stretch: normal"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255)"> <td style="line-height: normal; font-size-adjust: none; font-stretch: normal">   Expired</td> <td style="line-height: normal; font-size-adjust: none; font-stretch: normal"> </td> <td style="line-height: normal; text-align: left; font-size-adjust: none; font-stretch: normal"> </td> <td style="line-height: normal; text-align: right; font-size-adjust: none; font-stretch: normal">(66,667</td> <td style="line-height: normal; text-align: left; font-size-adjust: none; font-stretch: normal">)</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: normal; padding-bottom: 1pt; font-size-adjust: none; font-stretch: normal">   Canceled</td> <td style="line-height: normal; padding-bottom: 1pt; font-size-adjust: none; font-stretch: normal"> </td> <td style="line-height: normal; text-align: left; border-bottom: black 1pt solid; font-size-adjust: none; font-stretch: normal"> </td> <td style="line-height: normal; text-align: right; border-bottom: black 1pt solid; font-size-adjust: none; font-stretch: normal">(65,002</td> <td style="line-height: normal; text-align: left; padding-bottom: 1pt; font-size-adjust: none; font-stretch: normal">)</td> <td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left; padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255)"> <td style="line-height: normal; padding-bottom: 2.5pt; font-size-adjust: none; font-stretch: normal">Balance at March 31, 2016</td> <td style="line-height: normal; padding-bottom: 2.5pt; font-size-adjust: none; font-stretch: normal"> </td> <td style="line-height: normal; text-align: left; border-bottom: black 2.5pt double; font-size-adjust: none; font-stretch: normal"> </td> <td style="line-height: normal; text-align: right; border-bottom: black 2.5pt double; font-size-adjust: none; font-stretch: normal">9,238,998</td> <td style="line-height: normal; text-align: left; padding-bottom: 2.5pt; font-size-adjust: none; font-stretch: normal"> </td> <td style="line-height: normal; padding-bottom: 2.5pt; font-size-adjust: none; font-stretch: normal"> </td> <td style="line-height: normal; text-align: left; font-size-adjust: none; font-stretch: normal">$</td> <td style="line-height: normal; text-align: right; font-size-adjust: none; font-stretch: normal">0.58</td> <td style="line-height: normal; text-align: left; padding-bottom: 2.5pt; font-size-adjust: none; font-stretch: normal"> </td> <td style="line-height: normal; padding-bottom: 2.5pt; font-size-adjust: none; font-stretch: normal"> </td> <td style="line-height: normal; text-align: left; font-size-adjust: none; font-stretch: normal"> </td> <td style="line-height: normal; text-align: right; font-size-adjust: none; font-stretch: normal">7.4</td> <td style="line-height: normal; text-align: left; padding-bottom: 2.5pt; font-size-adjust: none; font-stretch: normal"> </td> <td style="line-height: normal; padding-bottom: 2.5pt; font-size-adjust: none; font-stretch: normal"> </td> <td style="line-height: normal; text-align: left; font-size-adjust: none; font-stretch: normal">$</td> <td style="line-height: normal; text-align: right; font-size-adjust: none; font-stretch: normal">  </td> <td style="line-height: normal; text-align: left; padding-bottom: 2.5pt; font-size-adjust: none; font-stretch: normal"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: normal; text-align: left; padding-bottom: 2.5pt; font-size-adjust: none; font-stretch: normal">Vested and Exercisable at   March 31, 2016</td> <td style="line-height: normal; padding-bottom: 2.5pt; font-size-adjust: none; font-stretch: normal"> </td> <td style="line-height: normal; text-align: left; border-bottom: black 2.5pt double; font-size-adjust: none; font-stretch: normal"> </td> <td style="line-height: normal; text-align: right; border-bottom: black 2.5pt double; font-size-adjust: none; font-stretch: normal">5,547,825</td> <td style="line-height: normal; text-align: left; padding-bottom: 2.5pt; font-size-adjust: none; font-stretch: normal"> </td> <td style="line-height: normal; padding-bottom: 2.5pt; font-size-adjust: none; font-stretch: normal"> </td> <td style="line-height: normal; text-align: left; font-size-adjust: none; font-stretch: normal">$</td> <td style="line-height: normal; text-align: right; font-size-adjust: none; font-stretch: normal">0.62</td> <td style="line-height: normal; text-align: left; padding-bottom: 2.5pt; font-size-adjust: none; font-stretch: normal"> </td> <td style="line-height: normal; padding-bottom: 2.5pt; font-size-adjust: none; font-stretch: normal"> </td> <td style="line-height: normal; text-align: left; font-size-adjust: none; font-stretch: normal"> </td> <td style="line-height: normal; text-align: right; font-size-adjust: none; font-stretch: normal">6.7</td> <td style="line-height: normal; text-align: left; padding-bottom: 2.5pt; font-size-adjust: none; font-stretch: normal"> </td> <td style="line-height: normal; padding-bottom: 2.5pt; font-size-adjust: none; font-stretch: normal"> </td> <td style="line-height: normal; text-align: left; font-size-adjust: none; font-stretch: normal">$</td> <td style="line-height: normal; text-align: right; font-size-adjust: none; font-stretch: normal">  </td> <td style="line-height: normal; text-align: left; padding-bottom: 2.5pt; font-size-adjust: none; font-stretch: normal"> </td></tr> </table>

The assumptions used in the Black-Scholes Model are set forth in the table below.   <table align="center" cellspacing="0" cellpadding="0" style="font-size: 10pt; line-height: normal; width: 80%; border-collapse: collapse; font-size-adjust: none; font-stretch: normal"> <tr style="vertical-align: bottom"> <td style="font: 12pt/normal Arial, Helvetica, Sans-Serif; font-size-adjust: none; font-stretch: normal"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center">Three Months Ended March 31, 2016</td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center">Year Ended December 31, 2015</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255)"> <td style="width: 58%; text-align: left">Risk-free interest rate</td> <td style="width: 8%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 11%; text-align: right">1.39</td> <td style="width: 1%; text-align: left">%</td> <td style="width: 8%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 11%; text-align: right">1.41-1.74</td> <td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Volatility</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">63.49</td> <td style="text-align: left">%</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">61.00-71.86</td> <td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255)"> <td style="text-align: left">Expected life in years</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">6</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">6</td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: left">Dividend yield</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">0.00</td> <td style="text-align: left">%</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">0.00</td> <td style="text-align: left">%</td></tr> </table>

Property and equipment consist of the following:   <table align="center" cellspacing="0" cellpadding="0" style="font-size: 10pt; line-height: normal; width: 80%; border-collapse: collapse; font-size-adjust: none; font-stretch: normal"> <tr style="vertical-align: bottom"> <td style="font: 12pt/normal Arial, Helvetica, Sans-Serif; text-align: justify; font-size-adjust: none; font-stretch: normal"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="text-align: center; border-bottom: black 1pt solid">March 31, 2016</td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="text-align: center; border-bottom: black 1pt solid">December 31, 2015</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255)"> <td style="width: 61%; text-align: justify">Network equipment</td> <td style="width: 8%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 12%; text-align: right">11,762,725</td> <td style="width: 1%; text-align: left"> </td> <td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 12%; text-align: right">11,310,494</td> <td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify">Office equipment</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">218,875</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">200,683</td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255)"> <td style="text-align: justify">Vehicles</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">158,803</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">158,803</td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify">Test equipment</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">117,871</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">115,712</td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255)"> <td style="text-align: justify">Furniture</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">84,094</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">81,838</td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify">Warehouse equipment</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">9,524</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">9,524</td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255)"> <td style="text-align: justify; padding-bottom: 1pt">Leasehold improvements</td> <td style="padding-bottom: 1pt"> </td> <td style="text-align: left; border-bottom: black 1pt solid"> </td> <td style="text-align: right; border-bottom: black 1pt solid">5,121</td> <td style="text-align: left; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="text-align: left; border-bottom: black 1pt solid"> </td> <td style="text-align: right; border-bottom: black 1pt solid">5,121</td> <td style="text-align: left; padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="font: 12pt/normal Arial, Helvetica, Sans-Serif; text-align: justify; font-size-adjust: none; font-stretch: normal"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">12,357,013</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">11,882,175</td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255)"> <td style="text-align: justify; padding-bottom: 1pt">Less: accumulated depreciation</td> <td style="padding-bottom: 1pt"> </td> <td style="text-align: left; border-bottom: black 1pt solid"> </td> <td style="text-align: right; border-bottom: black 1pt solid">(7,822,295</td> <td style="text-align: left; padding-bottom: 1pt">)</td> <td style="padding-bottom: 1pt"> </td> <td style="text-align: left; border-bottom: black 1pt solid"> </td> <td style="text-align: right; border-bottom: black 1pt solid">(7,398,735</td> <td style="text-align: left; padding-bottom: 1pt">)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: left; padding-bottom: 2.5pt; vertical-align: bottom">TOTAL PROPERTY AND EQUIPMENT</td> <td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left; border-bottom: black 2.5pt double">$</td> <td style="text-align: right; border-bottom: black 2.5pt double">4,534,718</td> <td style="text-align: left; padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left; border-bottom: black 2.5pt double">$</td> <td style="text-align: right; border-bottom: black 2.5pt double">4,483,440</td> <td style="text-align: left; padding-bottom: 2.5pt"> </td></tr> </table>

Intangible assets consist of the following:   <table cellspacing="0" cellpadding="0" style="font-size: 10pt; line-height: normal; width: 100%; border-collapse: collapse; font-size-adjust: none; font-stretch: normal"> <tr style="vertical-align: bottom"> <td style="font: 12pt/normal Arial, Helvetica, Sans-Serif; text-align: justify; font-size-adjust: none; font-stretch: normal"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="11" style="text-align: center; border-bottom: black 1pt solid">March 31, 2016</td></tr> <tr style="vertical-align: bottom"> <td style="font: 12pt/normal Arial, Helvetica, Sans-Serif; text-align: justify; font-size-adjust: none; font-stretch: normal"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="text-align: center; border-bottom: black 1pt solid">Cost</td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="text-align: center; border-bottom: black 1pt solid">Accumulated Amortization</td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="text-align: center; border-bottom: black 1pt solid">Net</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255)"> <td style="width: 46%; text-align: justify">Patents and trademarks</td> <td style="width: 5%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 11%; text-align: right">591,747</td> <td style="width: 1%; text-align: left"> </td> <td style="width: 5%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 11%; text-align: right">74,018</td> <td style="width: 1%; text-align: left"> </td> <td style="width: 5%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 11%; text-align: right">517,729</td> <td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify; padding-bottom: 1pt">Other intangible assets</td> <td style="padding-bottom: 1pt"> </td> <td style="text-align: left; border-bottom: black 1pt solid"> </td> <td style="text-align: right; border-bottom: black 1pt solid">56,263</td> <td style="text-align: left; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="text-align: left; border-bottom: black 1pt solid"> </td> <td style="text-align: right; border-bottom: black 1pt solid">43,473</td> <td style="text-align: left; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="text-align: left; border-bottom: black 1pt solid"> </td> <td style="text-align: right; border-bottom: black 1pt solid">12,790</td> <td style="text-align: left; padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255)"> <td style="text-align: left; padding-bottom: 2.5pt">     TOTAL INTANGIBLE ASSETS</td> <td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left; border-bottom: black 2.5pt double">$</td> <td style="text-align: right; border-bottom: black 2.5pt double">648,010</td> <td style="text-align: left; padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left; border-bottom: black 2.5pt double">$</td> <td style="text-align: right; border-bottom: black 2.5pt double">117,491</td> <td style="text-align: left; padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left; border-bottom: black 2.5pt double">$</td> <td style="text-align: right; border-bottom: black 2.5pt double">530,519</td> <td style="text-align: left; padding-bottom: 2.5pt"> </td></tr> </table>   <table cellspacing="0" cellpadding="0" style="font-size: 10pt; line-height: normal; width: 100%; border-collapse: collapse; font-size-adjust: none; font-stretch: normal"> <tr style="vertical-align: bottom"> <td style="font: 12pt/normal Arial, Helvetica, Sans-Serif; text-align: justify; font-size-adjust: none; font-stretch: normal"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="11" style="text-align: center; border-bottom: black 1pt solid">December 31, 2015</td></tr> <tr style="vertical-align: bottom"> <td style="font: 12pt/normal Arial, Helvetica, Sans-Serif; text-align: justify; font-size-adjust: none; font-stretch: normal"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="text-align: center; border-bottom: black 1pt solid">Cost</td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="text-align: center; border-bottom: black 1pt solid">Accumulated Amortization</td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="text-align: center; border-bottom: black 1pt solid">Net</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255)"> <td style="width: 46%; text-align: justify">Patents and trademarks</td> <td style="width: 5%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 11%; text-align: right">420,137</td> <td style="width: 1%; text-align: left"> </td> <td style="width: 5%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 11%; text-align: right">53,706</td> <td style="width: 1%; text-align: left"> </td> <td style="width: 5%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 11%; text-align: right">366,431</td> <td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify; padding-bottom: 1pt">Other intangible assets</td> <td style="padding-bottom: 1pt"> </td> <td style="text-align: left; border-bottom: black 1pt solid"> </td> <td style="text-align: right; border-bottom: black 1pt solid">56,263</td> <td style="text-align: left; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="text-align: left; border-bottom: black 1pt solid"> </td> <td style="text-align: right; border-bottom: black 1pt solid">41,929</td> <td style="text-align: left; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="text-align: left; border-bottom: black 1pt solid"> </td> <td style="text-align: right; border-bottom: black 1pt solid">14,334</td> <td style="text-align: left; padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255)"> <td style="text-align: left; padding-bottom: 2.5pt">     TOTAL INTANGIBLE ASSETS</td> <td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left; border-bottom: black 2.5pt double">$</td> <td style="text-align: right; border-bottom: black 2.5pt double">476,400</td> <td style="text-align: left; padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left; border-bottom: black 2.5pt double">$</td> <td style="text-align: right; border-bottom: black 2.5pt double">95,635</td> <td style="text-align: left; padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left; border-bottom: black 2.5pt double">$</td> <td style="text-align: right; border-bottom: black 2.5pt double">380,765</td> <td style="text-align: left; padding-bottom: 2.5pt"> </td></tr> </table>

Other assets consist of the following:   <table cellspacing="0" cellpadding="0" style="font-size: 10pt; line-height: normal; width: 100%; border-collapse: collapse; font-size-adjust: none; font-stretch: normal"> <tr style="vertical-align: bottom"> <td style="font: 12pt/normal Arial, Helvetica, Sans-Serif; text-align: justify; font-size-adjust: none; font-stretch: normal"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="11" style="text-align: center; border-bottom: black 1pt solid">March 31, 2016</td></tr> <tr style="vertical-align: bottom"> <td style="font: 12pt/normal Arial, Helvetica, Sans-Serif; text-align: justify; font-size-adjust: none; font-stretch: normal"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="text-align: center; border-bottom: black 1pt solid">Cost</td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="text-align: center; border-bottom: black 1pt solid">Accumulated Amortization</td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="text-align: center; border-bottom: black 1pt solid">Net</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255)"> <td style="width: 46%; text-align: justify">Deferred debt issuance costs</td> <td style="width: 5%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 11%; text-align: right">1,257,778</td> <td style="width: 1%; text-align: left"> </td> <td style="width: 5%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 11%; text-align: right">136,763</td> <td style="width: 1%; text-align: left"> </td> <td style="width: 5%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 11%; text-align: right">1,121,015</td> <td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify">Prepaid financing costs</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">805,917</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">101,919</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">703,998</td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255)"> <td style="text-align: justify">Deferred installation costs</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">1,825,804</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">1,323,523</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">502,281</td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify">Prepaid license fee</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">249,999</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">75,135</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">174,864</td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255)"> <td style="text-align: justify; padding-bottom: 1pt">Security deposit</td> <td style="padding-bottom: 1pt"> </td> <td style="text-align: left; border-bottom: black 1pt solid"> </td> <td style="text-align: right; border-bottom: black 1pt solid">46,124</td> <td style="text-align: left; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="text-align: left; border-bottom: black 1pt solid"> </td> <td style="text-align: right; border-bottom: black 1pt solid">  </td> <td style="text-align: left; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="text-align: left; border-bottom: black 1pt solid"> </td> <td style="text-align: right; border-bottom: black 1pt solid">46,124</td> <td style="text-align: left; padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: left; padding-bottom: 2.5pt; vertical-align: bottom">     TOTAL OTHER ASSETS</td> <td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left; border-bottom: black 2.5pt double">$</td> <td style="text-align: right; border-bottom: black 2.5pt double">4,185,622</td> <td style="text-align: left; padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left; border-bottom: black 2.5pt double">$</td> <td style="text-align: right; border-bottom: black 2.5pt double">1,637,340</td> <td style="text-align: left; padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left; border-bottom: black 2.5pt double">$</td> <td style="text-align: right; border-bottom: black 2.5pt double">2,548,282</td> <td style="text-align: left; padding-bottom: 2.5pt"> </td></tr> </table>   <table cellspacing="0" cellpadding="0" style="font-size: 10pt; line-height: normal; width: 100%; border-collapse: collapse; font-size-adjust: none; font-stretch: normal"> <tr style="vertical-align: bottom"> <td style="font: 12pt/normal Arial, Helvetica, Sans-Serif; text-align: justify; font-size-adjust: none; font-stretch: normal"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="11" style="text-align: center; border-bottom: black 1pt solid">December 31, 2015</td></tr> <tr style="vertical-align: bottom"> <td style="font: 12pt/normal Arial, Helvetica, Sans-Serif; text-align: justify; font-size-adjust: none; font-stretch: normal"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="text-align: center; border-bottom: black 1pt solid">Cost</td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="text-align: center; border-bottom: black 1pt solid">Accumulated Amortization</td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="text-align: center; border-bottom: black 1pt solid">Net</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255)"> <td style="width: 46%; text-align: justify">Deferred debt issuance costs</td> <td style="width: 5%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 11%; text-align: right">1,257,778</td> <td style="width: 1%; text-align: left"> </td> <td style="width: 5%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 11%; text-align: right">91,840</td> <td style="width: 1%; text-align: left"> </td> <td style="width: 5%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 11%; text-align: right">1,165,938</td> <td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify">Deferred financing costs</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">805,917</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">74,070</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">731,847</td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255)"> <td style="text-align: justify">Deferred installation costs</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">1,787,869</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">1,220,982</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">566,887</td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify">Prepaid license fee</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">249,999</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">71,037</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">178,962</td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255)"> <td style="text-align: justify; padding-bottom: 1pt">Security deposit</td> <td style="padding-bottom: 1pt"> </td> <td style="text-align: left; border-bottom: black 1pt solid"> </td> <td style="text-align: right; border-bottom: black 1pt solid">46,124</td> <td style="text-align: left; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="text-align: left; border-bottom: black 1pt solid"> </td> <td style="text-align: right; border-bottom: black 1pt solid">  </td> <td style="text-align: left; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="text-align: left; border-bottom: black 1pt solid"> </td> <td style="text-align: right; border-bottom: black 1pt solid">46,124</td> <td style="text-align: left; padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: left; padding-bottom: 2.5pt; vertical-align: bottom">     TOTAL OTHER ASSETS</td> <td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left; border-bottom: black 2.5pt double">$</td> <td style="text-align: right; border-bottom: black 2.5pt double">4,147,687</td> <td style="text-align: left; padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left; border-bottom: black 2.5pt double">$</td> <td style="text-align: right; border-bottom: black 2.5pt double">1,457,929</td> <td style="text-align: left; padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left; border-bottom: black 2.5pt double">$</td> <td style="text-align: right; border-bottom: black 2.5pt double">2,689,758</td> <td style="text-align: left; padding-bottom: 2.5pt"> </td></tr> </table>

The total consolidated VIE assets and liabilities reflected on our condensed consolidated balance sheets at March 31, 2016 and December 31, 2015 are as follows:   <table align="center" cellspacing="0" cellpadding="0" style="font-size: 10pt; line-height: normal; width: 80%; border-collapse: collapse; font-size-adjust: none; font-stretch: normal"> <tr style="vertical-align: bottom"> <td style="text-align: center; font-size: 12pt"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="text-align: center; border-bottom: black 1pt solid">March 31, 2016</td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="text-align: center; border-bottom: black 1pt solid">December 31, 2015</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; font-weight: bold">Assets</td> <td style="font-size: 12pt"> </td> <td colspan="3" style="text-align: right; font-size: 12pt"> </td> <td style="font-size: 12pt"> </td> <td colspan="3" style="text-align: right; font-size: 12pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255)"> <td style="width: 61%">Cash</td> <td style="width: 8%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 12%; text-align: right">332</td> <td style="width: 1%; text-align: left"> </td> <td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 12%; text-align: right">2,146</td> <td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1pt">Receivables</td> <td style="padding-bottom: 1pt"> </td> <td style="text-align: left; border-bottom: black 1pt solid"> </td> <td style="text-align: right; border-bottom: black 1pt solid">4,731</td> <td style="text-align: left; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="text-align: left; border-bottom: black 1pt solid"> </td> <td style="text-align: right; border-bottom: black 1pt solid">4,731</td> <td style="text-align: left; padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255)"> <td style="text-align: left">    Total current assets</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">5,063</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">6,877</td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: left; padding-bottom: 1pt">Property, net</td> <td style="padding-bottom: 1pt"> </td> <td style="text-align: left; border-bottom: black 1pt solid"> </td> <td style="text-align: right; border-bottom: black 1pt solid">43,463</td> <td style="text-align: left; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="text-align: left; border-bottom: black 1pt solid"> </td> <td style="text-align: right; border-bottom: black 1pt solid">50,382</td> <td style="text-align: left; padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255)"> <td style="text-align: left; padding-bottom: 2.5pt">     Total assets</td> <td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left; border-bottom: black 2.5pt double">$</td> <td style="text-align: right; border-bottom: black 2.5pt double">48,526</td> <td style="text-align: left; padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left; border-bottom: black 2.5pt double">$</td> <td style="text-align: right; border-bottom: black 2.5pt double">57,259</td> <td style="text-align: left; padding-bottom: 2.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="font-size: 12pt"> </td> <td style="font-size: 12pt"> </td> <td style="text-align: left; font-size: 12pt"> </td> <td style="text-align: right; font-size: 12pt"> </td> <td style="text-align: left; font-size: 12pt"> </td> <td style="font-size: 12pt"> </td> <td style="text-align: left; font-size: 12pt"> </td> <td style="text-align: right; font-size: 12pt"> </td> <td style="text-align: left; font-size: 12pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; font-weight: bold">Liabilities</td> <td style="font-size: 12pt"> </td> <td style="text-align: left; font-size: 12pt"> </td> <td style="text-align: right; font-size: 12pt"> </td> <td style="text-align: left; font-size: 12pt"> </td> <td style="font-size: 12pt"> </td> <td style="text-align: left; font-size: 12pt"> </td> <td style="text-align: right; font-size: 12pt"> </td> <td style="text-align: left; font-size: 12pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255)"> <td style="text-align: left">Accounts payable</td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right">134,573</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right">132,170</td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: left">Accrued interest</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">276,508</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">261,450</td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255)"> <td style="text-align: left">Other current liabilities</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">27,749</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">26,936</td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: left">Notes payable</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">441,498</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">441,498</td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255)"> <td style="text-align: left; padding-bottom: 1pt">Mandatorily redeemable interest</td> <td style="padding-bottom: 1pt"> </td> <td style="text-align: left; border-bottom: black 1pt solid"> </td> <td style="text-align: right; border-bottom: black 1pt solid">441,498</td> <td style="text-align: left; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="text-align: left; border-bottom: black 1pt solid"> </td> <td style="text-align: right; border-bottom: black 1pt solid">441,498</td> <td style="text-align: left; padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: left; padding-bottom: 2.5pt">            Total liabilities</td> <td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left; border-bottom: black 2.5pt double">$</td> <td style="text-align: right; border-bottom: black 2.5pt double">1,321,826</td> <td style="text-align: left; padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left; border-bottom: black 2.5pt double">$</td> <td style="text-align: right; border-bottom: black 2.5pt double">1,303,552</td> <td style="text-align: left; padding-bottom: 2.5pt"> </td></tr> </table>   The financial performance of the consolidated VIEs reflected on our condensed consolidated statements of operations for the three months ended March 31, 2016 and 2015 is as follows:   <table align="center" cellspacing="0" cellpadding="0" style="font-size: 10pt; line-height: normal; width: 80%; border-collapse: collapse; font-size-adjust: none; font-stretch: normal"> <tr style="vertical-align: bottom"> <td style="font-size: 12pt"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="7" style="text-align: center; border-bottom: black 1pt solid">March 31,</td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 12pt"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="text-align: center; border-bottom: black 1pt solid">2016</td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="text-align: center; border-bottom: black 1pt solid">2015</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255)"> <td style="width: 61%; padding-bottom: 1pt">Revenue</td> <td style="width: 8%; padding-bottom: 1pt"> </td> <td style="width: 1%; text-align: left; border-bottom: black 1pt solid">$</td> <td style="width: 12%; text-align: right; border-bottom: black 1pt solid">7,097</td> <td style="width: 1%; text-align: left; padding-bottom: 1pt"> </td> <td style="width: 3%; padding-bottom: 1pt"> </td> <td style="width: 1%; text-align: left; border-bottom: black 1pt solid">$</td> <td style="width: 12%; text-align: right; border-bottom: black 1pt solid">7,097</td> <td style="width: 1%; text-align: left; padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: left">Network operations expense</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">4,164</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">4,164</td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255)"> <td style="text-align: left">General and administrative expense</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">813</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">1,130</td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1pt">Depreciation</td> <td style="padding-bottom: 1pt"> </td> <td style="text-align: left; border-bottom: black 1pt solid"> </td> <td style="text-align: right; border-bottom: black 1pt solid">12,133</td> <td style="text-align: left; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="text-align: left; border-bottom: black 1pt solid"> </td> <td style="text-align: right; border-bottom: black 1pt solid">12,467</td> <td style="text-align: left; padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255)"> <td style="text-align: left; padding-bottom: 1pt">    Total operating costs</td> <td style="padding-bottom: 1pt"> </td> <td style="text-align: left; border-bottom: black 1pt solid"> </td> <td style="text-align: right; border-bottom: black 1pt solid">17,110</td> <td style="text-align: left; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="text-align: left; border-bottom: black 1pt solid"> </td> <td style="text-align: right; border-bottom: black 1pt solid">17,761</td> <td style="text-align: left; padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: left">      Operating loss</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(10,013</td> <td style="text-align: left">)</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(10,664</td> <td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255)"> <td style="text-align: left; padding-bottom: 1pt">Other expense</td> <td style="padding-bottom: 1pt"> </td> <td style="text-align: left; border-bottom: black 1pt solid"> </td> <td style="text-align: right; border-bottom: black 1pt solid">(22,207</td> <td style="text-align: left; padding-bottom: 1pt">)</td> <td style="padding-bottom: 1pt"> </td> <td style="text-align: left; border-bottom: black 1pt solid"> </td> <td style="text-align: right; border-bottom: black 1pt solid">(21,780</td> <td style="text-align: left; padding-bottom: 1pt">)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: left">Loss before taxes</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(32,220</td> <td style="text-align: left">)</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(32,444</td> <td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255)"> <td style="text-align: left; padding-bottom: 1pt">Provision for taxes</td> <td style="padding-bottom: 1pt"> </td> <td style="text-align: left; border-bottom: black 1pt solid"> </td> <td style="text-align: right; border-bottom: black 1pt solid">  </td> <td style="text-align: left; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="text-align: left; border-bottom: black 1pt solid"> </td> <td style="text-align: right; border-bottom: black 1pt solid">  </td> <td style="text-align: left; padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: left">Net loss</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(32,220</td> <td style="text-align: left">)</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(32,444</td> <td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255)"> <td style="text-align: left; padding-bottom: 1pt">Net loss attributable to noncontrolling interest</td> <td style="padding-bottom: 1pt"> </td> <td style="text-align: left; border-bottom: black 1pt solid"> </td> <td style="text-align: right; border-bottom: black 1pt solid">(16,110</td> <td style="text-align: left; padding-bottom: 1pt">)</td> <td style="padding-bottom: 1pt"> </td> <td style="text-align: left; border-bottom: black 1pt solid"> </td> <td style="text-align: right; border-bottom: black 1pt solid">(16,222</td> <td style="text-align: left; padding-bottom: 1pt">)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: left; padding-bottom: 2.5pt">Net loss attributable to CareView Communications, Inc.</td> <td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left; border-bottom: black 2.5pt double">$</td> <td style="text-align: right; border-bottom: black 2.5pt double">(16,110</td> <td style="text-align: left; padding-bottom: 2.5pt">)</td> <td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left; border-bottom: black 2.5pt double">$</td> <td style="text-align: right; border-bottom: black 2.5pt double">(16,222</td> <td style="text-align: left; padding-bottom: 2.5pt">)</td></tr> </table>

2021-04-20

2022-01-30

3692307 1151206

0.53

0.40

0.45

0.40

1.40

.40

.52

.53

0.52

1.25

.40

.52

2000000

3250000

5000000

4000000

5000000

2000000

5000000

805917

378000

0.0500

0.05

-168805

-84308

110156518

104333559

40000000

20000000

9316000

10684000

2329000

2671000

2329000

6000000

19533992

0.0139

0.0141

0.0174

0.6349

0.6100

0.7186

P6Y

0.0000

9350667

9238998

-66667

-6231310

-65002

-41002

5547825

0.58

0.3

0.62

P7Y7M6D P10Y P7Y4M24D

P6Y8M12D

15705

84308

84497

1000000

168805

1093105

1257778

2025-03-31

7336615

2882626

20000

1815000

190843

190106

842000

P1Y6M

467137

490119

3938

3060

11882175

12357013

11310494

200683

158803

115712

81838

9524

5121

11762725

218875

158803

117871

84094

9524

5121

7398735

7822295

476400

648010

591747

56263

420137

56263

95635

117491

74018

43473

53706

41929

4147687 4185622 1257778 805917 1825804 249999 46124 1257778 805917 1787869 249999 46124 1457929 1637340 136763 101919 1323523 75135 91840 74070 1220982 71037

235162

243683

135059

54771 102800

108526

68007

67500

11284

13267

25210

0.50

1151205

575603

1200000

575602

0.10

0.1350

0.1300

1124728 102457 20000 3000 100

332

2146

441498

22207

21780

-32220

-32444

In the event that a milestone relating to the placement of 9,000 billable units occurs on or before October 31, 2015.

(i) the placement of 27,750 billable units and (ii) the Company recording earnings before interest, tax, depreciation, and amortization (EBITDA) of not less than $7,000,000 on an annualized basis for the three calendar month period prior to the funding (on or before June 30, 2017).

Tranche Two Milestone, which changed from a minimum of 27,750 billable units (defined as one unit for each room control platform and two units for each nurse station monitor) to 31,500 Bed Equivalent Units (defined as a billable unit plus 14 units for each head-end server operating as the communication center and fractional units for mobile assets as applicable).

Interest only payments for the first eight interest payment dates and principal plus interest payments will commence on the ninth interest payment date. We may elect to pay a portion of the interest due in the form of additional loans (interest paid in kind) during the first eight interest payment dates.Each tranche will mature on the fifth anniversary of the date borrowed. We may elect to prepay the Loans at any time without any premium or penalty, subject to certain conditions.

Secured by a pledge of substantially all of the assets of the Company and certain of its domestic subsidiaries.

2025-06-26 44922 91840

27849

74071

9000 27250 31500 7000000

2018-01-08

1666667

4444445

Interim Financial Statements   The accompanying unaudited interim condensed consolidated financial statements of CareView Communications, Inc. (CareView, the Company, we, us or our) have been prepared in accordance with generally accepted accounting principles in the United States of America (GAAP) for interim financial information and with the instructions to Form 10-Q. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, such financial statements include all adjustments (consisting solely of normal recurring adjustments) necessary for the fair statement of the financial information included herein in accordance with GAAP and the rules and regulations of the Securities and Exchange Commission (the SEC). The balance sheet at December 31, 2015 has been derived from the audited consolidated financial statements at that date but does not include all of the information and footnotes required by GAAP for complete financial statements. The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the period. Actual results could differ from those estimates. Results of operations for interim periods are not necessarily indicative of results for the full year. The accompanying condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and related notes included in our Annual Report on Form 10-K for the year ended December 31, 2015 as filed with the SEC on March 30, 2016.

NOTE 3 – STOCKHOLDERS’ EQUITY   Warrants to Purchase Common Stock of the Company   We use the Black-Scholes-Merton option pricing model (the “Black-Scholes Model”) to determine the fair value of warrants to purchase Common Stock of the Company (“Warrants”) (except certain Warrants issued to HealthCor in 2011 as discussed in NOTE 11 and the warrants issued in connection with a private placement completed in April 2013 (the “Private Placement Warrants”). The Private Placement Warrants contain provisions that protect the holders from a decline in the issue price of our common stock or “down round” provisions. In accordance with the accounting standards, we determined that these instruments qualify as derivative liabilities and should be recorded at their fair value on the date of issuance and re-measured at fair value each reporting period with the change reported in earnings). The Black-Scholes Model is an acceptable model in accordance with the GAAP. The Black-Scholes Model requires the use of a number of assumptions including volatility of the stock price, the weighted average risk-free interest rate, and the weighted average term of the Warrant. The fair value of the Warrants issued to HealthCor and the Private Placement Warrants was computed using the Binomial Lattice model, incorporating transaction details such as the price of our Common Stock, contractual terms, maturity and risk free rates, as well as assumptions about future financings, volatility, and holder behavior. Due to the down round provisions associated with the exercise price of these Warrants, we determined that the Binomial Lattice model was the most appropriate model for valuing these instruments. As discussed in NOTE 11, the Warrants issued to HealthCor in 2011 were substantially amended and no longer contain down round provisions. The risk-free interest rate assumption is based upon observed interest rates on zero coupon U.S. Treasury bonds whose maturity period is appropriate for the term of the Warrants and is calculated by using the average daily historical stock prices through the day preceding the grant date. Estimated volatility is a measure of the amount by which our stock price is expected to fluctuate each year during the expected life of the award. Our estimated volatility is an average of the historical volatility of our stock prices (and that of peer entities whose stock prices were publicly available). Our calculation of estimated volatility is based on historical stock prices over a period equal to the expected life of the awards. Where appropriate we used the historical volatility of peer entities due to the lack of sufficient historical data of our stock price during 2007-2009.   Warrant Activity during the Three Months Ended March 31, 2016   During the three months ended March 31, 2016, no Warrants were issued and none were exercised or expired.   As of December 31, 2015, we recorded a warrant liability of $168,805 in our consolidated financial statements. At March 31, 2016, the Private Placement Warrants were re-valued with a fair value determination of $84,308, resulting in a difference of $84,497, which was included as change in fair value of warrant liability in other income and expense in the accompanying condensed consolidated financial statements.   Warrant Activity during the Three Months Ended March 31, 2015   On February 17, 2015, we entered into a Fifth Amendment to the Note and Warrant Purchase Agreement with HealthCor and certain other investors and agreed to sell and issue (i) additional notes in the initial aggregate principal amount of $6,000,000, with a conversion price per share equal to $0.52 (subject to adjustment for standard anti-dilution provisions) and (ii) additional Warrants for an aggregate of up to 3,692,307 shares of our Common Stock at an exercise price per share equal to $0.52 (subject to adjustment for standard anti-dilution provisions) (the “Fifth Amendment Warrants”). The fair value of the convertible debt and the Fifth Amendment Warrants was determined to be $7,336,615, resulting in a relative fair value of $1,093,105 for the Fifth Amendment Warrants on the date of grant. (See NOTE 11 for further details.)   On March 31, 2015, we issued HealthCor a Warrant for up to an aggregate of 1,000,000 shares of our Common Stock in consideration for certain prior waivers of the minimum cash balance requirement in the Purchase Agreement. This Warrant has an exercise price of $0.53 per share and an expiration date of March 31, 2025. (See NOTE 11 for further details).   During the three months ended March 31, 2015, warrants to purchase an aggregate of 2,882,626 shares of our Common Stock expired.   Options to Purchase Common Stock of the Company   During the three months ended March 31, 2016, we granted options to purchase 20,000 shares of our Common Stock (the ‘‘Option(s)’’) to an employee. During the three months ended March 31, 2015, we granted 1,815,000 Options to certain employees and members of our board of directors. During those same three month periods, 65,002 and 41,002 Options, respectively, were canceled and 66,667 and 6,231,310 Options, respectively, expired.   A summary of our stock option activity and related information follows:   <table align="center" cellpadding="0" cellspacing="0" style="width: 90%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse"> <tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Number of Shares Under Options</td> <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Weighted Average Exercise Price</td> <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Weighted Average Remaining Contractual Life</td> <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Aggregate Intrinsic Value</td> </tr> <tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"> <td style="width: 40%; font: 10pt Times New Roman, Times, Serif">Balance at December 31, 2015</td> <td style="width: 3%; font: 10pt Times New Roman, Times, Serif"> </td> <td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"> </td> <td style="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif">9,350,667</td> <td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"> </td> <td style="width: 3%; font: 10pt Times New Roman, Times, Serif"> </td> <td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">$</td> <td style="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif">0.58</td> <td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"> </td> <td style="width: 3%; font: 10pt Times New Roman, Times, Serif"> </td> <td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"> </td> <td style="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif">7.6</td> <td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"> </td> <td style="width: 3%; font: 10pt Times New Roman, Times, Serif"> </td> <td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">$</td> <td style="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif">15,705</td> <td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"> </td> </tr> <tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif">   Granted</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="text-align: left; font: 10pt Times New Roman, Times, Serif"> </td> <td style="text-align: right; font: 10pt Times New Roman, Times, Serif">20,000</td> <td style="text-align: left; font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td> <td style="text-align: right; font: 10pt Times New Roman, Times, Serif">0.30</td> <td style="text-align: left; font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="text-align: left; font: 10pt Times New Roman, Times, Serif"> </td> <td style="text-align: right; font: 10pt Times New Roman, Times, Serif">10.0</td> <td style="text-align: left; font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td> <td style="text-align: right; font: 10pt Times New Roman, Times, Serif">—  </td> <td style="text-align: left; font: 10pt Times New Roman, Times, Serif"> </td> </tr> <tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif">   Expired</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="text-align: left; font: 10pt Times New Roman, Times, Serif"> </td> <td style="text-align: right; font: 10pt Times New Roman, Times, Serif">(66,667</td> <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">)</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="text-align: left; font: 10pt Times New Roman, Times, Serif"> </td> <td style="text-align: right; font: 10pt Times New Roman, Times, Serif"> </td> <td style="text-align: left; font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="text-align: left; font: 10pt Times New Roman, Times, Serif"> </td> <td style="text-align: right; font: 10pt Times New Roman, Times, Serif"> </td> <td style="text-align: left; font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="text-align: left; font: 10pt Times New Roman, Times, Serif"> </td> <td style="text-align: right; font: 10pt Times New Roman, Times, Serif"> </td> <td style="text-align: left; font: 10pt Times New Roman, Times, Serif"> </td> </tr> <tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"> <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">   Canceled</td> <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(65,002</td> <td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">)</td> <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"> </td> <td style="text-align: left; font: 10pt Times New Roman, Times, Serif"> </td> <td style="text-align: right; font: 10pt Times New Roman, Times, Serif"> </td> <td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"> </td> <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"> </td> <td style="text-align: left; font: 10pt Times New Roman, Times, Serif"> </td> <td style="text-align: right; font: 10pt Times New Roman, Times, Serif"> </td> <td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"> </td> <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"> </td> <td style="text-align: left; font: 10pt Times New Roman, Times, Serif"> </td> <td style="text-align: right; font: 10pt Times New Roman, Times, Serif"> </td> <td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"> </td> </tr> <tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"> <td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif">Balance at March 31, 2016</td> <td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">9,238,998</td> <td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif"> </td> <td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"> </td> <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td> <td style="text-align: right; font: 10pt Times New Roman, Times, Serif">0.58</td> <td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif"> </td> <td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"> </td> <td style="text-align: left; font: 10pt Times New Roman, Times, Serif"> </td> <td style="text-align: right; font: 10pt Times New Roman, Times, Serif">7.4</td> <td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif"> </td> <td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"> </td> <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td> <td style="text-align: right; font: 10pt Times New Roman, Times, Serif">—  </td> <td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif"> </td> </tr> <tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"> <td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif">Vested and Exercisable at   March 31, 2016</td> <td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">5,547,825</td> <td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif"> </td> <td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"> </td> <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td> <td style="text-align: right; font: 10pt Times New Roman, Times, Serif">0.62</td> <td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif"> </td> <td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"> </td> <td style="text-align: left; font: 10pt Times New Roman, Times, Serif"> </td> <td style="text-align: right; font: 10pt Times New Roman, Times, Serif">6.7</td> <td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif"> </td> <td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"> </td> <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td> <td style="text-align: right; font: 10pt Times New Roman, Times, Serif">—  </td> <td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif"> </td> </tr> </table>   The valuation methodology used to determine the fair value of the Options issued was the Black-Scholes Model.   The assumptions used in the Black-Scholes Model are set forth in the table below.   <table align="center" cellpadding="0" cellspacing="0" style="width: 80%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse"> <tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="3" nowrap="nowrap" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Three Months Ended March 31, 2016</td> <td nowrap="nowrap" style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="3" nowrap="nowrap" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Year Ended December 31, 2015</td> </tr> <tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"> <td style="width: 56%; text-align: left; font: 10pt Times New Roman, Times, Serif">Risk-free interest rate</td> <td style="width: 8%; font: 10pt Times New Roman, Times, Serif"> </td> <td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"> </td> <td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif">1.39</td> <td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">%</td> <td style="width: 8%; font: 10pt Times New Roman, Times, Serif"> </td> <td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"> </td> <td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif">1.41-1.74</td> <td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">%</td> </tr> <tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif">Volatility</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="text-align: left; font: 10pt Times New Roman, Times, Serif"> </td> <td style="text-align: right; font: 10pt Times New Roman, Times, Serif">63.49</td> <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">%</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="text-align: left; font: 10pt Times New Roman, Times, Serif"> </td> <td style="text-align: right; font: 10pt Times New Roman, Times, Serif">61.00-71.86</td> <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">%</td> </tr> <tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"> <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">Expected life in years</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="text-align: left; font: 10pt Times New Roman, Times, Serif"> </td> <td style="text-align: right; font: 10pt Times New Roman, Times, Serif">6</td> <td style="text-align: left; font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="text-align: left; font: 10pt Times New Roman, Times, Serif"> </td> <td style="text-align: right; font: 10pt Times New Roman, Times, Serif">6</td> <td style="text-align: left; font: 10pt Times New Roman, Times, Serif"> </td> </tr> <tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"> <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">Dividend yield</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="text-align: left; font: 10pt Times New Roman, Times, Serif"> </td> <td style="text-align: right; font: 10pt Times New Roman, Times, Serif">0.00</td> <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">%</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="text-align: left; font: 10pt Times New Roman, Times, Serif"> </td> <td style="text-align: right; font: 10pt Times New Roman, Times, Serif">0.00</td> <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">%</td> </tr> </table>    The risk-free interest rate assumption is based upon observed interest rates on zero coupon U.S. Treasury bonds whose maturity period is appropriate for the expected term of the Option and is calculated by using the average daily historical stock prices through the day preceding the grant date. Estimated volatility is a measure of the amount by which our stock price is expected to fluctuate each year during the expected life of the award. Our estimated volatility is an average of the historical volatility of our stock prices. Our calculation of estimated volatility is based on historical stock prices over a period equal to the expected life of the awards.   Share-based compensation expense for Options charged to our operating results for the three months ended March 31, 2016 and 2015 ($190,843 and $190,106, respectively) is based on awards vested. The estimate of forfeitures are to be recorded at the time of grant and revised in subsequent periods if actual forfeitures differ from the estimates. We have not included an adjustment to our stock based compensation expense based on the nominal amount of the historical forfeiture rate. We do, however, revise our stock based compensation expense based on actual forfeitures during each reporting period.   At March 31, 2016, total unrecognized estimated compensation expense related to non-vested Options granted prior to that date was approximately $842,000, which is expected to be recognized over a weighted-average period of 1.5 years. No tax benefit was realized due to a continued pattern of operating losses.

NOTE 11 – AGREEMENT WITH HEALTHCOR On April 21, 2011, we entered into a Note and Warrant Purchase Agreement (as subsequently amended) (the “HealthCor Purchase Agreement”) with HealthCor. Pursuant to the terms HealthCor Purchase Agreement, we sold Senior Secured Convertible Notes to HealthCor in the principal amount of $9,316,000 and $10,684,000, respectively (collectively the “2011 HealthCor Notes”). The 2011 HealthCor Notes have a maturity date of April 20, 2021. We also issued Warrants to HealthCor for the purchase of an aggregate of up to 5,488,456 and 6,294,403 shares, respectively, of our Common Stock at an exercise price of $1.40 per share (collectively the “2011 HealthCor Warrants”). So long as no event of default has occurred, the outstanding principal balances of the 2011 HealthCor Notes accrue interest from April 21, 2011 through April 20, 2016 (the “First Five Year Note Period”) at the rate of 12.5% per annum, compounding quarterly and shall be added to the outstanding principal balances of the 2011 HealthCor Notes on the last day of each calendar quarter. Interest accruing from April 21, 2016 through April 20, 2021 (the “Second Five Year Note Period”) at a rate of 10% per annum, compounding quarterly, may be paid quarterly in arrears in cash or, at our option, such interest may be added to the outstanding principal balances of the 2011 HealthCor Notes on the last day of each calendar quarter. From the date any event of default occurs, the interest rate, then applicable, shall be increased by five percent (5%) per annum. HealthCor has the right, upon an event of default, to declare due and payable any unpaid principal amount of the 2011 HealthCor Notes then outstanding, plus previously accrued but unpaid interest and charges, together with the interest then scheduled to accrue (calculated at the default rate described in the immediately preceding sentence) through the end of the First Five Year Note Period or the Second Five Year Note Period, as applicable. At any time after April 21, 2011, HealthCor is entitled to convert any portion of the outstanding and unpaid accrued interest on and principal balances of the 2011 HealthCor Notes into fully paid and non-assessable shares of our Common Stock at a conversion rate of $1.25 per share, subject to adjustment in accordance with anti-dilution provisions set forth in the 2011 HealthCor Notes. As of March 31, 2016, the underlying shares of our Common Stock related to the 2011 HealthCor Notes totaled approximately 30,000,000. On January 31, 2012, we entered into the Second Amendment to the HealthCor Purchase Agreement with HealthCor (the “Second Amendment”) amending the HealthCor Purchase Agreement, and sold Senior Secured Convertible Notes to HealthCor in the principal amounts of $2,329,000 and $2,671,000, respectively (collectively the “2012 HealthCor Notes”). As provided by the Second Amendment, the 2012 HealthCor Notes are in substantially the same form as the 2011 HealthCor Notes, with changes to the “Issuance Date,” “Maturity Date,” “First Five Year Note Period” and other terms to take into account the timing of the issuance of the 2012 HealthCor Notes. The 2012 HealthCor Notes have a maturity date of January 30, 2022. In addition, the provisions regarding interest payments, interest acceleration, optional conversion, negative covenants, and events of default, preemptive rights and registration rights are the same as those of the 2011 HealthCor Notes. At any time after January 30, 2012, HealthCor is entitled to convert any portion of the outstanding and unpaid accrued interest on and principal balances of the 2012 HealthCor Notes into fully paid and non-assessable shares of our Common Stock at a conversion rate of $1.25 per share, subject to adjustment in accordance with anti-dilution provisions set forth in the 2012 HealthCor Notes. As of March 31, 2016, the underlying shares of our Common Stock related to the 2012 HealthCor Notes totaled approximately 7,000,000. On August 20, 2013, we entered into a Third Amendment to the HealthCor Purchase Agreement with HealthCor (the “Third Amendment”) to redefine our minimum cash balance requirements. Previously we were required to maintain a minimum cash balance of $5,000,000 and should we drop below that balance, it triggered a default. The Third Amendment allowed for a reduced minimum cash period, as defined in the HealthCor Purchase Agreement, which allowed us to drop below $5,000,000, but not below $4,000,000. All other terms and conditions of the HealthCor Purchase Agreement, including all amendments thereto, remain the same. Upon entering the reduced minimum cash period (which occurred on October 7, 2013), we had 120 days to return our minimum cash balance to the original $5,000,000. On January 16, 2014, we increased our cash balance to in excess of the original $5,000,000 minimum allowable balance. On January 16, 2014, we entered into a Fourth Amendment to the HealthCor Purchase Agreement with HealthCor (the “Fourth Amendment”) and sold Senior Secured Convertible Notes to HealthCor in the principal amounts of $2,329,000 and $2,671,000 (collectively the ‘‘2014 HealthCor Notes’’). As provided by the Fourth Amendment, the 2014 HealthCor Notes are in substantially the same form as the 2011 HealthCor Notes, with changes to the “Issuance Date,” “Maturity Date,” “First Five Year Note Period” and other terms to take into account the timing of the issuance of the 2014 HealthCor Notes. The 2014 HealthCor Notes have a maturity date of January 15, 2024. In addition, the provisions regarding interest payments, interest acceleration, optional conversion, negative covenants, and events of default, preemptive rights and registration rights are the same as those of the 2011 HealthCor Notes. At any time after January 16, 2014, HealthCor is entitled to convert any portion of the outstanding and unpaid accrued interest on and principal balances of the 2014 HealthCor Notes into fully paid and non-assessable shares of our Common Stock at a conversion rate of $0.40 per share, subject to adjustment in accordance with anti-dilution provisions set forth in the 2014 HealthCor Notes. Additionally we issued Warrants to HealthCor for the purchase of an aggregate of up to 4,000,000 shares of our Common Stock at an exercise price of $0.40 per share (collectively the “2014 HealthCor Warrants”). As of March 31, 2016, the underlying shares of our Common Stock related to the 2014 HealthCor Notes totaled approximately 16,000,000. On December 4, 2014, we entered into a Fifth Amendment to the HealthCor Purchase Agreement (the “Fifth Amendment”) with HealthCor and certain additional investors (such additional investors, the “New Investors” and, collectively with HealthCor Partners Fund, LP, the “Investors”) and agreed to sell and issue (i) additional notes in the initial aggregate principal amount of $6,000,000,with a conversion price per share of $0.52 (subject to adjustment as described therein) (the “Fifth Amendment Notes”) and (ii) additional Warrants for an aggregate of up to 3,692,308 shares of our Common Stock at an exercise price per share of $0.52 (subject to adjustment as described therein) (the “Fifth Amendment Warrants”). As provided by the Fifth Amendment, the Fifth Amendment Notes are in substantially the same form as the 2011 HealthCor Notes, with changes to the “Issuance Date,” “Maturity Date,” “First Five Year Note Period” and other terms to take into account the timing of the issuance of the Fifth Amendment Notes. The Fifth Amendment Notes have a maturity date of February 16, 2025. In addition, the provisions regarding interest payments, interest acceleration, optional conversion, negative covenants, and events of default, preemptive rights and registration rights are the same as those of the 2011 HealthCor Notes. The New Investors are composed of all but one of our current directors and one of our officers. On February 17, 2015, the Company and the Investors closed on the transactions contemplated by the Fifth Amendment. In connection with this closing, the Company and the Investors entered into an Amended and Restated Pledge and Security Agreement (the “Amended Security Agreement”), amending and restating that certain Pledge and Security Agreement dated as of April 20, 2011, and an Amended and Restated Intellectual Property Security Agreement (the “Amended IP Security Agreement”), amending and restating that certain Intellectual Property Security Agreement dated as of April 20, 2011. As of March 31, 2016, the underlying shares of our Common Stock related to the Fifth Amendment Notes totaled approximately 2,000,000 to HealthCor and 11,000,000 to the New Investors. On March 31, 2015, we entered into the Sixth Amendment to the HealthCor Purchase Agreement (the “Sixth Amendment”) pursuant to which, among other things, (i) the requirement to maintain a minimum cash balance of $5,000,000 was reduced to a minimum cash balance of $2,000,000 and (ii) the amendment provision was revised to permit the HealthCor Purchase Agreement to be amended by the Company and the holders of the majority of the Common Stock underlying the outstanding notes and warrants to purchase shares of our Common Stock sold pursuant to the HealthCor Purchase Agreement. On March 31, 2015, we also issued a warrant to HealthCor to purchase up to an aggregate of 1,000,000 shares of our Common Stock in consideration for certain prior waivers of the minimum cash balance requirement in the HealthCor Purchase Agreement (the “Sixth Amendment Warrant”). The Sixth Amendment Warrant has an exercise price per share of $0.53 (subject to adjustment as described therein) and an expiration date of March 31, 2025. On June 26, 2015, we (i) entered into a Seventh Amendment to the HealthCor Purchase Agreement (the “Seventh Amendment”) pursuant to which the HealthCor Purchase Agreement was amended to permit the Company to enter into and perform its obligations under the Credit Agreement entered into with PDL BioPharma, Inc., as administrative agent and lender (the “Lender”) (the “PDL Credit Agreement”); (ii) executed an Amendment to the Registration Rights Agreement between the Company and HealthCor dated April 21, 2011 (the “RR Agreement”) pursuant to which the RR Agreement was amended to make its priority of registration consistent with the Registration Rights Agreement executed by the Company and Lender (as detailed in NOTE 12); (iii) amended the 2011 HealthCor Notes to extend the maturity date, in the event that Tranche Two of the PDL Credit Agreement is funded, for such notes to 90 days after the earlier of the Tranche Two maturity date or repayment date, but not later than December 31, 2022, (iv) amended the 2012 HealthCor Notes, to set the maturity date at January 30, 2022 and, in the event that Tranche Two of the PDL Credit Agreement is funded, to extend such maturity date to 90 days after the earlier of the Tranche Two maturity date or repayment date, but later than December 31, 2022; and (v) amended each of the Senior Secured Convertible Notes issued under the HealthCor Purchase Agreement (the “HealthCor Notes”) to, among other things, subordinate the HealthCor Notes to the loans under the PDL Credit Agreement (as detailed in NOTE 12) and to increase certain event of default acceleration and payment thresholds. Accounting Treatment When issuing debt or equity securities convertible into common stock at a discount to the fair value of the common stock at the date the debt or equity financing is committed, a company is required to record a beneficial conversion feature (“BCF”) charge. We had three separate issuances of equity securities convertible into common stock that qualify under this accounting treatment, (i) the 2011 HealthCor Notes, (ii) the 2012 HealthCor Notes and (iii) the 2014 HealthCor Notes. Because the conversion option and the 2011 HealthCor Warrants on the 2011 HealthCor Notes were originally classified as a liability when issued due to the down round provision and the removal of the provision requiring liability treatment, and subsequently reclassified to equity on December 31, 2011 when the 2011 HealthCor Notes were amended, only the accrued interest capitalized as payment in kind (‘‘PIK’’) since reclassification qualifies under this accounting treatment. The face amount of the 2012 and 2014 HealthCor Notes and all accrued PIK interest also qualify for this accounting treatment. During the three months ended March 31, 2016 and 2015, we recorded a BCF of $516,844 and $456,987, respectively. The BCF was recorded as a charge to debt discount and a credit to additional paid in capital, with the debt discount, using the effective interest method, amortized to interest expense over the term of the notes. As Warrants were issued with the Fifth Amendment Notes, the proceeds were allocated to the instruments based on relative fair value as the Warrants did not contain any features requiring liability treatment and therefore were classified as equity. The Warrants issued with the Sixth Amendment also did not contain features requiring liability accounting and were recorded at fair value on the date of issuance with the offsetting credit recorded in equity. The value allocated to the Fifth Amendment Warrants was $1,093,105, which was recorded as debt discount with the credit to additional paid in capital. We recorded an aggregate of $592,688 and $552,066 in interest expense for the three months ended March 31, 2016 and 2015, respectively, related to these transactions. The carrying value of the debt with HealthCor and the New Investors at March 31, 2016 approximates fair value as the interest rates used are those currently available to us and would be considered level 3 inputs under the fair value hierarchy.   The value allocated to the Sixth Amendment Warrant was $378,000, which was recorded as deferred debt costs with the credit to additional paid in capital. We recorded an aggregate of $14,450 in financing costs for the three months ended March 31, 2016 related to this transaction. 5488456 6294403 4000000 3692308 1000000

0.100

0.125

30000000

7000000

16000000

11000000

2000000

14450

EX-101.SCH 7 crvw-20160331.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 00000001 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited) link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' DEFICIT (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000007 - Disclosure - BASIS OF PRESENTATION AND RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - LIQUIDITY AND MANAGEMENT'S PLAN link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - STOCKHOLDERS' EQUITY link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - OTHER CURRENT ASSETS link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - PROPERTY AND EQUIPMENT link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - OTHER ASSETS link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - OTHER CURRENT LIABILITIES link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - INCOME TAXES link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - JOINT VENTURE AGREEMENT link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - VARIABLE INTEREST ENTITIES link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - AGREEMENT WITH HEALTHCOR link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - AGREEMENT WITH PDL BIOPHARMA, INC. link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - BASIS OF PRESENTATION AND RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS (Policies) link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - BASIS OF PRESENTATION AND RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS (Tables) link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - STOCKHOLDERS' EQUITY (Tables) link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - OTHER CURRENT ASSETS (Tables) link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - PROPERTY AND EQUIPMENT (Tables) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - OTHER ASSETS (Tables) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - OTHER CURRENT LIABILITIES (Tables) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - VARIABLE INTEREST ENTITIES (Tables) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - BASIS OF PRESENTATION AND RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - BASIS OF PRESENTATION AND RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS (Details) link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - BASIS OF PRESENTATION AND RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS (Details 1) link:presentationLink link:calculationLink link:definitionLink 00000030 - Disclosure - LIQUIDITY AND MANAGEMENTS PLAN (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000031 - Disclosure - STOCKHOLDERS' EQUITY (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000032 - Disclosure - STOCKHOLDERS' EQUITY (Details Narrative 1) link:presentationLink link:calculationLink link:definitionLink 00000033 - Disclosure - STOCKHOLDERS' EQUITY (Details) link:presentationLink link:calculationLink link:definitionLink 00000034 - Disclosure - STOCKHOLDERS' EQUITY (Details 1) link:presentationLink link:calculationLink link:definitionLink 00000035 - Disclosure - OTHER CURRENT ASSETS (Details) link:presentationLink link:calculationLink link:definitionLink 00000036 - Disclosure - PROPERTY AND EQUIPMENT (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000037 - Disclosure - PROPERTY AND EQUIPMENT (Details) link:presentationLink link:calculationLink link:definitionLink 00000038 - Disclosure - OTHER ASSETS (Details) link:presentationLink link:calculationLink link:definitionLink 00000039 - Disclosure - OTHER ASSETS (Details 1) link:presentationLink link:calculationLink link:definitionLink 00000040 - Disclosure - OTHER CURRENT LIABILITIES (Details) link:presentationLink link:calculationLink link:definitionLink 00000041 - Disclosure - JOINT VENTURE AGREEMENT (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000042 - Disclosure - VARIABLE INTEREST ENTITIES (Details) link:presentationLink link:calculationLink link:definitionLink 00000043 - Disclosure - VARIABLE INTEREST ENTITIES (Details 1) link:presentationLink link:calculationLink link:definitionLink 00000044 - Disclosure - AGREEMENT WITH HEALTHCOR (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000045 - Disclosure - AGREEMENT WITH HEALTHCOR (Details Narrative 1) link:presentationLink link:calculationLink link:definitionLink 00000046 - Disclosure - AGREEMENT WITH PDL BIOPHARMA, INC. (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 8 crvw-20160331_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 9 crvw-20160331_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 10 crvw-20160331_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Common Stock [Member] Equity Components [Axis] Additional Paid in Capital [Member] Accumulated Deficit [Member] Noncontrolling Interest [Member] 2011 Senior Secured Convertible Note#1 [Member] Long-term Debt, Type [Axis] HealthCor Purchase Agreement [Member] Counterparty Name [Axis] 2011 Senior Secured Convertible Notes [Member] Second Five Year Note Period [Member] Variable Rate [Axis] First Five Year Note Period [Member] Recurring Measurement [Member] Measurement Frequency [Axis] Significant Other Unobservable Inputs (Level 3) [Member] Fair Value, Hierarchy [Axis] Fair Value [Member] Quoted Prices in Active Markets for Identical Assets (Level 1) [Member] Significant Other Observable Inputs (Level 2) [Member] PDL BioPharma, Inc (Administrative Agent and Lender) [Member] Legal Entity [Axis] Tranche One Debt [Member] Debt Instrument [Axis] Tranche Two Debt [Member] Stock Options [Member] Award Type [Axis] Lower Range [Member] Range [Axis] Upper Range [Member] HealthCor Second Amendment Purchase Agreement [Member] Senior Convertible Notes - 2014 Issuance [Member] Warrants Revalued [Member] Class of Warrant or Right [Axis] HealthCor Partners Fund [Member] Purchase Agreement Warrants [Member] Warrants [Member] Employees and Board of Directors [Member] Title of Individual [Axis] Network Equipment [Member] Property, Plant and Equipment, Type [Axis] Office Equipment [Member] Vehicles [Member] Test Equipment [Member] Furniture [Member] Warehouse Equipment [Member] Leasehold Improvements [Member] Patents and Trademarks [Member] Finite-Lived Intangible Assets by Major Class [Axis] Other Intangible Assets [Member] Deferred Debt Issuance Costs [Member] BalanceSheetLocation [Axis] Prepaid Financing Costs [Member] Deferred Installation Costs [Member] Prepaid License Fee [Member] Security Deposit [Member] Deferred Financing Costs [Member] Joint Venture - Rockwell [Member] Variable Interest Entity [Member] Variable Interest Entities [Axis] PDL BioPharma, Inc (Administrative Agent and Lender) - First Amendment [Member] PDL BioPharma, Inc (Administrative Agent and Lender) - Restated Amendment [Member] 2011 Senior Secured Convertible Note#2 [Member] 2012 Senior Secured Convertible Notes [Member] 2012 Senior Secured Convertible Note#1 [Member] 2012 Senior Secured Convertible Note#2 [Member] HealthCor Third Amendment Purchase Agreement [Member] HealthCor Fourth Amendment Purchase Agreement [Member] 2014 Senior Secured Convertible Note#2 [Member] 2014 Senior Secured Convertible Note#1 [Member] 2014 Senior Secured Convertible Notes [Member] HealthCor Fifth Amendment Purchase Agreement [Member] New Investors [Member] HealthCor [Member] HealthCor Sixth Amendment Purchase Agreement [Member] Document And Entity Information Entity Registrant Name Entity Central Index Key Document Type Document Period End Date Amendment Flag Current Fiscal Year End Date Entity a Well-known Seasoned Issuer Entity a Voluntary Filer Entity's Reporting Status Current Entity Filer Category Entity Public Float Entity Common Stock, Shares Outstanding Document Fiscal Period Focus Document Fiscal Year Focus Statement of Financial Position [Abstract] ASSETS Current Assets: Cash and cash equivalents Accounts receivable, net Other current assets Total current assets Property and equipment, net Other Assets: Restricted cash Intangible assets, net Other assets Total other assets Total assets LIABILITIES AND STOCKHOLDERS' DEFICIT Current Liabilities: Accounts payable Notes payable Mandatorily redeemable equity in joint venture Accrued interest Other current liabilities Total current liabilities Long-term Liabilities: Senior secured convertible notes, net of debt discount and debt costs of $22,951,069 and $23,041,363, respectively Loan payable Fair value of warrant liability Total long-term liabilities Total liabilities Commitments and Contingencies Stockholders' Deficit: Preferred stock - par value $0.001; 20,000,000 shares authorized; no shares issued and outstanding Common stock - par value $0.001; 300,000,000 shares authorized; 139,380,748 issued and outstanding Additional paid in capital Accumulated deficit Total CareView Communications Inc. stockholders' deficit Noncontrolling interest Total stockholders' deficit Total liabilities and stockholders' deficit Statement [Table] Statement [Line Items] Schedule of Financial Instruments Subject to Mandatory Redemption by Settlement Terms [Axis] Debt discount and debt issuance costs (in dollars) Preferred stock, par value (in dollars per share) Preferred stock, shares authorized Preferred stock, shares issued Preferred stock, shares outstanding Common stock, par value (in dollars per share) Common stock, shares authorized Common stock, shares issued Common stock, shares outstanding Income Statement [Abstract] Revenues, net Operating expenses: Network operations General and administration Sales and marketing Research and development Depreciation and amortization Total operating expense Operating loss Other income and (expense) Interest expense Change in fair value of warrant liability Interest income Other income Total other income (expense) Loss before taxes Provision for income taxes Net loss Net loss attributable to noncontrolling interest Net loss attributable to CareView Communications, Inc. Net loss per share attributable to CareView Communications, Inc., basic and diluted (in dollars per share) Weighted average number of common shares outstanding, basic and diluted (in shares) Increase (Decrease) in Stockholders' Equity [Roll Forward] Balance, beginning Balance, beginning (in shares) Stock options granted as compensation Beneficial conversion features for senior secured convertible notes Net loss Balance, ending Balance, ending (in shares) Statement of Cash Flows [Abstract] CASH FLOWS FROM OPERATING ACTIVITES Adjustments to reconcile net loss to net cash flows used in operating activities: Depreciation Amortization of debt discount and debt costs Amortization of deferred installation costs Amortization of deferred debt issuance and debt financing costs Amortization of intangible assets Interest incurred and paid in kind Stock based compensation related to options granted (Gain) loss on disposal of assets Change in fair value of warrant liability Changes in operating assets and liabilities: Accounts receivable Other current assets Other assets Accounts payable Accrued expenses and other current liabilities Net cash flows used in operating activities CASH FLOWS FROM INVESTING ACTIVITIES Purchase of property and equipment Payment for deferred installation costs EX-101.PRE 11 crvw-20160331_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 12 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information - shares	3 Months Ended
Document and Entity Information - shares	Mar. 31, 2016	May. 13, 2016
Document And Entity Information
Entity Registrant Name	CareView Communications Inc
Entity Central Index Key	0001377149
Document Type	10-Q
Document Period End Date	Mar. 31, 2016
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity a Well-known Seasoned Issuer	No
Entity a Voluntary Filer	No
Entity's Reporting Status Current	Yes
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		139,380,742
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2016

XML 13 R2.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited) - USD ($)	Mar. 31, 2016	Dec. 31, 2015
Current Assets:
Cash and cash equivalents	$ 15,568,573	$ 17,678,969
Accounts receivable, net	1,185,132	1,176,404
Other current assets	493,179	471,075
Total current assets	17,246,884	19,326,448
Property and equipment, net	4,534,718	4,483,440
Other Assets:
Restricted cash	3,250,000	3,250,000
Intangible assets, net	530,519	380,765
Other assets	2,548,282	2,689,758
Total other assets	6,328,801	6,320,523
Total assets	28,110,403	30,130,411
Current Liabilities:
Accounts payable	387,303	332,402
Notes payable	441,498	441,498
Mandatorily redeemable equity in joint venture	441,498	441,498
Accrued interest	276,508	261,450
Other current liabilities	586,043	479,226
Total current liabilities	2,132,850	1,956,074
Long-term Liabilities:
Senior secured convertible notes, net of debt discount and debt costs of $22,951,069 and $23,041,363, respectively	35,593,463	33,729,093
Loan payable	20,000,000	20,000,000
Fair value of warrant liability	84,308	168,805
Total long-term liabilities	55,677,771	53,897,898
Total liabilities	$ 57,810,621	$ 55,853,972
Commitments and Contingencies
Stockholders' Deficit:
Preferred stock - par value $0.001; 20,000,000 shares authorized; no shares issued and outstanding
Common stock - par value $0.001; 300,000,000 shares authorized; 139,380,748 issued and outstanding	$ 139,381	$ 139,381
Additional paid in capital	83,142,148	82,434,461
Accumulated deficit	(112,463,946)	(107,795,712)
Total CareView Communications Inc. stockholders' deficit	(29,182,417)	(25,221,870)
Noncontrolling interest	(517,801)	(501,691)
Total stockholders' deficit	(29,700,218)	(25,723,561)
Total liabilities and stockholders' deficit	$ 28,110,403	$ 30,130,411

XML 14 R3.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited) (Parenthetical) - USD ($)	Mar. 31, 2016	Dec. 31, 2015
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized	20,000,000	20,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized	300,000,000	300,000,000
Common stock, shares issued	139,380,748	139,380,748
Common stock, shares outstanding	139,380,748	139,380,748
2011 Senior Secured Convertible Note#1 [Member]
Debt discount and debt issuance costs (in dollars)	$ 22,951,069	$ 23,041,363

XML 15 R4.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Income Statement [Abstract]
Revenues, net	$ 1,495,793	$ 1,000,554
Operating expenses:
Network operations	1,152,107	830,094
General and administration	1,054,858	838,309
Sales and marketing	221,688	197,622
Research and development	249,098	225,196
Depreciation and amortization	445,416	415,904
Total operating expense	3,123,167	2,507,125
Operating loss	(1,627,374)	(1,506,571)
Other income and (expense)
Interest expense	(3,151,557)	(2,045,901)
Change in fair value of warrant liability	84,497	(238,101)
Interest income	4,970	1,143
Other income	5,120	1,125
Total other income (expense)	(3,056,970)	(2,281,734)
Loss before taxes	$ (4,684,344)	$ (3,788,305)
Provision for income taxes
Net loss	$ (4,684,344)	$ (3,788,305)
Net loss attributable to noncontrolling interest	(16,110)	(16,222)
Net loss attributable to CareView Communications, Inc.	$ (4,668,234)	$ (3,772,083)
Net loss per share attributable to CareView Communications, Inc., basic and diluted (in dollars per share)	$ (0.03)	$ (0.03)
Weighted average number of common shares outstanding, basic and diluted (in shares)	139,380,748	139,380,748

XML 16 R5.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' DEFICIT (Unaudited) - 3 months ended Mar. 31, 2016 - USD ($)	Common Stock [Member]	Additional Paid in Capital [Member]	Accumulated Deficit [Member]	Noncontrolling Interest [Member]	Total
Balance, beginning at Dec. 31, 2015	$ 139,381	$ 82,434,461	$ (107,795,712)	$ (501,691)	$ (25,723,561)
Balance, beginning (in shares) at Dec. 31, 2015	139,380,748
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock options granted as compensation		190,843			190,843
Beneficial conversion features for senior secured convertible notes		516,844			516,844
Net loss			(4,668,234)	(16,110)	(4,684,344)
Balance, ending at Mar. 31, 2016	$ 139,381	$ 83,142,148	$ (112,463,946)	$ (517,801)	$ (29,700,218)
Balance, ending (in shares) at Mar. 31, 2016	139,380,748

XML 17 R6.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
CASH FLOWS FROM OPERATING ACTIVITES
Net loss	$ (4,684,344)	$ (3,788,305)
Adjustments to reconcile net loss to net cash flows used in operating activities:
Depreciation	423,560	409,634
Amortization of debt discount and debt costs	607,138	552,066
Amortization of deferred installation costs	102,541	66,631
Amortization of deferred debt issuance and debt financing costs	72,772
Amortization of intangible assets	21,856	6,270
Interest incurred and paid in kind	1,774,076	1,471,707
Stock based compensation related to options granted	190,843	190,106
(Gain) loss on disposal of assets		43,740
Change in fair value of warrant liability	(84,497)	238,101
Changes in operating assets and liabilities:
Accounts receivable	(8,728)	8,639
Other current assets	(18,929)	(238,795)
Other assets	4,098	4,098
Accounts payable	54,901	183,405
Accrued expenses and other current liabilities	121,875	(77,177)
Net cash flows used in operating activities	(1,422,838)	(929,880)
CASH FLOWS FROM INVESTING ACTIVITIES
Purchase of property and equipment	(474,838)	(103,098)
Payment for deferred installation costs	(37,935)	(47,371)
Patent and trademark costs	(174,785)	(10,273)
Net cash flows used in investing activities	(687,558)	(160,742)
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from notes and loan payable		5,931,520
Net cash flows provided by financing activities		5,931,520
Increase (decrease) in cash	(2,110,396)	4,840,898
Cash and cash equivalent, beginning of period	17,678,969	2,546,262
Cash and cash equivalents, end of period	15,568,573	7,387,160
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:
Cash paid for interest	682,150	5,150
SUPPLEMENTAL SCHEDULE OF NON-CASH FINANCING ACTIVITIES:
Beneficial conversion features for senior secured convertible notes	$ 516,844	456,987
Warrants issued in connection with senior secured convertible notes		$ 1,471,105

XML 18 R7.htm IDEA: XBRL DOCUMENT

BASIS OF PRESENTATION AND RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS

3 Months Ended

Mar. 31, 2016

Organization, Consolidation and Presentation of Financial Statements [Abstract]

BASIS OF PRESENTATION AND RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS

NOTE 1 – BASIS OF PRESENTATION AND RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS

Interim Financial Statements

Fair Value of Financial Instruments

Assets and liabilities recorded in the condensed consolidated balance sheets at fair value are categorized based on a hierarchy of inputs, as follows:

Level 1 - Unadjusted quoted prices in active markets for identical assets or liabilities.

Level 3 - Unobservable inputs for the asset or liability.

The following table provides the financial assets and liabilities reported at fair value and measured on a recurring basis:

Description		Assets/ (Liabilities) Measured at Fair Value				Quoted Prices in Active Markets for Identical Assets (Level 1)				Significant Other Observable Inputs (Level 2)				Significant Other Unobservable Inputs (Level 3)
Fair value of warrant liability		$	(84,308	)		$	—			$	—			$	(84,308	)

The following table provides a summary of changes in fair value associated with the Level 3 liabilities for the three months ended March 31, 2016

	Fair Value Measurements Using Significant Unobservable Inputs (Level 3)
Balance at January 1, 2016	$	(168,805	)
Issuances of derivative liabilities		—
Change in fair value of warrant liability		(84,497	)
Transfers in and/out of Level 3		—
Ending balance at March 31, 2016	$	(84,308	)

Earnings Per Share

Recently Issued and Newly Adopted Accounting Pronouncements

XML 19 R8.htm IDEA: XBRL DOCUMENT

LIQUIDITY AND MANAGEMENT'S PLAN

3 Months Ended

Mar. 31, 2016

Organization, Consolidation and Presentation of Financial Statements [Abstract]

LIQUIDITY AND MANAGEMENT'S PLAN

NOTE 2 – LIQUIDITY AND MANAGEMENT’S PLAN

XML 20 R9.htm IDEA: XBRL DOCUMENT

STOCKHOLDERS' EQUITY

3 Months Ended

Mar. 31, 2016

Stockholders' Equity Note [Abstract]

STOCKHOLDERS' EQUITY

NOTE 3 – STOCKHOLDERS’ EQUITY

Warrants to Purchase Common Stock of the Company

Warrant Activity during the Three Months Ended March 31, 2016

During the three months ended March 31, 2016, no Warrants were issued and none were exercised or expired.

Warrant Activity during the Three Months Ended March 31, 2015

During the three months ended March 31, 2015, warrants to purchase an aggregate of 2,882,626 shares of our Common Stock expired.

Options to Purchase Common Stock of the Company

A summary of our stock option activity and related information follows:

	Number of Shares Under Options			Weighted Average Exercise Price		Weighted Average Remaining Contractual Life		Aggregate Intrinsic Value
Balance at December 31, 2015		9,350,667		$	0.58		7.6	$	15,705
Granted		20,000		$	0.30		10.0	$	—
Expired		(66,667	)
Canceled		(65,002	)
Balance at March 31, 2016		9,238,998		$	0.58		7.4	$	—
Vested and Exercisable at March 31, 2016		5,547,825		$	0.62		6.7	$	—

The valuation methodology used to determine the fair value of the Options issued was the Black-Scholes Model.

The assumptions used in the Black-Scholes Model are set forth in the table below.

	Three Months Ended March 31, 2016			Year Ended December 31, 2015
Risk-free interest rate		1.39	%		1.41-1.74	%
Volatility		63.49	%		61.00-71.86	%
Expected life in years		6			6
Dividend yield		0.00	%		0.00	%

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB Topic 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74567-122707

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB Topic 4.C)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(d))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Preferred Stock
-URI http://asc.fasb.org/extlink&oid=6521494

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

+ Details

XML 21 R10.htm IDEA: XBRL DOCUMENT

OTHER CURRENT ASSETS

3 Months Ended

Mar. 31, 2016

Other Current Assets

OTHER CURRENT ASSETS

NOTE 4 – OTHER CURRENT ASSETS

Other current assets consist of the following:

	March 31, 2016		December 31, 2015
Prepaid expenses	$	490,119	$	467,137
Other current assets		3,060		3,938
TOTAL OTHER CURRENT ASSETS	$	493,179	$	471,075

XML 22 R11.htm IDEA: XBRL DOCUMENT

PROPERTY AND EQUIPMENT

3 Months Ended

Mar. 31, 2016

Property, Plant and Equipment [Abstract]

PROPERTY AND EQUIPMENT

NOTE 5 – PROPERTY AND EQUIPMENT

Property and equipment consist of the following:

	March 31, 2016			December 31, 2015
Network equipment	$	11,762,725		$	11,310,494
Office equipment		218,875			200,683
Vehicles		158,803			158,803
Test equipment		117,871			115,712
Furniture		84,094			81,838
Warehouse equipment		9,524			9,524
Leasehold improvements		5,121			5,121
		12,357,013			11,882,175
Less: accumulated depreciation		(7,822,295	)		(7,398,735	)
TOTAL PROPERTY AND EQUIPMENT	$	4,534,718		$	4,483,440

Depreciation expense for the three months ended March 31, 2016 and 2015 was $423,560 and $409,634, respectively.

XML 23 R12.htm IDEA: XBRL DOCUMENT

OTHER ASSETS

3 Months Ended

Mar. 31, 2016

Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]

OTHER ASSETS

NOTE 6 – OTHER ASSETS

Intangible assets consist of the following:

	March 31, 2016
	Cost		Accumulated Amortization		Net
Patents and trademarks	$	591,747	$	74,018	$	517,729
Other intangible assets		56,263		43,473		12,790
TOTAL INTANGIBLE ASSETS	$	648,010	$	117,491	$	530,519

	December 31, 2015
	Cost		Accumulated Amortization		Net
Patents and trademarks	$	420,137	$	53,706	$	366,431
Other intangible assets		56,263		41,929		14,334
TOTAL INTANGIBLE ASSETS	$	476,400	$	95,635	$	380,765

Other assets consist of the following:

	March 31, 2016
	Cost		Accumulated Amortization		Net
Deferred debt issuance costs	$	1,257,778	$	136,763	$	1,121,015
Prepaid financing costs		805,917		101,919		703,998
Deferred installation costs		1,825,804		1,323,523		502,281
Prepaid license fee		249,999		75,135		174,864
Security deposit		46,124		—		46,124
TOTAL OTHER ASSETS	$	4,185,622	$	1,637,340	$	2,548,282

Other assets consist of the following:

	December 31, 2015
	Cost		Accumulated Amortization		Net
Deferred debt issuance costs	$	1,257,778	$	91,840	$	1,165,938
Deferred financing costs		805,917		74,070		731,847
Deferred installation costs		1,787,869		1,220,982		566,887
Prepaid license fee		249,999		71,037		178,962
Security deposit		46,124		—		46,124
TOTAL OTHER ASSETS	$	4,147,687	$	1,457,929	$	2,689,758

XML 24 R13.htm IDEA: XBRL DOCUMENT

OTHER CURRENT LIABILITIES

3 Months Ended

Mar. 31, 2016

Payables and Accruals [Abstract]

OTHER CURRENT LIABILITIES

NOTE 7 – OTHER CURRENT LIABILITIES

Other current liabilities consist of the following:

	March 31, 2016		December 31, 2015
Accrued taxes	$	243,683	$	235,162
Accrued insurance		135,059		—
Allowance for system removal		102,800		54,771
Accrued paid time off		68,007		108,526
Accrued professional services		11,284		67,500
Other accrued liabilities		25,210		13,267
TOTAL OTHER CURRENT LIABILITIES	$	586,043	$	479,226

XML 25 R14.htm IDEA: XBRL DOCUMENT

INCOME TAXES

3 Months Ended

Mar. 31, 2016

Income Tax Disclosure [Abstract]

INCOME TAXES

NOTE 8 – INCOME TAXES

XML 26 R15.htm IDEA: XBRL DOCUMENT

JOINT VENTURE AGREEMENT

3 Months Ended

Mar. 31, 2016

Equity Method Investments and Joint Ventures [Abstract]

JOINT VENTURE AGREEMENT

NOTE 9 – JOINT VENTURE AGREEMENT

XML 27 R16.htm IDEA: XBRL DOCUMENT

VARIABLE INTEREST ENTITIES

3 Months Ended

Mar. 31, 2016

Variable Interest Entities

VARIABLE INTEREST ENTITIES

NOTE 10 – VARIABLE INTEREST ENTITIES

The total consolidated VIE assets and liabilities reflected on our condensed consolidated balance sheets at March 31, 2016 and December 31, 2015 are as follows:

	March 31, 2016		December 31, 2015
Assets
Cash	$	332	$	2,146
Receivables		4,731		4,731
Total current assets		5,063		6,877
Property, net		43,463		50,382
Total assets	$	48,526	$	57,259

Liabilities
Accounts payable	$	134,573	$	132,170
Accrued interest		276,508		261,450
Other current liabilities		27,749		26,936
Notes payable		441,498		441,498
Mandatorily redeemable interest		441,498		441,498
Total liabilities	$	1,321,826	$	1,303,552

The financial performance of the consolidated VIEs reflected on our condensed consolidated statements of operations for the three months ended March 31, 2016 and 2015 is as follows:

	March 31,
	2016			2015
Revenue	$	7,097		$	7,097
Network operations expense		4,164			4,164
General and administrative expense		813			1,130
Depreciation		12,133			12,467
Total operating costs		17,110			17,761
Operating loss		(10,013	)		(10,664	)
Other expense		(22,207	)		(21,780	)
Loss before taxes		(32,220	)		(32,444	)
Provision for taxes		—			—
Net loss		(32,220	)		(32,444	)
Net loss attributable to noncontrolling interest		(16,110	)		(16,222	)
Net loss attributable to CareView Communications, Inc.	$	(16,110	)	$	(16,222	)

XML 28 R17.htm IDEA: XBRL DOCUMENT

AGREEMENT WITH HEALTHCOR

3 Months Ended

Mar. 31, 2016

Agreement With Healthcor

AGREEMENT WITH HEALTHCOR

NOTE 11 – AGREEMENT WITH HEALTHCOR

Accounting Treatment

XML 29 R18.htm IDEA: XBRL DOCUMENT

AGREEMENT WITH PDL BIOPHARMA, INC.

3 Months Ended

Mar. 31, 2016

Agreement With Pdl Biopharma Inc.

AGREEMENT WITH PDL BIOPHARMA

NOTE 12 – AGREEMENT WITH PDL BIOPHARMA, INC.

Accounting Treatment

XML 30 R19.htm IDEA: XBRL DOCUMENT

BASIS OF PRESENTATION AND RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS (Policies)

3 Months Ended

Mar. 31, 2016

Basis Of Presentation And Recently Issued Accounting Pronouncements Policies

Interim Financial Statements

Fair Value of Financial Instruments

Assets and liabilities recorded in the condensed consolidated balance sheets at fair value are categorized based on a hierarchy of inputs, as follows:

Level 1 - Unadjusted quoted prices in active markets for identical assets or liabilities.

Level 3 - Unobservable inputs for the asset or liability.

The following table provides the financial assets and liabilities reported at fair value and measured on a recurring basis:

Description		Assets/ (Liabilities) Measured at Fair Value				Quoted Prices in Active Markets for Identical Assets (Level 1)				Significant Other Observable Inputs (Level 2)				Significant Other Unobservable Inputs (Level 3)
Fair value of warrant liability		$	(84,308	)		$	—			$	—			$	(84,308	)

The following table provides a summary of changes in fair value associated with the Level 3 liabilities for the three months ended March 31, 2016

	Fair Value Measurements Using Significant Unobservable Inputs (Level 3)
Balance at January 1, 2016	$	(168,805	)
Issuances of derivative liabilities		—
Change in fair value of warrant liability		(84,497	)
Transfers in and/out of Level 3		—
Ending balance at March 31, 2016	$	(84,308	)

Earnings Per Share

Recently Issued and Newly Adopted Accounting Pronouncements

XML 31 R20.htm IDEA: XBRL DOCUMENT

BASIS OF PRESENTATION AND RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS (Tables)

3 Months Ended

Mar. 31, 2016

Accounting Policies [Abstract]

Schedule of financial assets and liabilities reported at fair value and measured on a recurring basis

The following table provides the financial assets and liabilities reported at fair value and measured on a recurring basis:

Description		Assets/ (Liabilities) Measured at Fair Value				Quoted Prices in Active Markets for Identical Assets (Level 1)				Significant Other Observable Inputs (Level 2)				Significant Other Unobservable Inputs (Level 3)
Fair value of warrant liability		$	(84,308	)		$	—			$	—			$	(84,308	)

Schedule of summary of changes in fair value associated with the Level 3 liabilities

The following table provides a summary of changes in fair value associated with the Level 3 liabilities for the three months ended March 31, 2016

	Fair Value Measurements Using Significant Unobservable Inputs (Level 3)
Balance at January 1, 2016	$	(168,805	)
Issuances of derivative liabilities		—
Change in fair value of warrant liability		(84,497	)
Transfers in and/out of Level 3		—
Ending balance at March 31, 2016	$	(84,308	)

XML 32 R21.htm IDEA: XBRL DOCUMENT

STOCKHOLDERS' EQUITY (Tables)

3 Months Ended

Mar. 31, 2016

Stockholders' Equity Note [Abstract]

Schedule of stock option activity

A summary of our stock option activity and related information follows:

	Number of Shares Under Options			Weighted Average Exercise Price		Weighted Average Remaining Contractual Life		Aggregate Intrinsic Value
Balance at December 31, 2015		9,350,667		$	0.58		7.6	$	15,705
Granted		20,000		$	0.30		10.0	$	—
Expired		(66,667	)
Canceled		(65,002	)
Balance at March 31, 2016		9,238,998		$	0.58		7.4	$	—
Vested and Exercisable at March 31, 2016		5,547,825		$	0.62		6.7	$	—

Schedule of assumptions used in the Black-Scholes Model

The assumptions used in the Black-Scholes Model are set forth in the table below.

	Three Months Ended March 31, 2016			Year Ended December 31, 2015
Risk-free interest rate		1.39	%		1.41-1.74	%
Volatility		63.49	%		61.00-71.86	%
Expected life in years		6			6
Dividend yield		0.00	%		0.00	%

XML 33 R22.htm IDEA: XBRL DOCUMENT

OTHER CURRENT ASSETS (Tables)

3 Months Ended

Mar. 31, 2016

Other Current Assets

Schedule of other current assets

Other current assets consist of the following:

	March 31, 2016		December 31, 2015
Prepaid expenses	$	490,119	$	467,137
Other current assets		3,060		3,938
TOTAL OTHER CURRENT ASSETS	$	493,179	$	471,075

XML 34 R23.htm IDEA: XBRL DOCUMENT

PROPERTY AND EQUIPMENT (Tables)

3 Months Ended

Mar. 31, 2016

Property, Plant and Equipment [Abstract]

Schedule of property and equipment

Property and equipment consist of the following:

	March 31, 2016			December 31, 2015
Network equipment	$	11,762,725		$	11,310,494
Office equipment		218,875			200,683
Vehicles		158,803			158,803
Test equipment		117,871			115,712
Furniture		84,094			81,838
Warehouse equipment		9,524			9,524
Leasehold improvements		5,121			5,121
		12,357,013			11,882,175
Less: accumulated depreciation		(7,822,295	)		(7,398,735	)
TOTAL PROPERTY AND EQUIPMENT	$	4,534,718		$	4,483,440

XML 35 R24.htm IDEA: XBRL DOCUMENT

OTHER ASSETS (Tables)

3 Months Ended

Mar. 31, 2016

Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]

Schedule of intangible assets

Intangible assets consist of the following:

	March 31, 2016
	Cost		Accumulated Amortization		Net
Patents and trademarks	$	591,747	$	74,018	$	517,729
Other intangible assets		56,263		43,473		12,790
TOTAL INTANGIBLE ASSETS	$	648,010	$	117,491	$	530,519

	December 31, 2015
	Cost		Accumulated Amortization		Net
Patents and trademarks	$	420,137	$	53,706	$	366,431
Other intangible assets		56,263		41,929		14,334
TOTAL INTANGIBLE ASSETS	$	476,400	$	95,635	$	380,765

Schedule of other assets

Other assets consist of the following:

	March 31, 2016
	Cost		Accumulated Amortization		Net
Deferred debt issuance costs	$	1,257,778	$	136,763	$	1,121,015
Prepaid financing costs		805,917		101,919		703,998
Deferred installation costs		1,825,804		1,323,523		502,281
Prepaid license fee		249,999		75,135		174,864
Security deposit		46,124		—		46,124
TOTAL OTHER ASSETS	$	4,185,622	$	1,637,340	$	2,548,282

	December 31, 2015
	Cost		Accumulated Amortization		Net
Deferred debt issuance costs	$	1,257,778	$	91,840	$	1,165,938
Deferred financing costs		805,917		74,070		731,847
Deferred installation costs		1,787,869		1,220,982		566,887
Prepaid license fee		249,999		71,037		178,962
Security deposit		46,124		—		46,124
TOTAL OTHER ASSETS	$	4,147,687	$	1,457,929	$	2,689,758

XML 36 R25.htm IDEA: XBRL DOCUMENT

OTHER CURRENT LIABILITIES (Tables)

3 Months Ended

Mar. 31, 2016

Payables and Accruals [Abstract]

Schedule of other current liabilities

Other current liabilities consist of the following:

	March 31, 2016		December 31, 2015
Accrued taxes	$	243,683	$	235,162
Accrued insurance		135,059		—
Allowance for system removal		102,800		54,771
Accrued paid time off		68,007		108,526
Accrued professional services		11,284		67,500
Other accrued liabilities		25,210		13,267
TOTAL OTHER CURRENT LIABILITIES	$	586,043	$	479,226

XML 37 R26.htm IDEA: XBRL DOCUMENT

VARIABLE INTEREST ENTITIES (Tables)

3 Months Ended

Mar. 31, 2016

Variable Interest Entities

Schedule of VIE assets and liabilities and results of operations

The total consolidated VIE assets and liabilities reflected on our condensed consolidated balance sheets at March 31, 2016 and December 31, 2015 are as follows:

	March 31, 2016		December 31, 2015
Assets
Cash	$	332	$	2,146
Receivables		4,731		4,731
Total current assets		5,063		6,877
Property, net		43,463		50,382
Total assets	$	48,526	$	57,259

Liabilities
Accounts payable	$	134,573	$	132,170
Accrued interest		276,508		261,450
Other current liabilities		27,749		26,936
Notes payable		441,498		441,498
Mandatorily redeemable interest		441,498		441,498
Total liabilities	$	1,321,826	$	1,303,552

The financial performance of the consolidated VIEs reflected on our condensed consolidated statements of operations for the three months ended March 31, 2016 and 2015 is as follows:

	March 31,
	2016			2015
Revenue	$	7,097		$	7,097
Network operations expense		4,164			4,164
General and administrative expense		813			1,130
Depreciation		12,133			12,467
Total operating costs		17,110			17,761
Operating loss		(10,013	)		(10,664	)
Other expense		(22,207	)		(21,780	)
Loss before taxes		(32,220	)		(32,444	)
Provision for taxes		—			—
Net loss		(32,220	)		(32,444	)
Net loss attributable to noncontrolling interest		(16,110	)		(16,222	)
Net loss attributable to CareView Communications, Inc.	$	(16,110	)	$	(16,222	)

- Definition

Tabular disclosure of the significant judgments and assumptions made in determining whether a variable interest (as defined) held by the entity requires the variable interest entity (VIE) (as defined) to be consolidated and (or) disclose information about its involvement with the VIE, individually or in aggregate (as applicable); the nature of restrictions, if any, on the consolidated VIE's assets and on the settlement of its liabilities reported by an entity in its statement of financial position, including the carrying amounts of such assets and liabilities; the nature of, and changes in, the risks associated with involvement in the VIE; how involvement with the VIE affects the entity's financial position, financial performance, and cash flows; the lack of recourse if creditors (or beneficial interest holders) of the consolidated VIE have no recourse to the general credit of the primary beneficiary (if applicable); the terms of arrangements, giving consideration to both explicit arrangements and implicit variable interests, if any, that could require the entity to provide financial support to the VIE, including events or circumstances that could expose the entity to a loss; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; the significant factors considered and judgments made in determining that the power to direct the activities of a VIE that most significantly impact the VIE's economic performance are shared (as defined); the carrying amounts and classification of assets and liabilities of the VIE included in the statement of financial position; the entity's maximum exposure to loss, if any, as a result of its involvement with the VIE, including how the maximum exposure is determined and significant sources of the entity's exposure to the VIE; a comparison of the carrying amounts of the assets and liabilities and the entity's maximum exposure to loss; information about any liquidity arrangements, guarantees, and (or) other commitments by third parties that may affect the fair value or risk of the entity's variable interest in the VIE; whether or not the entity has provided financial support or other support (explicitly or implicitly) to the VIE that it was not previously contractually required to provide or whether the entity intends to provide that support, including the type and amount of the support and the primary reasons for providing the support; and supplemental information the entity determines necessary to provide.

+ References + Details

XML 38 R27.htm IDEA: XBRL DOCUMENT

BASIS OF PRESENTATION AND RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS (Details Narrative) - shares	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Accounting Policies [Abstract]
Anti-dilutive common share equivalents excluded from EPS calculation	110,156,518	104,333,559

XML 39 R28.htm IDEA: XBRL DOCUMENT

BASIS OF PRESENTATION AND RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS (Details) - USD ($)	Mar. 31, 2016	Dec. 31, 2015
Fair value of warrant liability	$ (84,308)	$ (168,805)
Recurring Measurement [Member] \| Significant Other Unobservable Inputs (Level 3) [Member]
Fair value of warrant liability	(84,308)
Recurring Measurement [Member] \| Fair Value [Member]
Fair value of warrant liability	$ (84,308)

XML 40 R29.htm IDEA: XBRL DOCUMENT

BASIS OF PRESENTATION AND RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS (Details 1) - USD ($)	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Change in Fair Value of Level 3 Liabilities
Balance, beginning of period	$ (168,805)
Change in fair value of warrant liability	(84,497)	$ 238,101
Balance, end of period	$ (84,308)

XML 41 R30.htm IDEA: XBRL DOCUMENT

LIQUIDITY AND MANAGEMENTS PLAN (Details Narrative) - USD ($)	Oct. 07, 2015	Mar. 31, 2016	Dec. 31, 2015	Jun. 26, 2015	Mar. 31, 2015	Dec. 31, 2014
Cash and cash equivalents		$ 15,568,573	$ 17,678,969		$ 7,387,160	$ 2,546,262
Restricted cash		3,250,000	$ 3,250,000
Minimum cash balance required under existing loan documents		2,000,000
Proceeds from issuance of debt, net	$ 19,533,992
PDL BioPharma, Inc (Administrative Agent and Lender) [Member]
Minimum cash balance required under existing loan documents				$ 3,250,000
Debt face amount				40,000,000
PDL BioPharma, Inc (Administrative Agent and Lender) [Member] \| Tranche One Debt [Member]
Debt face amount		20,000,000		20,000,000
PDL BioPharma, Inc (Administrative Agent and Lender) [Member] \| Tranche Two Debt [Member]
Debt face amount		$ 20,000,000		$ 20,000,000

XML 42 R31.htm IDEA: XBRL DOCUMENT

STOCKHOLDERS' EQUITY (Details Narrative) - USD ($)			3 Months Ended
STOCKHOLDERS' EQUITY (Details Narrative) - USD ($)	Mar. 31, 2015	Feb. 17, 2015	Mar. 31, 2016	Mar. 31, 2015	Dec. 31, 2015
Fair value of the warrants					$ 168,805
Senior secured convertible notes			$ 35,593,463		$ 33,729,093
HealthCor Second Amendment Purchase Agreement [Member]
Fair value of the warrants		$ 1,093,105
Senior secured convertible notes		6,000,000
Fair value of convertible debt		$ 7,336,615
Debt conversion rate		$ 0.52
HealthCor Second Amendment Purchase Agreement [Member] \| Senior Convertible Notes - 2014 Issuance [Member]
Warrants issued for financing costs, warrants		3,692,307
Warrants Revalued [Member]
Fair value of warrants at re-value			84,308
Fair value adjustment recorded as non-cash costs			$ 84,497
Purchase Agreement Warrants [Member] \| HealthCor Partners Fund [Member]
Warrants outstanding	1,000,000			1,000,000
Warrant exercise price (in dollars per share)	$ 0.53			$ 0.53
Warrant expiration date	Mar. 31, 2025
Warrants [Member]
Noncash exercise of warrants, shares forfeited for exercise				2,882,626

XML 43 R32.htm IDEA: XBRL DOCUMENT

STOCKHOLDERS' EQUITY (Details Narrative 1) - USD ($)	3 Months Ended
STOCKHOLDERS' EQUITY (Details Narrative 1) - USD ($)	Mar. 31, 2016	Mar. 31, 2015
Options granted	20,000
Options shares expired	(66,667)	(6,231,310)
Options shares cancelled	(65,002)	(41,002)
Share-based compensation expense	$ 190,843	$ 190,106
Unrecognized estimated compensation expense	$ 842,000
Period for recognization of unrecognized compensation expense	1 year 6 months
Stock Options [Member] \| Employees and Board of Directors [Member]
Options granted		1,815,000

XML 44 R33.htm IDEA: XBRL DOCUMENT

STOCKHOLDERS' EQUITY (Details) - USD ($)	3 Months Ended
STOCKHOLDERS' EQUITY (Details) - USD ($)	Mar. 31, 2016	Mar. 31, 2015
Number Options
Stock Options Outstanding, Beginning	9,350,667
Granted	20,000
Expired	(66,667)	(6,231,310)
Cancelled	(65,002)	(41,002)
Stock Options Outstanding, Ending	9,238,998
Stock Options, vested and exercisable	5,547,825
Weighted Average Exercise Price
Stock Options Outstanding, Beginning	$ 0.58
Granted	0.3
Stock Options Outstanding, Ending	0.58
Stock Options, vested and exercisable	$ 0.62
Weighted Average Remaining Contractual Life
Stock Options Outstanding, Beginning	7 years 7 months 6 days
Granted	10 years
Stock Options Outstanding, Ending	7 years 4 months 24 days
Stock Options, vested and exercisable	6 years 8 months 12 days
Aggregate Intrinsic Value
Stock Options Outstanding, Beginning	$ 15,705

XML 45 R34.htm IDEA: XBRL DOCUMENT

STOCKHOLDERS' EQUITY (Details 1) - Stock Options [Member]	3 Months Ended	12 Months Ended
	Mar. 31, 2016	Dec. 31, 2015
Black-Scholes Model:
Risk-free interest rate	1.39%
Volatility	63.49%
Expected life	6 years	6 years
Dividend yield	0.00%	0.00%
Lower Range [Member]
Black-Scholes Model:
Risk-free interest rate		1.41%
Volatility		61.00%
Upper Range [Member]
Black-Scholes Model:
Risk-free interest rate		1.74%
Volatility		71.86%

XML 46 R35.htm IDEA: XBRL DOCUMENT

OTHER CURRENT ASSETS (Details) - USD ($)	Mar. 31, 2016	Dec. 31, 2015
Other Current Assets Details
Prepaid expenses	$ 490,119	$ 467,137
Other current assets	3,060	3,938
TOTAL OTHER CURRENT ASSETS	$ 493,179	$ 471,075

XML 47 R36.htm IDEA: XBRL DOCUMENT

PROPERTY AND EQUIPMENT (Details Narrative) - USD ($)	3 Months Ended
PROPERTY AND EQUIPMENT (Details Narrative) - USD ($)	Mar. 31, 2016	Mar. 31, 2015
Property, Plant and Equipment [Abstract]
Depreciation expense	$ 423,560	$ 409,634

XML 48 R37.htm IDEA: XBRL DOCUMENT

PROPERTY AND EQUIPMENT (Details) - USD ($)	Mar. 31, 2016	Dec. 31, 2015
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 12,357,013	$ 11,882,175
Less: accumulated depreciation	(7,822,295)	(7,398,735)
Property and equipment, net	4,534,718	4,483,440
Network Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	11,762,725	11,310,494
Office Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	218,875	200,683
Vehicles [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	158,803	158,803
Test Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	117,871	115,712
Furniture [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	84,094	81,838
Warehouse Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	9,524	9,524
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 5,121	$ 5,121

XML 49 R38.htm IDEA: XBRL DOCUMENT

OTHER ASSETS (Details) - USD ($)	Mar. 31, 2016	Dec. 31, 2015
Finite-Lived Intangible Assets [Line Items]
Cost	$ 648,010	$ 476,400
Accumulated Amortization	117,491	95,635
Intangible assets, Net	530,519	380,765
Patents and Trademarks [Member]
Finite-Lived Intangible Assets [Line Items]
Cost	591,747	420,137
Accumulated Amortization	74,018	53,706
Intangible assets, Net	517,729	366,431
Other Intangible Assets [Member]
Finite-Lived Intangible Assets [Line Items]
Cost	56,263	56,263
Accumulated Amortization	43,473	41,929
Intangible assets, Net	$ 12,790	$ 14,334

XML 50 R39.htm IDEA: XBRL DOCUMENT

OTHER ASSETS (Details 1) - USD ($)	Mar. 31, 2016	Dec. 31, 2015
Cost	$ 4,185,622	$ 4,147,687
Accumulated Amortization	1,637,340	1,457,929
Other assets	2,548,282	2,689,758
Deferred Debt Issuance Costs [Member]
Cost	1,257,778	1,257,778
Accumulated Amortization	136,763	91,840
Other assets	1,121,015	1,165,938
Prepaid Financing Costs [Member]
Cost	805,917
Accumulated Amortization	101,919
Other assets	703,998
Deferred Installation Costs [Member]
Cost	1,825,804	1,787,869
Accumulated Amortization	1,323,523	1,220,982
Other assets	502,281	566,887
Prepaid License Fee [Member]
Cost	249,999	249,999
Accumulated Amortization	75,135	71,037
Other assets	174,864	178,962
Security Deposit [Member]
Cost	$ 46,124	$ 46,124
Accumulated Amortization
Other assets	$ 46,124	$ 46,124
Deferred Financing Costs [Member]
Cost		805,917
Accumulated Amortization		74,070
Other assets		$ 731,847

XML 51 R40.htm IDEA: XBRL DOCUMENT

OTHER CURRENT LIABILITIES (Details) - USD ($)	Mar. 31, 2016	Dec. 31, 2015
OTHER CURRENT LIABILITIES:
Accrued taxes	$ 243,683	$ 235,162
Accrued insurance	135,059
Allowance for system removal	102,800	$ 54,771
Accrued paid time off	68,007	108,526
Accrued professional services	11,284	67,500
Other accrued liabilities	25,210	13,267
TOTAL OTHER CURRENT LIABILITIES	$ 586,043	$ 479,226

XML 52 R41.htm IDEA: XBRL DOCUMENT

JOINT VENTURE AGREEMENT (Details Narrative)			1 Months Ended
JOINT VENTURE AGREEMENT (Details Narrative)	Jan. 27, 2012 USD ($) Number	Nov. 16, 2009 USD ($) shares	Oct. 31, 2015 USD ($)	Mar. 31, 2016 USD ($)	Dec. 31, 2015 USD ($)
Other current liabilities				$ 586,043	$ 479,226
Joint Venture - Rockwell [Member]
Percentage owned by company of each joint venture		50.00%
Funding by Rockwell into the Joint Venture, cash		$ 1,151,205
Promissory note amounts		575,603		1,200,000
Investment Interest issued to Rockwell as Preferential Return		$ 575,602
Interest rate on project notes and preferential returns, per investment agreement		10.00%
Fair value of warrants issued to Rockwell for providing funding			$ 102,457
Discount on debt recorded				636,752
Monthly revenue lost due to Hillcrest termination	$ 20,000
De-installation costs incurred	$ 3,000
Number of units remaining at Hillcrest site \| Number	100
Other current liabilities				$ 10,250
Joint Venture - Rockwell [Member] \| Warrants [Member]
Warrants issued for financing costs, warrants \| shares		1,151,206
Fair value of warrants issued to Rockwell for providing funding		$ 1,124,728

XML 53 R42.htm IDEA: XBRL DOCUMENT

VARIABLE INTEREST ENTITIES (Details) - USD ($)	Mar. 31, 2016	Dec. 31, 2015
Assets
Receivables	$ 1,185,132	$ 1,176,404
Total current assets	17,246,884	19,326,448
Property, net	4,534,718	4,483,440
Total assets	28,110,403	30,130,411
Liabilities
Accounts payable	387,303	332,402
Accrued interest	276,508	261,450
Other current liabilities	586,043	479,226
Total liabilities	57,810,621	55,853,972
Variable Interest Entity [Member]
Assets
Cash	332	2,146
Receivables	4,731	4,731
Total current assets	5,063	6,877
Property, net	43,463	50,382
Total assets	48,526	57,259
Liabilities
Accounts payable	134,573	132,170
Accrued interest	276,508	261,450
Other current liabilities	27,749	26,936
Notes payable	441,498	441,498
Mandatorily redeemable interest	441,498	441,498
Total liabilities	$ 1,321,826	$ 1,303,552

XML 54 R43.htm IDEA: XBRL DOCUMENT

VARIABLE INTEREST ENTITIES (Details 1) - USD ($)	3 Months Ended
VARIABLE INTEREST ENTITIES (Details 1) - USD ($)	Mar. 31, 2016	Mar. 31, 2015
Revenue	$ 1,495,793	$ 1,000,554
Network operations expense	1,152,107	830,094
General and administrative expense	1,054,858	838,309
Depreciation	445,416	415,904
Total operating costs	3,123,167	2,507,125
Operating loss	(1,627,374)	(1,506,571)
Loss before taxes	$ (4,684,344)	$ (3,788,305)
Provision for taxes
Net loss attributable to noncontrolling interest	$ (16,110)	$ (16,222)
Net loss attributable to CareView Communications, Inc.	(4,668,234)	(3,772,083)
Variable Interest Entity [Member]
Revenue	7,097	7,097
Network operations expense	4,164	4,164
General and administrative expense	813	1,130
Depreciation	12,133	12,467
Total operating costs	17,110	17,761
Operating loss	(10,013)	(10,664)
Other expense	(22,207)	(21,780)
Loss before taxes	$ (32,220)	$ (32,444)
Provision for taxes
Net loss	$ (32,220)	$ (32,444)
Net loss attributable to noncontrolling interest	(16,110)	(16,222)
Net loss attributable to CareView Communications, Inc.	$ (16,110)	$ (16,222)

XML 55 R44.htm IDEA: XBRL DOCUMENT

AGREEMENT WITH HEALTHCOR (Details Narrative)			3 Months Ended
AGREEMENT WITH HEALTHCOR (Details Narrative)	Jan. 31, 2012 USD ($) $ / shares	Apr. 21, 2011 USD ($) $ / shares shares	Mar. 31, 2016 Number	Feb. 17, 2015 $ / shares
HealthCor Purchase Agreement [Member] \| 2011 Senior Secured Convertible Notes [Member]
Increase in interest rate (per annum) should default occur		5.00%
Debt conversion price		$ 1.25
Number of shares the note may be converted into \| Number			30,000,000
HealthCor Purchase Agreement [Member] \| 2011 Senior Secured Convertible Notes [Member] \| First Five Year Note Period [Member]
Interest rate, provided no default		12.50%
HealthCor Purchase Agreement [Member] \| 2011 Senior Secured Convertible Notes [Member] \| Second Five Year Note Period [Member]
Interest rate, provided no default		10.00%
HealthCor Purchase Agreement [Member] \| 2011 Senior Secured Convertible Note#2 [Member]
Note amount \| $		$ 10,684,000
Debt Maturity Date		Apr. 20, 2021
Issuance of warrants \| shares		6,294,403
Exercise price of warrants		$ 1.40
HealthCor Purchase Agreement [Member] \| 2011 Senior Secured Convertible Note#1 [Member]
Note amount \| $		$ 9,316,000
Debt Maturity Date		Apr. 20, 2021
Issuance of warrants \| shares		5,488,456
Exercise price of warrants		$ 1.40
HealthCor Second Amendment Purchase Agreement [Member]
Debt conversion price				$ 0.52
HealthCor Second Amendment Purchase Agreement [Member] \| 2012 Senior Secured Convertible Notes [Member]
Debt conversion price	$ 1.25
Number of shares the note may be converted into \| Number			7,000,000
HealthCor Second Amendment Purchase Agreement [Member] \| 2012 Senior Secured Convertible Note#1 [Member]
Note amount \| $	$ 2,329,000
Debt Maturity Date	Jan. 30, 2022
HealthCor Second Amendment Purchase Agreement [Member] \| 2012 Senior Secured Convertible Note#2 [Member]
Note amount \| $	$ 2,671,000
Debt Maturity Date	Jan. 30, 2022

XML 56 R45.htm IDEA: XBRL DOCUMENT

AGREEMENT WITH HEALTHCOR (Details Narrative 1)				3 Months Ended
AGREEMENT WITH HEALTHCOR (Details Narrative 1)	Mar. 31, 2015 USD ($) $ / shares shares	Dec. 04, 2014 USD ($) $ / shares shares	Jan. 16, 2014 USD ($) $ / shares shares	Mar. 31, 2016 USD ($) Number	Mar. 31, 2015 USD ($) $ / shares	Aug. 21, 2013 USD ($)
Minimum cash balance required under existing loan documents				$ 2,000,000
Beneficial conversion features for senior secured convertible notes				516,844	$ 456,987
Interest Expense				$ 3,151,557	2,045,901
HealthCor Third Amendment Purchase Agreement [Member]
Minimum cash balance required under existing loan documents						$ 5,000,000
HealthCor Third Amendment Purchase Agreement [Member] \| Lower Range [Member]
Minimum cash balance required under existing loan documents						4,000,000
HealthCor Third Amendment Purchase Agreement [Member] \| Upper Range [Member]
Minimum cash balance required under existing loan documents			$ 5,000,000			$ 5,000,000
HealthCor Fourth Amendment Purchase Agreement [Member] \| 2014 Senior Secured Convertible Note#1 [Member]
Note amount			2,329,000
HealthCor Fourth Amendment Purchase Agreement [Member] \| 2014 Senior Secured Convertible Note#2 [Member]
Note amount			$ 2,671,000
HealthCor Fourth Amendment Purchase Agreement [Member] \| 2014 Senior Secured Convertible Notes [Member]
Issuance of warrants \| shares			4,000,000
Exercise price of warrants \| $ / shares			$ .40
Debt conversion price \| $ / shares			$ .40
Number of shares the note may be converted into \| Number				16,000,000
HealthCor Fifth Amendment Purchase Agreement [Member]
Note amount		$ 6,000,000
Issuance of warrants \| shares		3,692,308
Exercise price of warrants \| $ / shares		$ .52
Debt conversion price \| $ / shares		$ .52
Debt discount		$ 1,093,105
Interest Expense				$ 592,688	$ 552,066
HealthCor Fifth Amendment Purchase Agreement [Member] \| HealthCor [Member]
Number of shares the note may be converted into \| Number				2,000,000
HealthCor Fifth Amendment Purchase Agreement [Member] \| New Investors [Member]
Number of shares the note may be converted into \| Number				11,000,000
HealthCor Sixth Amendment Purchase Agreement [Member]
Issuance of warrants \| shares	1,000,000
Exercise price of warrants \| $ / shares	$ .53				$ .53
Minimum cash balance required under existing loan documents	$ 5,000,000				$ 5,000,000
Deferred debt costs	378,000				378,000
Aggregate financing costs	14,450
HealthCor Sixth Amendment Purchase Agreement [Member] \| Lower Range [Member]
Minimum cash balance required under existing loan documents	$ 2,000,000				2,000,000
HealthCor Purchase Agreement [Member]
Beneficial conversion features for senior secured convertible notes				$ 516,844	$ 456,987

XML 57 R46.htm IDEA: XBRL DOCUMENT

AGREEMENT WITH PDL BIOPHARMA, INC. (Details Narrative)			3 Months Ended	6 Months Ended
AGREEMENT WITH PDL BIOPHARMA, INC. (Details Narrative)	Oct. 07, 2015 Number $ / shares	Jun. 26, 2015 USD ($) Number $ / shares shares	Mar. 31, 2016 USD ($)	Dec. 31, 2015 USD ($)
Fair value				$ 168,805
Minimum cash balance required under existing loan documents			$ 2,000,000
Restricted cash			3,250,000	3,250,000
PDL BioPharma, Inc (Administrative Agent and Lender) [Member]
Debt face amount		$ 40,000,000
Description of payment terms		Interest only payments for the first eight interest payment dates and principal plus interest payments will commence on the ninth interest payment date. We may elect to pay a portion of the interest due in the form of additional loans (interest paid in kind) during the first eight interest payment dates.Each tranche will mature on the fifth anniversary of the date borrowed. We may elect to prepay the Loans at any time without any premium or penalty, subject to certain conditions.
Description of collateral		Secured by a pledge of substantially all of the assets of the Company and certain of its domestic subsidiaries.
Minimum cash balance required under existing loan documents		$ 3,250,000
PDL BioPharma, Inc (Administrative Agent and Lender) [Member] \| Warrants [Member]
Number common stock called \| shares		4,444,445
Exercise price (in dollars per shares) \| $ / shares		$ 0.40
Warrant expiration date		Jun. 26, 2025
Fair value		$ 1,257,778
Amortized interest expense			44,922	91,840
Deferred financing costs			805,917
Amortized deferred financing costs			27,849	$ 74,071
PDL BioPharma, Inc (Administrative Agent and Lender) [Member] \| Tranche One Debt [Member]
Debt face amount		$ 20,000,000	20,000,000
Description of debt milestone placement		In the event that a milestone relating to the placement of 9,000 billable units occurs on or before October 31, 2015.
Interest rate		13.50%
Number of billable units \| Number		9,000
Date of first required debt repyment		Jan. 08, 2018
Debt periodic repayment		$ 1,666,667
PDL BioPharma, Inc (Administrative Agent and Lender) [Member] \| Tranche Two Debt [Member]
Debt face amount		$ 20,000,000	$ 20,000,000
Description of debt milestone placement		(i) the placement of 27,750 billable units and (ii) the Company recording earnings before interest, tax, depreciation, and amortization (EBITDA) of not less than $7,000,000 on an annualized basis for the three calendar month period prior to the funding (on or before June 30, 2017).
Interest rate		13.00%
Number of billable units \| Number		27,250
Earning before interest, tax, depreciation, and amortization milestone		$ 7,000,000
Increase of interest rate if default occurs		5.00%
PDL BioPharma, Inc (Administrative Agent and Lender) - First Amendment [Member] \| Warrants [Member]
Exercise price (in dollars per shares) \| $ / shares	$ 0.45
PDL BioPharma, Inc (Administrative Agent and Lender) - First Amendment [Member] \| Tranche Two Debt [Member]
Description of debt milestone placement	Tranche Two Milestone, which changed from a minimum of 27,750 billable units (defined as one unit for each room control platform and two units for each nurse station monitor) to 31,500 Bed Equivalent Units (defined as a billable unit plus 14 units for each head-end server operating as the communication center and fractional units for mobile assets as applicable).
Number of billable units \| Number	31,500
PDL BioPharma, Inc (Administrative Agent and Lender) - Restated Amendment [Member] \| Warrants [Member]
Exercise price (in dollars per shares) \| $ / shares	$ 0.40

EXCEL 58 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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�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�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end XML 59 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 60 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 62 FilingSummary.xml IDEA: XBRL DOCUMENT 3.4.0.3 html 125 207 1 false 56 0 false 5 false false R1.htm 00000001 - Document - Document and Entity Information Sheet http://care-view.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 00000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited) Sheet http://care-view.com/role/CondensedConsolidatedBalanceSheets CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited) Statements 2 false false R3.htm 00000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited) (Parenthetical) Sheet http://care-view.com/role/CondensedConsolidatedBalanceSheetsParenthetical CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited) (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) Sheet http://care-view.com/role/CondensedConsolidatedStatementsOfOperations CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) Statements 4 false false R5.htm 00000005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' DEFICIT (Unaudited) Sheet http://care-view.com/role/CondensedConsolidatedStatementsOfStockholdersDeficit CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' DEFICIT (Unaudited) Statements 5 false false R6.htm 00000006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) Sheet http://care-view.com/role/CondensedConsolidatedStatementsOfCashFlows CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) Statements 6 false false R7.htm 00000007 - Disclosure - BASIS OF PRESENTATION AND RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS Sheet http://care-view.com/role/BasisOfPresentationAndRecentlyIssuedAccountingPronouncements BASIS OF PRESENTATION AND RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS Notes 7 false false R8.htm 00000008 - Disclosure - LIQUIDITY AND MANAGEMENT'S PLAN Sheet http://care-view.com/role/LiquidityAndManagementsPlan LIQUIDITY AND MANAGEMENT'S PLAN Notes 8 false false R9.htm 00000009 - Disclosure - STOCKHOLDERS' EQUITY Sheet http://care-view.com/role/StockholdersEquity STOCKHOLDERS' EQUITY Notes 9 false false R10.htm 00000010 - Disclosure - OTHER CURRENT ASSETS Sheet http://care-view.com/role/OtherCurrentAssets OTHER CURRENT ASSETS Notes 10 false false R11.htm 00000011 - Disclosure - PROPERTY AND EQUIPMENT Sheet http://care-view.com/role/PropertyAndEquipment PROPERTY AND EQUIPMENT Notes 11 false false R12.htm 00000012 - Disclosure - OTHER ASSETS Sheet http://care-view.com/role/OtherAssets OTHER ASSETS Notes 12 false false R13.htm 00000013 - Disclosure - OTHER CURRENT LIABILITIES Sheet http://care-view.com/role/OtherCurrentLiabilities OTHER CURRENT LIABILITIES Notes 13 false false R14.htm 00000014 - Disclosure - INCOME TAXES Sheet http://care-view.com/role/IncomeTaxes INCOME TAXES Notes 14 false false R15.htm 00000015 - Disclosure - JOINT VENTURE AGREEMENT Sheet http://care-view.com/role/JointVentureAgreement JOINT VENTURE AGREEMENT Notes 15 false false R16.htm 00000016 - Disclosure - VARIABLE INTEREST ENTITIES Sheet http://care-view.com/role/VariableInterestEntities VARIABLE INTEREST ENTITIES Notes 16 false false R17.htm 00000017 - Disclosure - AGREEMENT WITH HEALTHCOR Sheet http://care-view.com/role/AgreementWithHealthcor AGREEMENT WITH HEALTHCOR Notes 17 false false R18.htm 00000018 - Disclosure - AGREEMENT WITH PDL BIOPHARMA, INC. Sheet http://care-view.com/role/AgreementWithPdlBiopharmaInc. AGREEMENT WITH PDL BIOPHARMA, INC. Notes 18 false false R19.htm 00000019 - Disclosure - BASIS OF PRESENTATION AND RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS (Policies) Sheet http://care-view.com/role/BasisOfPresentationAndRecentlyIssuedAccountingPronouncementsPolicies BASIS OF PRESENTATION AND RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS (Policies) Policies 19 false false R20.htm 00000020 - Disclosure - BASIS OF PRESENTATION AND RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS (Tables) Sheet http://care-view.com/role/BasisOfPresentationAndRecentlyIssuedAccountingPronouncementsTables BASIS OF PRESENTATION AND RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS (Tables) Tables http://care-view.com/role/BasisOfPresentationAndRecentlyIssuedAccountingPronouncements 20 false false R21.htm 00000021 - Disclosure - STOCKHOLDERS' EQUITY (Tables) Sheet http://care-view.com/role/StockholdersEquityTables STOCKHOLDERS' EQUITY (Tables) Tables http://care-view.com/role/StockholdersEquity 21 false false R22.htm 00000022 - Disclosure - OTHER CURRENT ASSETS (Tables) Sheet http://care-view.com/role/OtherCurrentAssetsTables OTHER CURRENT ASSETS (Tables) Tables http://care-view.com/role/OtherCurrentAssets 22 false false R23.htm 00000023 - Disclosure - PROPERTY AND EQUIPMENT (Tables) Sheet http://care-view.com/role/PropertyAndEquipmentTables PROPERTY AND EQUIPMENT (Tables) Tables http://care-view.com/role/PropertyAndEquipment 23 false false R24.htm 00000024 - Disclosure - OTHER ASSETS (Tables) Sheet http://care-view.com/role/OtherAssetsTables OTHER ASSETS (Tables) Tables http://care-view.com/role/OtherAssets 24 false false R25.htm 00000025 - Disclosure - OTHER CURRENT LIABILITIES (Tables) Sheet http://care-view.com/role/OtherCurrentLiabilitiesTables OTHER CURRENT LIABILITIES (Tables) Tables http://care-view.com/role/OtherCurrentLiabilities 25 false false R26.htm 00000026 - Disclosure - VARIABLE INTEREST ENTITIES (Tables) Sheet http://care-view.com/role/VariableInterestEntitiesTables VARIABLE INTEREST ENTITIES (Tables) Tables http://care-view.com/role/VariableInterestEntities 26 false false R27.htm 00000027 - Disclosure - BASIS OF PRESENTATION AND RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS (Details Narrative) Sheet http://care-view.com/role/BasisOfPresentationAndRecentlyIssuedAccountingPronouncementsDetailsNarrative BASIS OF PRESENTATION AND RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS (Details Narrative) Details http://care-view.com/role/BasisOfPresentationAndRecentlyIssuedAccountingPronouncementsTables 27 false false R28.htm 00000028 - Disclosure - BASIS OF PRESENTATION AND RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS (Details) Sheet http://care-view.com/role/BasisOfPresentationAndRecentlyIssuedAccountingPronouncementsDetails BASIS OF PRESENTATION AND RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS (Details) Details http://care-view.com/role/BasisOfPresentationAndRecentlyIssuedAccountingPronouncementsTables 28 false false R29.htm 00000029 - Disclosure - BASIS OF PRESENTATION AND RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS (Details 1) Sheet http://care-view.com/role/BasisOfPresentationAndRecentlyIssuedAccountingPronouncementsDetails1 BASIS OF PRESENTATION AND RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS (Details 1) Details http://care-view.com/role/BasisOfPresentationAndRecentlyIssuedAccountingPronouncementsTables 29 false false R30.htm 00000030 - Disclosure - LIQUIDITY AND MANAGEMENTS PLAN (Details Narrative) Sheet http://care-view.com/role/LiquidityAndManagementsPlanDetailsNarrative LIQUIDITY AND MANAGEMENTS PLAN (Details Narrative) Details http://care-view.com/role/LiquidityAndManagementsPlan 30 false false R31.htm 00000031 - Disclosure - STOCKHOLDERS' EQUITY (Details Narrative) Sheet http://care-view.com/role/StockholdersEquityDetailsNarrative STOCKHOLDERS' EQUITY (Details Narrative) Details http://care-view.com/role/StockholdersEquityTables 31 false false R32.htm 00000032 - Disclosure - STOCKHOLDERS' EQUITY (Details Narrative 1) Sheet http://care-view.com/role/StockholdersEquityDetailsNarrative1 STOCKHOLDERS' EQUITY (Details Narrative 1) Details http://care-view.com/role/StockholdersEquityTables 32 false false R33.htm 00000033 - Disclosure - STOCKHOLDERS' EQUITY (Details) Sheet http://care-view.com/role/StockholdersEquityDetails STOCKHOLDERS' EQUITY (Details) Details http://care-view.com/role/StockholdersEquityTables 33 false false R34.htm 00000034 - Disclosure - STOCKHOLDERS' EQUITY (Details 1) Sheet http://care-view.com/role/StockholdersEquityDetails1 STOCKHOLDERS' EQUITY (Details 1) Details http://care-view.com/role/StockholdersEquityTables 34 false false R35.htm 00000035 - Disclosure - OTHER CURRENT ASSETS (Details) Sheet http://care-view.com/role/OtherCurrentAssetsDetails OTHER CURRENT ASSETS (Details) Details http://care-view.com/role/OtherCurrentAssetsTables 35 false false R36.htm 00000036 - Disclosure - PROPERTY AND EQUIPMENT (Details Narrative) Sheet http://care-view.com/role/PropertyAndEquipmentDetailsNarrative PROPERTY AND EQUIPMENT (Details Narrative) Details http://care-view.com/role/PropertyAndEquipmentTables 36 false false R37.htm 00000037 - Disclosure - PROPERTY AND EQUIPMENT (Details) Sheet http://care-view.com/role/PropertyAndEquipmentDetails PROPERTY AND EQUIPMENT (Details) Details http://care-view.com/role/PropertyAndEquipmentTables 37 false false R38.htm 00000038 - Disclosure - OTHER ASSETS (Details) Sheet http://care-view.com/role/OtherAssetsDetails OTHER ASSETS (Details) Details http://care-view.com/role/OtherAssetsTables 38 false false R39.htm 00000039 - Disclosure - OTHER ASSETS (Details 1) Sheet http://care-view.com/role/OtherAssetsDetails1 OTHER ASSETS (Details 1) Details http://care-view.com/role/OtherAssetsTables 39 false false R40.htm 00000040 - Disclosure - OTHER CURRENT LIABILITIES (Details) Sheet http://care-view.com/role/OtherCurrentLiabilitiesDetails OTHER CURRENT LIABILITIES (Details) Details http://care-view.com/role/OtherCurrentLiabilitiesTables 40 false false R41.htm 00000041 - Disclosure - JOINT VENTURE AGREEMENT (Details Narrative) Sheet http://care-view.com/role/JointVentureAgreementDetailsNarrative JOINT VENTURE AGREEMENT (Details Narrative) Details http://care-view.com/role/JointVentureAgreement 41 false false R42.htm 00000042 - Disclosure - VARIABLE INTEREST ENTITIES (Details) Sheet http://care-view.com/role/VariableInterestEntitiesDetails VARIABLE INTEREST ENTITIES (Details) Details http://care-view.com/role/VariableInterestEntitiesTables 42 false false R43.htm 00000043 - Disclosure - VARIABLE INTEREST ENTITIES (Details 1) Sheet http://care-view.com/role/VariableInterestEntitiesDetails1 VARIABLE INTEREST ENTITIES (Details 1) Details http://care-view.com/role/VariableInterestEntitiesTables 43 false false R44.htm 00000044 - Disclosure - AGREEMENT WITH HEALTHCOR (Details Narrative) Sheet http://care-view.com/role/AgreementWithHealthcorDetailsNarrative AGREEMENT WITH HEALTHCOR (Details Narrative) Details http://care-view.com/role/AgreementWithHealthcor 44 false false R45.htm 00000045 - Disclosure - AGREEMENT WITH HEALTHCOR (Details Narrative 1) Sheet http://care-view.com/role/AgreementWithHealthcorDetailsNarrative1 AGREEMENT WITH HEALTHCOR (Details Narrative 1) Details http://care-view.com/role/AgreementWithHealthcor 45 false false R46.htm 00000046 - Disclosure - AGREEMENT WITH PDL BIOPHARMA, INC. (Details Narrative) Sheet http://care-view.com/role/AgreementWithPdlBiopharmaInc.DetailsNarrative AGREEMENT WITH PDL BIOPHARMA, INC. (Details Narrative) Details http://care-view.com/role/AgreementWithPdlBiopharmaInc. 46 false false All Reports Book All Reports crvw-20160331.xml crvw-20160331.xsd crvw-20160331_cal.xml crvw-20160331_def.xml crvw-20160331_lab.xml crvw-20160331_pre.xml true true ZIP 64 0001387131-16-005510-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001387131-16-005510-xbrl.zip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�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